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XPF-ERCC1 is a structure specific endonuclease in which the XPF subunit is involved in 
nucleolytic activity and the ERCC1 subunit is involved in DNA binding. They are essential for 
multiple genome maintenance mechanisms which include the repair of bulky DNA monoadducts 
via nucleotide excision repair (NER) and also the repair of DNA interstrand crosslinks.  In 
humans, the deficiency of XPF-ERCC1 results in two major syndromes: Xeroderma 
pigmentosum (XP), characterized by predisposition to skin cancer and XFE, characterized by 
symptoms of premature aging. The mechanism behind XP has been attributed to the inability to 
carry out NER. However, the mechanism behind the contribution of XPF-ERCC1 deficiency to 
aging has not yet been established. 
The most successful chemotherapeutic agents are crosslinking agents that cause both 
monoadducts and interstrand crosslinks in DNA. Unfortunately, ~50% of tumors are resistant to 
these drugs. Numerous studies implicate XPF-ERCC1 as a major culprit in tumor resistance 
because of its pivotal role in repairing DNA damage but to date, there is no conclusive evidence 
of this.  
This dissertation aims to advance our understanding of the mechanistic contribution of 
XPF-ERCC1 to two major issues of public health relevance, cancer and aging. The first chapter 
examines the importance of DNA binding residues of XPF-ERCC1 located in the c-terminus of 
both proteins. The results revealed that mutations in DNA binding residues located in the HhH 
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 v 
domain of ERCC1 and the nuclease domain of XPF have a deleterious effect on nuclease and 
NER activity. Analysis of the n-terminus of XPF revealed that mutations in the n-terminus 
confer selective crosslink sensitivity to cells thereby identifying target regions of the XPF gene 
that could be exploited to generate an ICL repair pathway specific defect. To probe the 
functionality of XPF-ERCC1 as biomarkers of chemoresistance, we developed a novel 
monoclonal antibody, 1E4, which could be used to establish a positive correlation between XPF-
ERCC1 protein levels and patient sensitivity to crosslinking regimes. To examine whether DNA 
repair capacity of an individual can predict lifespan, and to determine a way to diagnose 
disorders such as XP, we developed a novel semi-automated assay to measure the NER capacity 
of suspension cells.  
 vi 
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1.0  INTRODUCTION 
This chapter was adapted from a review on XPF-ERCC1 that is pending publication. 
 
Bhagwat, N.R.1, Su, Y.2., Madireddy, A.1, Scharer, O.D.3, and L.J. Niedernhofer4 
 
1Department of Human Genetics, University  of  Pittsburgh Graduate School of Public Health, 
130 DeSoto Street, Pittsburgh, PA, 15261, USA 
2Department of Chemistry, 3Department of Pharmacological Sciences, Stony Brook University, 
Stony Brook, NY 11794-3400, 3current address: Herbert Irving Comprehensive Cancer Center, 
Columbia University, New York, NY 10032, 
4Department of Microbiology and Molecular Genetics, University of Pittsburgh School of 
Medicine, Pittsburgh, Pennsylvania. 
 
 
XPF-ERCC1 is a structure-specific endonuclease initially discovered for its role in nucleotide 
excision repair (NER), a DNA repair pathway that removes helix distorting lesions formed by 
UV light and environmental mutagens from the nuclear genome (Sijbers et al., 1996a). 
Consistent with this finding, people with mutations in the XPF gene suffer from Xeroderma 
pigmentosum (XP), a prototypical inherited DNA repair disorder characterized by extreme 
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sensitivity to UV light and a more than 1000-fold increased incidence of skin cancer. 
Subsequently, XPF-ERCC1 and its homologs in yeast, Drosophila and plants have been found to 
function in a p lethora of DNA damage repair and DNA damage tolerance mechanisms. 
Consequently, mice deficient in XPF-ERCC1 and two more recently identified human patients 
not only suffer from cancer predisposition, but also show developmental abnormalities and 
symptoms of accelerated aging (Jaspers et al., 2007; Niedernhofer et al., 2006). Here we review 
our understanding of the biochemical, structural, cell biological and genetic basis of the various 
functions of XPF-ERCC1 and aim to connect their functions to the aging and cancer related 
phenotypes caused by XPF-ERCC1 deficiency. 
 
1.1 XPF FAMILY MEMBERS 
XPF-ERCC1 is a member of the XPF family of endonucleases. This family is characterized by 
the presence of at least two out of three structural motifs: a DEXH-helicase, an ERKX3D-
nuclease and a C-terminal helix-hairpin-helix motif. The XPF family has no known homologs in 
bacteria (Aravind et al., 1999). It likely arose in archaea, in which there is just one family 
member, Hef (Figure 1-1) (Komori et al., 2002). The N-terminal region of the XPF-family shows 
similarities to the archaeal superfamily 2 (SF2) RNA helicases, and the C-terminal region has a 
conserved (V/I)ERKX3D nuclease (Sgouros et al., 1999). Euryarchaeal Hef orthologs retain the 
DExH helicase motif (Komori et al., 2002), though crenarchaea, e.g., Aeropyrum pernix and 
Sulfolobus solfataricus, do not (Figure 1-1) (Nishino et al., 2003). In eukaryotes, the XPF family 
has diversified, giving rise to multiple orthologs that specialize in different DNA repair 
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pathways. Eukaryotic XPF homologs show conservation of the N-terminus but have lost their 
ability to hydrolyze ATP by mutation in the DEXH motifs and are therefore helicase-inactive 
(Sgouros et al., 1999). 
 
Figure 1-1 Homologs of XPF and ERCC1 
Homologs of ERCC1 and XPF in different model organisms are shown with their relative 
position on the evolutionary tree. 
 
In eukaryotes, XPF heterodimerizes with ERCC1, with XPF retaining the nuclease motif 
(Enzlin and Scharer, 2002)  whereas in archaea, Hef/XPF forms homodimers. The XPF family is 
highly conserved and all eukaryotes studied to date have homologs of XPF-ERCC1 (Figure 1-1). 
The eukaryotic XPF has three major domains: a DEXH helicase-like domain, an ERKX3D 
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nuclease domain and a helix-hairpin-helix like domain (Figure 1-2) (Aravind et al., 1999; 
Sgouros et al., 1999). ERCC1, the smaller of the two partners, does not have the DEXH domain 
and has lost its ERKX3D motif through gene divergence (Gaillard and Wood, 2001). It has only 
two domains: the central domain, which is nuclease-dead, but is involved in protein-protein 
interactions (Tsodikov et al., 2007) and a C-terminal HhH2 domain (Figure 1-2), which interacts 
with the corresponding domain of XPF (de Laat et al., 1998d). The heterodimeric interaction of 
ERCC1 and XPF stabilizes these proteins in vivo (Niedernhofer et al., 2006). Consequently, XP-
F cells have a reduced expression of ERCC1 (Biggerstaff et al., 1993; Yagi et al., 1997), which is 
restored by the expression of exogenous wild-type XPF (Yagi et al., 1998), and Ercc1 mutant 
cells have a reduced level of XPF, which is restored by exogenous expression of ERCC1 
(Houtsmuller et al., 1999). 
 
Figure 1-2 Structural domains in XPF and ERCC1 
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Schematic representation of XPF and ERCC1 showing the extents in amino acid numbers of the 
helicase-like (black box), the nuclease (red box) and the HhH2-like (dark green box) domains of 
XPF and the central (orange box) and HhH2 (light green box) domains of ERCC1. 
 
 All XPF family members in eukaryotes function as heterodimers (Bailly et al., 1992; 
Bardwell et al., 1992; Boddy et al., 2001; Ciccia et al., 2007; Sijbers et al., 1996a). In vertebrates 
there are three types of proteins in the XPF family: those that have nuclease activity (XPF and 
MUS81), one with translocase activity (FANCM), and those that do not  have either of these 
activities, but are binding partners of proteins with these activities (ERCC1, EME1 and 2, and 
FAAP24). Together, they form three endonucleases and one translocase (Figure 1-3). 
 All XPF family members in eukaryotes function as heterodimers (Bailly et al., 1992; 
Bardwell et al., 1992; Boddy et al., 2001; Ciccia et al., 2007; Sijbers et al., 1996a). In vertebrates 
there are three types of proteins in the XPF family: those that have nuclease activity (XPF and 
MUS81), one with translocase activity (FANCM), and those that do not  have either of these 
activities, but are binding partners of proteins with these activities (ERCC1, EME1 and 2, and 
FAAP24). Together, they form three endonucleases and one translocase (Figure 1-3). 
 The most recently discovered members of the XPF family are FANCM and FAAP24 
(Ciccia et al., 2007; Meetei et al., 2005). These proteins heterodimerize to form a translocase that 
has an affinity for splayed arm substrates (Ciccia et al., 2007). It lacks helicase or nuclease 
activity and may be involved in loading of the Fanconi anemia (FA) core complex on t o the 
chromatin during ICL repair (Kim et al., 2008a). 
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Figure 1-3 Orthologs of XPF 
Members of the XPF family in archaea, yeast and vertebrates are shown. Archaea have only one 
member of the family (Hef/XPF). Yeast S. cerevisiae and S. pombe have 4 members, the 
homologs of ERCC1 (Rad10/Swi10) and XPF (Rad1/Rad16) and homologs of MUS81 (Mus81) 
and EME1 (Mms4/Eme1). Vertebrates possess three additional members, EME2, which 
dimerizes with MUS81 to form the EME2-MUS81 endonuclease, and FANCM and FAAP24, 
which participate in the Fanconi anemia DNA repair pathway. Heterodimers formed by these 
proteins and their functions in vertebrates are listed in the box. 
 
  
1.2 BIOLOGICAL FUNCTIONS OF XPF-ERCC1 AND ITS HOMOLOGS 
1.2.1 Nucleotide Excision Repair 
NER is a DNA repair pathway that repairs a wide variety of helix-distorting lesions formed by 
ultra violet (UV) light, environmental mutagens and cancer chemotherapeutic agents. It is a 
complex pathway involving over 30 proteins that perform a highly coordinated excision of the 
damage as a single-stranded oligonucleotide and restoration of the original DNA sequence using 
the non-damaged strand as a template (de Laat et al., 1999; Gillet and Scharer, 2006). 
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A role of XPF-ERCC1 in NER was first identified for its homologs in S. cerevisiae. rad1 
and rad10 mutants were found to be hypersensitive to UV irradiation and defective in the 
incision step of NER (Reynolds et al., 1981; Wilcox and Prakash, 1981). Rad10-Rad1 showed 
that it was only functional as an endonuclease when it was a heterodimer (Davies et al., 1995). It 
showed specificity for substrates with singlestrand/doublestrand (ss/ds) DNA junctions with 3’ 
single-stranded overhangs, releasing the 3’ overhangs (Bardwell et al., 1994; Davies et al., 
1995). Similarly, in higher eukaryotes, the roles for ERCC1 and XPF in NER was discovered by 
the ability of these proteins to restore UV resistance to NER-deficient Chinese Hamster Ovary 
(CHO) cell lines (Brookman et al., 1996; van Duin et al., 1986). Subsequently, XPF-ERCC1 was 
shown to possess structural specificity similar to Rad10-Rad1 in incising ss/dsDNA junctions, 
consistent with performing the incision 5’ to a lesion in NER (de Laat et al., 1998a; Sijbers et al., 
1996a). 
NER consists of two pathways, global genome NER (GG-NER) and transcription-
coupled NER (TC-NER) that feed into a common nucleotide excision repair pathway (Hanawalt 
and Spivak, 2008) (Figure 1-4). As the name suggests, GG-NER deals with DNA d amage 
throughout the genome, whereas TC-NER allows the cell to preferentially repair the transcribed 
strand of genes. TC-NER is initiated by a stalled RNA polymerase II at a DNA lesion (Leadon 
and Lawrence, 1991; Venema et al., 1992) and also requires the CSA, CSB and XAB2 proteins 
(Henning et al., 1995; Nakatsu et al., 2000; Troelstra et al., 1992). GG-NER by contrast is 
initiated by XPC-RAD23B, which detects the helical distortion induced by lesions in DNA 
(Araki et al., 2001; Min and Pavletich, 2007; Sugasawa et al., 1998; Volker et al., 2001), and in 
some cases with the help of the UV-DDB protein complex (Scrima et al., 2008). Following 
damage recognition the two pathways are believed to operate by the sequential recruitment and 
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assembly of the same downstream proteins (Fousteri et al., 2006; Houtsmuller et al., 1999; 
Volker et al., 2001)Figure 1-4. The ten-subunit transcription factor and NER factor TFIIH is 
recruited to the site of damage, the DNA opens up and the presence of the lesion is then verified 
by one of the two helicase subunits of TFIIH, XPD (Schaeffer et al., 1993) (Schaeffer et al., 
1994) (Sugasawa et al., 2009). Engagement of TFIIH with the lesion provides a landing platform 
for the next set of NER factors, XPA, RPA and XPG (Riedl et al., 2003; Tapias et al., 2004; 
Wakasugi and Sancar, 1998). RPA has a preferred binding site of 30 n ucleotides of ssDNA, 
binds the non-damaged strand of DNA to help position the two endonucleases XPF-ERCC1 and 
XPG and to protect the gap during repair synthesis (de Laat et al., 1998a; Riedl et al., 2003) XPG 
is a latent endonuclease with a role in assembling the NER preincision complex as well as 
making the inision 3’ to the lesion (Mu et al., 1997; Wakasugi et al., 1997). XPA interacts with 
TFIIH, RPA and DNA in the pre-incision complex and then recruits XPF-ERCC1 through its 
interaction with ERCC1 (Li et al., 1994; Li et al., 1995; Park and Sancar, 1994; Saijo et al., 
1996). In addition to a core folded region, XPA has unstructured regions. One of these, 
encompassing a GGGF motif undergoes a disorder to order transition upon binding to the central 
domain of ERCC1 and is necessary and sufficient for the interaction with XPA and recruitment 
of XPF-ERCC1 to damaged sites in DNA (Orelli et al., 2010a; Tsodikov et al., 2007). Previously 
thought to be a simple matter of cutting and pasting, dual incision and repair DNA synthesis is 
now known to be a complex and tightly coordinated process starting with 5’ incision by XPF-
ERCC1, followed by initiation of repair DNA synthesis, 3’incision by XPG and completion of 
repair synthesis and ligation (Staresincic et al., 2009a). Repair synthesis involves at least three 
polymerases (Pol δ, Pol ε and Pol κ) and accessory factors and the nick may be sealed by either 
DNA ligase III/XRCC1 (Moser et al., 2007; Shivji et al., 1995). 
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Figure 1-4 Schematic of the NER pathway 
 
1.2.2 Interstrand Crosslink Repair  
ICLs are formed when a bifunctional alkylating agent covalently binds a base on each strand of 
duplex DNA, thereby preventing strand separation necessary for replication or transcription 
(McHugh et al., 2001). In S-phase cells ICLs are converted into DSBs making crosslinks 
extremely cytotoxic. The basic model of ICL repair has been developed based on r esearch in 
prokaryotic and eukaryotic model systems (Dronkert and Kanaar, 2001). In E.coli, ICL repair 
consists of the removal of the crosslink from the DNA by a process controlled by uvrB and 
subsequent recombination repair by the recA gene product (Kohn et al., 1965; Lawley and 
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Brookes, 1965, 1968). The ICL repair mechanism in S. cerevisiae is well studied and appears to 
be different from its mammalian counterpart. In this case, unlike XPF-ERCC1 in mammals, 
Rad10-Rad1 seems to be involved in ICL repair as a part of the NER machinery. In yeast, ICL 
REPAIR is performed by a combination of NER proteins, homologous recombination (HR) 
repair proteins (Jachymczyk et al., 1981), PSO2/SNM1 (Henriques and Moustacchi, 1980; 
Henriques et al., 1989; Ruhland et al., 1981), base excision repair (BER) proteins (McHugh et 
al., 1999), mismatch repair (MMR) proteins (Durant et al., 1999) and translesion synthesis (TLS) 
proteins (Sarkar et al., 2006). The ICL repair mechanism in mammals remains poorly defined 
(for detailed review, see (Sengerova et al., 2011). Proteins from multiple DNA damage repair 
and tolerance pathways appear to be involved in ICL repair. Data from genetic analysis and 
crosslink hypersensitivity of mutant cells and organisms shows the involvement of XPF-ERCC1 
(Collins, 1993), HR proteins such as XRCC2 and XRCC3 (De Silva et al., 2000; Liu et al., 
1998), MSH2-MSH3 (MutSβ) heterodimer (Zhang et al., 2002), RPA, PCNA (Li et al., 2000; 
Zhang et al., 2003), PSO4 complex (PSO4/PRP19, CDC5L, PLRG1, SPF27) (Zhang et al., 
2005), WRN (Zhang et al., 2005), BRCA2 (Yu et al., 2000), EME1-MUS81 (Abraham et al., 
2003; McPherson et al., 2004), SNM1a and SNM1b (Bae et al., 2008; Dronkert et al., 2000; 
Hazrati et al., 2008; Ishiai et al., 2004; Wang et al., 2011) and the Fanconi anemia (FA) proteins 
(Auerbach and Wolman, 1976; Crossan and Patel, 2012; Crossan et al., 2011b; Fujiwara and 
Tatsumi, 1977; Sasaki and Tonomura, 1973; Thompson and Hinz, 2009). 
When the replication machinery encounters a crosslink, because the two strands of DNA 
cannot be separated, it cannot move past the damage, and the replication fork is therefore 
blocked. This activates ataxia telangiectasia and Rad3 related (ATR) protein (Stiff et al., 2006), 
which along with its downstream target CHK1 phosphorylates multiple proteins, which include 
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the FA proteins FANCA, FANCG, FANCE, FANCD2, FANCI and FANCM (Andreassen et al., 
2004; Collins et al., 2009; Matsuoka et al., 2007; Meetei et al., 2005; Pichierri and Rosselli, 
2004; Qiao et al., 2004; Smogorzewska et al., 2007; Wang et al., 2007; Yamashita et al., 1998), 
and Histone H2A.x (H2AX) (Ward and Chen, 2001) and Nijmegen breakage syndrome 1(NBS1) 
(Pichierri and Rosselli, 2004). These phosphorylations activate the FA DNA repair pathway 
leading to monoubiquitination of FANCD2 and FANCI – the ID complex – that act as a signal 
for cell cycle checkpoints and DNA repair (Meetei et al., 2003; Smogorzewska et al., 2007). This 
step is not dependent on XPF-ERCC1, and FANCD2 monoubiquitination appears to be normal 
although persistent in XPF-ERCC1 deficient cells (Bhagwat et al., 2009b) (Figure 1-5). The 
repair of a crosslink involves its removal from both strands of DNA one at a time and therefore 
poses a considerable challenge to cells. A number of endonucleases have been implicated in the 
incision step of ICL repair, such as XPF-ERCC1 (De Silva et al., 2000; Kuraoka et al., 2000; 
Niedernhofer et al., 2004) EME1-MUS81 (Hanada et al., 2007; Hanada et al., 2006), SLX1-
SLX4 (Andersen et al., 2009; Fekairi et al., 2009; Joyce et al., 2009; Munoz et al., 2009b; 
Parmar et al., 2009; Stoepker et al., 2011a; Svendsen et al., 2009) and FAN1  (O'Donnell and 
Durocher, 2010; Smogorzewska et al., 2010). Initial incision is probably made by the XPF-
ERCC1 ortholog EME1-MUS81, producing a DSB (Hanada et al., 2007; Hanada et al., 2006). 
ICL-induced DSBs can occur even in the absence of XPF-ERCC1 (Niedernhofer et al., 2004). 
However, XPF-ERCC1 is required for the resolution of these breaks as it makes the incision on 
the other side of the crosslink, thereby releasing it from one strand, a process known as 
“unhooking” (De Silva et al., 2000; Kuraoka et al., 2000; Niedernhofer et al., 2004). This 
function of XPF-ERCC1 is necessary for the efficient binding of FANCD2 to the chromatin 
(Bhagwat et al., 2009b; McCabe et al., 2008). Once the ICL is unhooked, the hSNM1a 
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exonuclease then removes the crosslinked oligonucleotides giving rise to a gapped intermediate 
which forms a good substrate for (Wang et al., 2011) a translesion polymerase, such as polζ to 
fill the gap in an error prone fashion (Raschle et al., 2008). The FA proteins then coordinate the 
repair of the replication fork through recruitment of the homologous recombination repair (HRR) 
(Thompson and Hinz, 2009). 
 
Figure 1-5 Schematic of the ICL DNA repair pathway 
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1.2.3 Double Strand Break Repair  
 
DNA DSBs are extremely cytotoxic and can lead to cell cycle arrest, and cell death if left 
unrepaired (Khanna and Jackson, 2001). Homologous recombination and non-homologous end 
joining are the two major DSB repair pathways. In addition, a number of often overlapping error-
prone pathways take over when repair by classical pathways is not possible. These alternate 
pathways, including single strand annealing (SSA) and microhomology-mediated end joining 
(MMEJ), depend on sequence homology to a variable degree. A large portion of our knowledge 
about these alternative DSB repair pathways comes from yeast systems (for detailed review, see 
(Paques and Haber, 1999). 
 Rad10-Rad1, the Saccharomyces cerevisiae homolog of XPF-ERCC1 functions in single 
strand annealing (SSA) and micro homology mediated end joining (MMEJ), which repair DSBs 
in regions of DNA containing sequence-repeats. SSA (Figure1-4) is a Rad52 dependent process 
(Mortensen et al., 1996) that uses regions of intrachromosomal sequence repeats with 29bp or 
more homology (Sugawara et al., 2000). After exonuclease-processing of the DSB ends, 3’ 
overhangs are formed on both sides (Sugawara and Haber, 1992; Sun et al., 1991). Rad10-Rad1 
can prune the ends to remove nonhomologous sequences and allow repair to occur (Fishman-
Lobell and Haber, 1992; Ivanov and Haber, 1995). SSA is dependent on Msh2 and Msh3 for 
regions of homology <1kb (Sugawara et al., 1997). Msh2 interacts with Rad10 (Bertrand et al., 
1998) and probably recruits Rad10-Rad1 to the DSB for end processing (Paques and Haber, 
1997). 
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 A role for mammalian XPF-ERCC1 in SSA-mediated DSB repair was suggested by the 
deficiency of Ercc1 mutant CHO cells in processing heteroduplex intermediates of the 
recombination between repeat sequences (Sargent et al., 2000; Sargent et al., 1997). XPF-
ERCC1 is required to remove 3’ single stranded tails that are formed in these intermediates and 
failure to remove these, leads to deletions at the sites of recombination. XPF-ERCC1 interacts 
with RAD52 and this interaction enhances the ability of the nuclease in incising 3’ single 
stranded flaps (Motycka et al., 2004). It was later discovered that XPF-ERCC1 has a role in SSA 
and in gene conversions similar to yeast (Al-Minawi et al., 2008). Irrespective of the sequence 
homology status, XPF-ERCC1 is required for integration of exogenous DNA into the genome, 
for example, the targeted gene replacement in mouse ES cells (Niedernhofer et al., 2001). 
 MMEJ is an alternative end joining pathway that depends on s equence homologies as 
small as 1-5 nucleotides (Roth and Wilson, 1986). Studies in yeast show that it is independent of 
Rad52 and Ku86 (Yu and Gabriel, 2003), but requires Mre11-Rad50-Xrs2 (the MRX complex) 
(Haber, 2006; Ma et al., 2003), Msh2, Pms1 (Decottignies, 2007), Nej1, error prone DNA 
polymerases including Pol4, Rad30, Rev3, and Pol32, the flap endonuclease Sae2, and Tel1 (Lee 
and Lee, 2007). Similar to SSA, the role of Rad10-Rad1 in this pathway is probably the removal 
of non-homologous 3’ single stranded overhangs. 
 In mammals, the existence of the MMEJ pathway is evident from persistent end joining 
repair in non-homologous end joining (NHEJ) deficient cells (Feldmann et al., 2000; Guirouilh-
Barbat et al., 2004; Kabotyanski et al., 1998). Ercc1-/- mouse embryonic fibroblasts (MEFs) are 
hypersensitive to γ-irradiation, but Ercc1-/- mouse embryonic stem (ES) cells are not (Ahmad et 
al., 2008). This pattern of cell type-specific hypersensitivity is reminiscent of that seen in the 
NHEJ-deficient DNA-PKCS null cells (Gao et al., 1998) suggesting that this is not a defect in 
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HRR. Ercc1-/-Ku86-/- mice are not viable and the double knockout MEFs are more sensitive to 
radiation than either of the single mutants. However, a linearized plasmid DNA with 
microhomologies on bot h ends shows large deletions after repair in Ercc1 mutant CHO cells 
(Ahmad et al., 2008). These data suggest that XPF-ERCC1 functions in MMEJ. 
 In S. pombe, individual cells undergo spontaneous mating-type switch during growth. 
This involves formation of a defined DSB at a switching signal locus followed by 
recombination-mediated repair. Strains rad16 (swi9, RAD10 homolog) and swi10 (RAD1 
homolog) have a defect in mating-type switching recombination (Carr et al., 1994; Schmidt et 
al., 1989). Additionally, they are sensitive to ionizing radiation (IR) (Schmidt et al., 1989). In A. 
thaliana, deficiency of AtERCC1 leads to IR sensitivity, indicating a role for AtERCC1 in DSB 
repair (Hefner et al., 2003). In Drosophila, mutation of mei-9 (XPF homolog) also leads to IR 
sensitivity (Baker et al., 1978). Thus, XPF-ERCC1 and its homologs function in multiple 
subtypes of DSB repair. 
1.2.4 Meiotic Recombination 
Meiosis is accompanied by crossover events between homologous chromosomes, allowing for 
segregation of polymorphisms. This crossover is brought about by meiotic recombination, a 
mechanism akin to the HRR mechanism, but between homologous chromosomes with divergent 
sequences, instead of sister chromatids that are identical at the sequence level. Drosophila mei-9 
mutants are defective in meiotic crossover. They display a marked decrease in crossovers and an 
increase in chromosome non-disjunction (Carpenter and Baker, 1982; Yildiz et al., 2004). There 
is also an increase in postmeiotic segregation, indicating a failure to repair heteroduplex DNA 
formed during noncrossover recombination events (Yildiz et al., 2004). These findings suggest 
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that MEI-9 is required for the resolution of Holliday junctions (HJ) formed during meiosis. MEI-
9 interacts with MUS312, and disruption of the MUS312-MEI-9 interaction produces a 
phenotype similar to the loss of either MUS312 or MEI-9 (Yildiz et al., 2002). Recent evidence 
suggests that HDM, a single-stranded-DNA binding protein, forms a complex with MUS312, 
MEI-9 and ERCC1 that resolves the HJs (Joyce et al., 2009). Interestingly, the human ortholog 
of MUS312, SLX4/FANCP binds multiple different endonucleases including XPF-ERCC1 
(Fekairi et al., 2009; Svendsen et al., 2009). 
 Mice have elevated Xpf and Ercc1 mRNA levels in the meiotic and early postmeiotic 
cells involved in spermatogenesis (Shannon et al., 1999). Both male and female Ercc1-mutant 
mice are infertile. XPF-ERCC1 is important at all stages of development and maturation of both 
male and female gametes, but there is no evidence that it is required for meiotic crossovers (Hsia 
et al., 2003). 
1.2.5 Telomere Maintenance 
Telomeres have 3’ single stranded overhangs with G-rich repeat sequences. This is an ideal 
substrate for cleavage by XPF-ERCC1. XPF-ERCC1 was found to be associated with the 
telomeric TRF2 complex, and prevents recombination of telomeric DNA with interstitial 
telomere-like repeats. The absence of XPF-ERCC1 produces telomeric DNA-containing double 
minute (TDM) chromosomes. On the other hand, in the absence of TRF2, XPF-ERCC1 cleaves 
the 3’ overhangs allowing telomeres to be subjected to NHEJ. This leads to telomere fusions and 
dicentric chromosomes (Zhu et al., 2003). In essence, XPF-ERCC1 and TRF2 seem to be acting 
antagonistically, preventing each other from damaging the telomere. Strangely, TRF2-dependent 
loss of telomeres, caused by TRF2 overexpression is dependent on XPF-ERCC1 (Munoz et al., 
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2005). What is even more perplexing is that this action requires the physical presence of XPF-
ERCC1, but not its nuclease activity (Wu et al., 2007). Also, overexpression of wild-type but not 
nuclease-dead XPF reduces the telomere binding of TRF2. Apparently, XPF-ERCC1 acts on the 
telomere through two distinct mechanisms, a nuclease-dependent mechanism that affects TRF2 
binding, and a n uclease-independent mechanism that limits telomere length (Wu et al., 2008). 
XPF-ERCC1 interacts with TRF1 in a very similar way and contributes to telomere shortening 
and end-fusions in the absence of TRF1 (Munoz et al., 2009b). A similar mechanism exists in A. 
thaliana, where XPF-ERCC1 prevents recombination of telomeres with interstitial telomeric 
repeats (Vannier et al., 2009). 
1.2.6 Repair of Topoisomerase 1 Lesions 
Progression of replication forks along DNA creates superhelical strain on t he unreplicated 
duplex. Topoisomerase I (Top1) releases this supercoiling by transiently cutting one strand of the 
duplex and forming a protein-DNA complex with that strand, allowing it to unwind in an ATP 
dependent mechanism (Champoux, 2001). When a replication fork collides with a Top1-DNA 
intermediate, it is  blocked, leading to a DSB (Hsiang et al., 1989). Top1 poisons such as 
camptothecin cause the Top1 protein to remain attached to the 3’ end of the unreplicated DNA 
rendering it inaccessible to repair. Tdp1 removes the Top1 molecule and creates a 3’ phosphate 
(Pouliot et al., 1999). In S. cerevisiae this substrate is further processed by the activities of Tpp1, 
Apn1 and Apn2 to convert it from a repair-blocking lesion to a 3’ hydroxyl group amenable to 
repair (Vance and Wilson, 2001). Although the yeast RAD1 and RAD10 mutants are not sensitive 
to Top1 poisons such as camptothecin, Rad10-Rad1 was found to function in a backup pathway 
for repair of Top1 lesions (Liu et al., 2002; Vance and Wilson, 2002). In the absence of Tdp1, 
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Rad10-Rad1 likely incises a 3’ single stranded flap, removing an oligonucleotide containing the 
Top1-DNA intermediate and allowing for a Rad52-dependent homologous recombination to 
repair the fork (Vance and Wilson, 2002). 
1.2.7 Repair of Abasic Sites 
Apurinic/apyrimidinic (AP) sites are produced as a result of depurination or depyrimidination of 
DNA due to spontaneous hydrolysis of the bond between the base and the DNA backbone. In a 
mammalian cell, over a span of 24 hour s, approximately 10,000 pur ines (Lindahl, 1979) and 
about 500 pyrimidines (Lindahl and Karlstrom, 1973) are lost by this process. AP sites are also 
produced by DNA glycosylases as intermediates of base excision repair (BER) (Duncan et al., 
1976; Lindahl, 1976). In S. cerevisiae removal of misincorporated uracil by uracil DNA 
glycosylase appears to be the major endogenous contributor towards AP sites (Guillet and 
Boiteux, 2003). S. cerevisiae mutants defective in both yeast AP endonucleases are viable, but 
triple mutants apn1 apn2 rad1 and apn1 apn2 rad10 are not viable, suggesting that Rad10-Rad1 
functions in a backup pathway of AP site repair (Guillet and Boiteux, 2002). Although NER 
plays a role in removal of AP sites (Swanson et al., 1999; Torres-Ramos et al., 2000) this 
mechanism seems to be independent of NER, as evident from the viability of apn1 apn2 rad14 
strains (Guillet and Boiteux, 2002). In this case, the genetic evidence suggests that similar to the 
Top1 lesion repair, Rad10-Rad1 works by removing the 3’ flap resulting from the spontaneous 
hydrolysis of the abasic site (Boiteux and Guillet, 2004). Similarly, in mammals, the abasic sites 
produced by activation-induced cytidine deaminase (AID) during class-switch recombination in 
B-cells are repaired by XPF-ERCC1 (Schrader et al., 2004). 
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1.3 PHYSIOLOGOCAL FUNCTIONS OF XPF-ERCC1 
1.3.1 Human diseases associated with defects in XPF-ERCC1 
The severity and manifestation of XPF-ERCC1 deficiency in humans varies significantly. 
Interpretation of the phenotype is complicated by the involvement of XPF-ERCC1 in multiple 
genome maintenance mechanisms. 
1.3.1.1 Xeroderma pigmentosum 
Xeroderma pigmentosum (XP) was the first hereditary condition to be associated with a defect in 
the repair of UV-induced DNA damage (J.E. Cleaver, Nature 1968). XP is an autosomal 
recessive syndrome characterized by sun sensitivity with a 2000-fold increase in skin cancers 
over sun-exposed areas, which include basal cell carcinoma, squamous cell carcinoma, malignant 
melanoma, keratoacanthoma, fibrosarcoma, and angioma (Kraemer et al., 1987). There is also 
evidence for increased incidence of sarcomas. Patients with mutations affecting both global and 
transcription-coupled NER present with progressive neurodegeneration, probably due to 
accumulation of damage in transcribed genes (Brooks, 2008). The severity and age of 
presentation varies widely amongst patients, depending on the mutation and the protein affected. 
Using somatic cell hybridization, the eight complementation groups of XP from XP-A through G 
and the variant form, XP-V were identified (de Weerd-Kastelein et al., 1974; Keijzer et al., 1979; 
Kraemer et al., 1975; Lehmann et al., 1975). XP-F was first reported in Japan and usually 
presents with a mild phenotype with late onset of disease (Matsumura et al., 1998), although in 
some cases a l ate onset neurodegenerative phenotype is seen. Mutant XPF protein may fail to 
localize to the nucleus, leading to mislocalization of both ERCC1 and XPF to the cytoplasm 
 20 
(Ahmad et al., 2010). This produces a phenotype disproportionate to the ability of these mutants 
to reconstitute NER in vitro. There is no known ERCC1 mutation that presents as XP. 
1.3.1.2  XFE progeroid syndrome 
Most patients with XPF mutations have a mild XP phenotype. However, a patient with XPF 
R153P mutation presented with a progeroid phenotype in addition to sun sensitivity 
(Niedernhofer et al., 2006). Arginine-153 lies in the helicase-like domain of XPF and is highly 
conserved. To date this remains the only published case of the XFE (XPF-ERCC1) progeroid 
syndrome. Remarkably, despite photosensitivity and abnormal skin pigmentation, there was no 
evidence of skin cancer. There was evidence of growth retardation, including short stature, 
microcephaly and developmental delay. Further investigations showed an array of aging-related 
degenerative changes. Although the patient had a normal birth-weight, he was cachexic at 
presentation. His skin was dry and atrophic, and lacked subcutaneous fat. He had bird-like facies 
with prominent bones and an aged appearance. Neurodegeneration was evident from cerebral 
atrophy, tremors and ataxia with loss of coordination, impaired hearing and vision loss with optic 
atrophy. Scoliosis, muscle wasting and hypotonia suggested musculoskeletal degeneration. In 
addition, there was hypertension, renal and hepatic insufficiency, and anemia, which 
distinguished this case from the DeSanctis-Cacchione and Cockayne syndromes. The patient 
died at the age of 16 years from multi-organ failure following pneumonia. These symptoms are 
remarkably similar to the presentation of the Ercc1-/- (Niedernhofer et al., 2006) and the Xpf -/- 
(Tian et al., 2004) mouse models which also show an accelerated aging phenotype. 
 Fibroblasts obtained from a skin biopsy of the patient showed markedly decreased UV 
induced unscheduled DNA synthesis (UV-UDS) (~5% of wild-type). They were more sensitive 
to UV than XP-F patient fibroblasts, though less so than XP-A fibroblasts. They were exquisitely 
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hypersensitive to the crosslinking agent MMC, indicating that a d eficiency in ICL repair may 
have a significant contribution to this phenotype. XPF has been shown to play an important role 
in mitosis by its suggested interaction with kinesin, KIF11 (Tan et al., 2012). Consequently, the 
abnormality in mitosis caused by the severe deficiency of XPF in the XFE patient might be 
responsible for the accelerated aging phenotype observed. 
1.3.1.3 Cranio-occulo-facio-skeletal syndrome (COFS) 
The only known patient with an ERCC1 mutation was born with low birth-weight, microcephaly 
with premature closure of the fontanels, bilateral microphthalmia, blepharophimosis, high nasal 
bridge, short filtrum, micrognathia, low-set and posteriorly-rotated ears, arthrogryposis with 
rocker-bottom feet, flexion contractures of the hands, and bilateral congenital hip dislocation. 
Magnetic resonance imaging showed a s implified gyral pattern and cerebellar hypoplasia. This 
patient was diagnosed with COFS. Classic COFS is defined by microcephaly, hypotonia, 
microphthalmia, cataracts, blepharophimosis, large ear pinnae, prominent root of the nose, 
micrognathia, widely set nipples, camptodactyly, flexure contractures at the elbows and knees, 
generalized osteoporosis, dysplastic acetabula, coxa valga, rocker-bottom feet and failure to 
thrive (Pena and Shokeir, 1974). Previously, COFS has been diagnosed in patients with 
mutations of either CSB (Meira et al., 2000) or XPD (Graham et al., 2001). 
1.3.2 Mouse models of XPF-ERCC1 deficiency 
1.3.2.1 Ercc1-/- mouse 
Two groups independently made Ercc1-/- mice (McWhir et al., 1993a; Weeda et al., 1997a). In 
the first case, Ercc1 was targeted with a neo insert between exons 4 a nd 6 us ing an HPRT 
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minigene based system (Selfridge et al., 1992). In the second case, two mouse models were 
made, one with a neo insert in exon 7 (Ercc1-knockout mouse) and the other with a stop codon at 
position 292 of  ERCC1, producing a truncated version of the transcript (Ercc1*292 or Ercc17∆ 
allele, discussed further under Ercc1 hypomorphs). The Ercc1-knockout mice are born at sub-
Mendelian ratios due to an early embryonic lethality. All mutant mice are runted at birth and 
display shortened lifespan of about 3 - 4 weeks. The mutant mice show abnormalities of liver, 
with large polyploid nuclei. Mice die of hepatic failure and show increased p53 in liver, kidneys 
and brain (McWhir et al., 1993a). The primary MEFs isolated from these mice grow slower than 
their wild-type counterparts (Niedernhofer et al., 2006; Weeda et al., 1997a). These MEFs and 
mouse livers have elevated p21 levels, suggesting that they are undergoing senescent changes 
(Nunez et al., 2000; Weeda et al., 1997a). Also, as noted before, the Ercc1-/- mice have delayed 
cerebellar development (Jaspers et al., 2007). This phenotype is dramatically different from that 
of Xpa-/- mice, which are phenotypically nearly indistinguishable from the wild-type littermates 
(de Vries et al., 1995). Ercc1-/- mice have reduced hematopoietic reserve and demonstrate a 
multilineage cytopenia with reduction in stress induced erythropoiesis and fatty replacement of 
the bone marrow (Prasher et al., 2005). This resembles Fanconi anemia, a disease characterized 
by hypersensitivity to ICL repair (Parmar et al., 2009). This suggests that at least a part of the 
phenotype of Ercc1-/- mice is due to a deficiency in ICL repair. Additionally, these mice show 
neurodegenerative changes including dystonia and ataxia, musculoskeletal degeneration evident 
from sarcopenia and kyphosis and renal failure. Combined with the cellular senescence these 
findings suggest accelerated aging and led to the identification of anew human progeria caused 
by the reduced expression of XPF-ERCC1 (Niedernhofer et al., 2006). 
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1.3.2.2 Xpf m/m mouse 
Mutant XPF mice were generated by mimicking the XPF mutation in patient XP23OS (Tian et 
al., 2004). Mouse Xpf was mutated with a neo insert between exons 7 and 8 and a stop codon at 
position 445 (Tian et al., 2004). This mutation eliminated Xpf activity without affecting normal 
mouse development. In keeping with the obligate heterodimeric nature of ERCC1 and XPF, the 
mouse is a phenocopy of the Ercc1-/- mouse. The mice are runted, with enlarged and polyploid 
hepatocytes and die within 3 weeks of birth. Further analysis was not done. 
1.3.2.3 Ercc1 hypomorphs 
The Ercc1∆/∆ mice were generated by inserting a stop codon at position 292 of Ercc1 (Weeda et 
al., 1997a). This resulted in a truncated transcript and presumably a protein that is seven amino 
acids short at the C-terminus. The C-terminus of ERCC1 is indispensible for its function (Sijbers 
et al., 1996b) and so the truncation should significantly affect the function of XPF-ERCC1. In 
fact, the transcript from the ∆ allele is reduced to about 15% of the wild-type allele (Weeda et al., 
1997a). The Ercc1∆/∆ mice live for about 6 months from birth, a lifespan intermediate between 
the Ercc1-/- and wild-type mice. Aside from liver changes reminiscent of the knockout mice, they 
also display ferritin deposition in the spleens, thin skin lacking subcutaneous fat and renal 
tubular dilatation with abnormal nuclei and proteinuria indicative of renal insufficiency. Unlike 
the Ercc1-/- mice, TUNEL assay shows no evidence of increased apoptosis in tissues. The mice 
are infertile, but histologically both ovaries and testes appear normal. The hepatocellular 
functions observed in the Ercc1-/∆ mice mimic the phenotype observed in old wild-type mice 
(Gregg SQ., 2012). Ercc1-/∆ mice with LacZ transgene were analyzed by recovery of LacZ 
containing plasmid and isolating clones lacking LacZ expression. LacZ mutants were further 
analyzed to determine the type of mutations leading to inactivation of the gene. This LacZ 
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mutation analysis shows a rapid accumulation of mutations in the livers of these animals. 
Mutations included point mutations similar to the NER deficient Xpa-/- mice and deletions and 
translocations, probably stemming from the loss of ICL repair and DSB repair related functions 
of XPF-ERCC1 (Dolle et al., 2006). 
1.3.2.4 Ercc1 conditional mutants 
In order to correct the hepatic failure of Ercc1-/- mice, transgenic Ercc1 was expressed with a 
liver specific transthyretin promoter (Selfridge et al., 2001). This prevented the polyploidy of 
hepatocytes and liver failure, and increased lifespan up t o 61 – 88 days, but the mice died of 
renal failure with a similar polyploid phenotype in the proximal tubule cells. These mice also had 
elevated plasma lactate levels, pointing towards possible mitochondrial consequences of ERCC1 
deficiency. Neurodegeneration was evident from lack of coordination, ataxia and loss of visual 
acuity, but no histological changes in the brain were detected (Lawrence et al., 2008). 
 Ercc1-/- mice have an extremely short lifespan, making it d ifficult to study the UV 
sensitivity of their skin. To overcome this problem, mice were made with a floxed Ercc1 allele 
under bovine K5 promoter. These mice showed 20-fold increase in sensitivity to the short-term 
erythematous changes in epidermis with UV-B irradiation. They also displayed a rapid onset of 
tumors, mainly squamous cell carcinomas, which grew faster than those in wild-type animals 
(Doig et al., 2006). 
1.3.3 Altered expression of XPF-ERCC1 in cancers 
XPF-ERCC1 functions in major genome maintenance pathways including NER (Sijbers et al., 
1996a), ICL repair (De Silva et al., 2000), DSB repair (Murray et al., 1996; Murray and 
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Rosenberg, 1996) and telomere maintenance (Wu et al., 2008; Zhu et al., 2003). Various 
chemotherapeutic agents and radiotherapy kill cancer cells by damaging their DNA. Cisplatin, a 
common chemotherapeutic drug, induces cytotoxicity through DNA lesions that are cleared by 
the NER and ICL repair pathways. Being the only proteins to be essential to both pathways has 
made ERCC1 and XPF attractive biomarkers. If XPF-ERCC1 expression is variable in cancers, it 
may have a bearing on the growth characteristics of tumors, their response to various therapies 
and overall patient survival. This promise has led to extensive attempts at devising strategies to 
evaluate the effect of both ERCC1 and XPF, but mainly ERCC1, on t umor biology. These 
include studies of short nucleotide polymorphisms (SNP), mRNA levels, and 
Immunohistochemistry for protein levels. 
1.3.3.1 SNPs 
SNPs may affect protein expression or function based on t heir nature and location. A non-
conservative base substitution may change amino acid sequence, thereby directly affecting 
protein function. A conservative substitution may alter rate of mRNA translation by altering the 
choice of tRNA or effect on pr otein folding due to slow translation. Polymorphisms near 
promoters or introns can affect protein expression through transcription. There is however no 
direct evidence that, polymorphisms of ERCC1 or XPF can affect protein levels. A survey of 
polymorphisms in NER genes found that ERCC1 contains at least seven SNPs and XPF has six. 
ERCC1 contains no SNPs with amino acid substitutions, while XPF has one that leads to P379S 
substitution (Shen et al., 1998). A commonly studied silent polymorphism of ERCC1, codon 
118(C/T) changes a commonly used codon AAC to AAT, one that is infrequently used. This can 
potentially reduce the translation of the mRNA leading to reduced protein levels (Yu et al., 
1997). Once again, there is no evidence of a difference in protein or mRNA levels caused by this 
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SNP. Despite this, ERCC1 SNPs have shown correlation with outcomes of many different types 
of tumors. Of these, non-small cell lung carcinoma (NSCLC) has been the most extensively 
studied. Numerous studies have found correlation between risk, survival and treatment response 
in NSCLC with either or both of codon 118 and C8092A polymorphisms of ERCC1 (Isla et al., 
2004; Kalikaki et al., 2009; Park et al., 2006; Su et al., 2007; Takenaka et al., 2009; Zienolddiny 
et al., 2006). On the other hand, a large meta-analysis of multiple studies failed to find any 
correlation (Kiyohara and Yoshimasu, 2007). Several other cancers, including esophageal cancer 
(Doecke et al., 2008; Pan et al., 2009), ovarian cancer (Steffensen et al., 2008), squamous cell 
carcinoma of head and neck (Quintela-Fandino et al., 2006), basal cell carcinoma (Yin et al., 
2003) and bladder cancer (Garcia-Closas et al., 2006) have shown correlation of outcome or 
chemotherapy resistance to ERCC1 genotypes. However, studies involving pancreatic 
adenocarcinoma (McWilliams et al., 2008), carcinoma of prostate (Hooker et al., 2008), 
colorectal carcinoma (Hansen et al., 2008; Monzo et al., 2007), glioma (Chen et al., 2007), renal 
cell carcinoma (Hirata et al., 2006) and cervical carcinoma (Chung et al., 2006) did not find any 
link to ERCC1 SNPs. 
1.3.3.2 mRNA 
Interest in ERCC1 mRNA levels stemmed from the thought that these may be representative of 
the functional ERCC1 in cells. There is no evidence to suggest that ERCC1 is regulated at the 
level of transcription. In fact, mRNA levels of ERCC1 and XPF have absolutely no correlation to 
their respective protein levels (Deloia et al., 2012). All the same, multiple studies have suggested 
a correlation between the level of ERCC1 mRNA in tumors or tumor cell lines from gastric, 
ovarian, colorectal, esophageal and non-small cell lung cancer and resistance to cisplatin (Altaha 
et al., 2004; Dabholkar et al., 1992; Dabholkar et al., 1994; Joshi et al., 2005; Langer et al., 2005; 
 27 
Lord et al., 2002; Metzger et al., 1998; Reed et al., 2000; Rosell et al., 2002; Shirota et al., 2001; 
Warnecke-Eberz et al., 2004). However, the mechanism behind the predictive correlation 
remains undefined and may not be dependent on t he DNA repair functions of the proteins. 
Similar to SNPs, mRNA levels of ERCC1 are the most extensively studied in Non-small cell 
lung cancer (NSCLC). Based on f indings that patients with low ERCC1 expression in tumors 
respond better to cisplatin-based therapy (Lord et al., 2002), a cl inical trial was carried out. 
Patients who received tailored chemotherapy based on the ERCC1 expression performed better 
than those who received a standard control therapy with docetaxel and cisplatin (Cobo et al., 
2007). Patients with low ERCC1 levels performed somewhat better than those with high ERCC1 
levels and this is further certified by a recent study that identified that down regulation of XPF-
ERCC1 by RNAi in cell lines from NSCLC, breast and ovarian cancer patients led to a 
significantly increased cisplatin cytotoxicity (Arora et al., 2010). 
1.3.3.3 Protein levels in tumors 
Measurement of XPF-ERCC1 levels by IHC of paraffin-embedded tumor samples is an attractive 
biomarker to study the effect of the protein levels on tumor response to various chemotherapeutic 
agents and patient survival. This is due to the relative ease of availability of samples, relative 
stability of proteins over RNA and advantage of processing large sets of samples economically 
over a short period of time. ERCC1 protein levels have been implicated in conferring resistance 
to a wide range of cancer types. Amongst the various tumors that have been under investigation, 
melanomas (Li and Melton, 2012), NSCLC (Niedernhofer et al., 2007), esophageal cancer (Kim 
et al., 2008b), ovarian cancer (Steffensen et al., 2008), testicular cancer (Welsh et al., 2004), 
breast cancer (Chen et al., 2012), and HNSCC (Jun et al., 2008) have shown a significant 
correlation between chemotherapy resistance and ERCC1. These studies demonstrate the utility 
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of ERCC1 as a predictive marker in a wide variety of tumors. NSCLC remains the most studied 
tumor type (Hwang et al., 2008; Lee et al., 2008; Olaussen et al., 2006a; Zheng et al., 2007). 
However, there are mixed results as to whether ERCC1 levels are predictive of resistance 
depending on t he type of therapy administered. High ERCC1 expression correlated with poor 
response to cisplatin chemotherapy and poor survival outcome (Olaussen et al., 2006a). On the 
other hand, high ERCC1 was associated with better survival following surgery (Lee et al., 2008; 
Zheng et al., 2007). Unfortunately, the antibody (8F1) used in almost all studies is not specific 
for ERCC1 (Niedernhofer et al., 2007). It recognizes human ERCC1, but also a second unknown 
nuclear antigen, and is unable to discriminate between cells expressing XPF-ERCC1 and cells 
that do not (Niedernhofer et al., 2007). We rigorously tested antibodies against ERCC1 and XPF 
and found ones that are best suited for clinical measurement of XPF-ERCC1 (Bhagwat et al., 
2009c). Our results show that ERCC1 and XPF levels in lung tumors vary considerably between 
patients, but are closely correlated to each other and either of these proteins can be used as a 
surrogate biomarker. The use of XPF as a biomarker to predict patient outcome has been largely 
unexplored with the exception of a report that suggests that low expression of XPF is a 
significant risk factor for HNSCC as measured by the reverse-protein microarray assay  (Wei et 
al., 2005). This evidence is supported by reports that suggest a significant correlation between 
lower XPF protein expression and longer progression-free survival of HNSCC treated with DNA 
damaging agents and evidence of significantly higher XPF protein levels that were found in 
metastases of HNSCC as compared to primary cancer tissue (Koberle et al., 2010; Vaezi et al., 
2011). These studies highlight the influence of ERCC1 and XPF protein levels on cancer 
outcome, but more analysis is essential to clarify the utility of ERCC1 and XPF as cancer 
biomarkers. 
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1.4 SIGNIFICANCE 
In summary, XPF-ERCC1 is a s tructure specific endonuclease that is important for multiple 
genome maintenance mechanisms which include nucleotide excision repair, interstrand crosslink 
repair, and double strand break repair. The proteins are evolutionarily conserved in eukaryotes 
highlighting the biological importance of the proteins and they function as heterodimers that are 
unstable is the absence of one another. In humans, deficiency of XPF-ERCC1 leads to the 
development of the cancer prone syndrome Xeroderma pigmentosum and also the progeroid 
syndrome, XFE, are characterized by accelerated aging. It has been well established that XP that 
results from a deficiency in XPF is due to its inability to efficiently participate in NER. However, 
the specific repair pathway of XPF-ERCC1 and the kind of lesions that lead to the accelerated 
aging phenotype observed in both mice and humans deficient in XPF-ERCC1 remain unknown.  
XPF-ERCC1 is involved in the repair of bulky monoadducts and intrastrand crosslinks by 
the nucleotide excision repair pathway and are also involved in the repair of interstrand 
crosslinks through the ICL repair pathway. These lesions collectively constitute the damage 
induced by chemotherapeutic drugs and the involvement of XPF-ERCC1 in repair of all of these 
lesions via multiple DNA repair mechanism has implicated them being used as biomarkers of 
chemoresistance. Even though the DNA repair functions of XPF-ERCC1 have been associated 
with chemoresistance, the exact mechanism remains unclear. In addition, since chemotherapeutic 
agents such as platinum drugs exert their cytotoxicity primarily through the formation of 
interstrand crosslinks, identifying ways to weaken the crosslink repair capacity of the cancer 
cells will help overcome chemoresistance.  
 
 30 
Having reviewed the major functions of XPF-ERCC1 in DNA repair and their biological 
importance in preventing a wide range of disorders in the first chapter, we continue the journey 
and take another step forward in an attempt to provide more scientific insight into the 
mechanisms underlying the contribution of XPF-ERCC1 to cancer and aging.  
Chapter 2 a ims to collectively probe the importance of four DNA binding domains of 
XPF-ERCC1 located in the c-terminus of both proteins in NER and ICL repair. Analysis of cells 
harboring mutations in the DNA binding domains of XPF-ERCC1, the nuclease domain of XPF 
and the central domain of ERCC1, by testing their ability to incise model substrates and also 
comparing their sensitivities to different forms of DNA insult will help categorize the domains of 
both XPF and ERCC1 by their importance in DNA repair functions. 
Chapter 3 of the dissertation document aims to test the hypothesis that the roles of XPF-
ERCC1 in repair can be uncoupled by the disruption of specific protein:protein interactions that 
recruit XPF-ERCC1 to different DNA repair pathways. The c-terminus of XPF-ERCC1, the 
central domain of ERCC1, and the nuclease domain of XPF are well characterized. However, not 
much is known about the n-terminus of XPF and conserved residues in this region of XPF have 
been implicated in being important to interstrand crosslink repair. To explore the n-terminus and 
determine regions of the XPF gene that might be selectively essential for ICL repair but not 
NER, mutations in different conserved residues of the n-terminus of XPF will be targeted.  The 
XPF mutants include an n-terminal deletion, a hemagglutin (HA) tag in the n-terminus, the 
G314E mutant that is known to disrupt the interaction between XPF and SLX4 in Drosophila, 
and the WLF-A mutant that harbors mutations in 3 conserved residues that lie in the n-terminus 
of XPF. The impact of each of these mutations on the protein function is estimated by observing 
the sensitivities of each mutant cell line to different forms of DNA insult such as UV, Mitomycin 
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C (MMC) and ionizing radiation (IR). In the future, this mutation that renders cells selectively 
sensitive to crosslink agents would in invaluable in understanding the link between XPF-ERCC1, 
cancer and aging. With respect to chemoresistance, this region of the XPF gene can be utilized to 
generate small molecule inhibitors that can sensitize patients who are resistant to chemotherapy. 
In addition, studying the phenotype of a mouse model harboring this mutant form of the XPF 
protein, that is deficient in ICL repair while still being able to carry out NER, will help 
understand whether the accelerated aging that is observed in both mice and humans deficient in 
XPF-ERCC1 is due to the accumulation of ICLs in the organism. 
Chapter 4 of  the dissertation aims to develop and characterize novel monoclonal 
antibodies against purified XPF-ERCC1 in complex that can be used to establish a conclusive 
association between the proteins levels and chemosensitivity by immunohistochemical analysis. 
Efforts towards breaching chemoresistance have been confined to utilizing the SNP data, mRNA 
levels and protein levels of XPF-ERCC1 as biomarkers. In the last few decades, there have been 
over 1000 published papers looking at the association between XPF-ERCC1 and the sensitivity 
of patients to chemotherapeutic regimes. However, the data does not conclusively establish an 
association between XPF-ERCC1 protein or mRNA levels and chemoresistance. The major 
cause for this is the lack of mechanistic understanding and also the deficit of proper scientific 
tools for analysis. The identification of good antibodies with good specificity and sensitivity will 
take us a step closer in predicting a patient response to a chemotherapeutic regime. The second 
and extended implication of the study is in identifying an antibody that will have antigen 
specificity to both XPF and ERCC1 thereby having the inherent potential to bind and destabilize 
the proteins. An antibody of this nature could potentially be used for adjuvant antibody therapy. 
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Finally, in Chapter 5, we aim to develop a method to measure the NER capacity of suspension 
cells.  M easurement of repair has been mainly focused on determining the activity of one or 
more proteins in a repair pathway. While this approach shows promise, the activity of one or 
more proteins cannot be trusted to represent the overall repair capacity of a cell considering each 
pathway involves the coordinated activity of more than 30 proteins. Hence, the development of 
assays that can measure overall repair representative of all the proteins in a pathway will 
overcome this shortcoming. An assay that can measure the NER capacity of suspension cells 
such as blood cells will help tremendously in predicting an individual’s predisposition to 
disorders such as XP very easily thereby helping patients and their families incorporate 
protective measures as early as possible. Measuring the repair capacity of lymphocytes from 
cancer patients using the method developed will help prospectively predict the extent of side 
effects that may be expected when a patient is exposed to a chemotherapeutic regime. In 
addition, the assay thus developed can be used to determine whether DNA repair capacity is 
heritable and also to determine whether DNA repair capacity if predictive of extended lifespan. 
A mechanistic understanding of aging is expected to help pave the way toward delaying the 
degenerative changes associated with age thereby improving quality of life and alleviating the 
age related financial burden on health care. 
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2.0  MULTIPLE DNA BINDING DOMAINS MEDIATE THE FUNCTION OF XPF-
ERCC1 IN NUCLEOTIDE EXCISION REPAIR 
This chapter was published in the Journal of Biological Chemistry. My contribution to this 
chapter is included as figure 7.  
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DNA binding domains mediate the function of XPF-ERCC1 in nucleotide excision repair. J Biol 
Chem. [PMID: 22547097] 
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2.1 INTRODUCTION 
Structure-specific endonucleases are widespread enzymes that incise DNA as components of 
most DNA repair and recombination pathways. The activity of these enzymes needs to be tightly 
regulated since they might otherwise inadvertently fragment DNA (Fagbemi et al., 2011). One of 
the most important pathways depending on t he action of endonucleases is nucleotide excision 
repair (NER), which addresses lesions induced by UV light, environmental mutagens and certain 
cancer chemotherapeutic agents. In NER, an oligonucleotide of 24-32 nucleotides in length 
containing the damage is removed and the original DNA sequence restored using the non-
damaged strand as a template (Gillet and Schärer, 2006). NER can be initiated in two ways: 
Transcription coupled NER (TC-NER) is triggered when RNA polymerase II is stalled by a 
bulky DNA lesion during transcription (Hanawalt and Spivak, 2008); Global genome NER (GG-
NER) occurs anywhere in the genome and is initiated by the damage sensor XPC-RAD23B, in 
some cases with the help of the UV-DDB-ubiquitin ligase complex (Min and Pavletich, 2007; 
Sugasawa et al., 1998; Sugasawa et al., 2005). Subsequently, TFIIH verifies the presence of the 
lesion and opens up the DNA helix, allowing the formation of a pre-incision complex containing 
the endonuclease XPG, the single stranded DNA binding protein RPA and the architectural 
protein XPA (Riedl et al., 2003; Tapias et al., 2004; Wakasugi and Sancar, 1998). Finally, the 
second endonuclease, XPF-ERCC1 is recruited to the pre-incision complex (Tsodikov et al., 
2007; Volker et al., 2001) and incises the DNA 5’ to the lesion, triggering initiation of repair 
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synthesis, incision 3’ to the lesion by XPG, completion of repair synthesis and ligation (Moser et 
al., 2007; Ogi et al., 2010; Staresincic et al., 2009b). 
The two structure-specific endonucleases involved in NER, XPG and XPF-ERCC1, are 
multifunctional proteins, with diverse roles in NER and other pathways. XPG is a latent 
endonuclease, fulfilling first a structural and subsequently a catalytic role in NER. It has 
additional roles in transcription in conjunction with TFIIH (Fagbemi et al., 2011). The roles of 
XPG outside of NER are manifest in the severe phenotypes of many XP-G patients (Lehmann, 
2003; Raschle et al., 2008). By contrast, most of the known XP-F patients present with a mild 
XP phenotype and have significant residual NER activity due to the presence of low levels of 
active XPF protein (Ahmad et al., 2010). However, a subset of patients and mice with 
deficiencies in XPF or ERCC1 are much more severely affected and suffer symptoms not caused 
by NER deficiency alone including developmental abnormalities, premature aging and early 
death, (Jaspers et al., 2007; McWhir et al., 1993b; Niedernhofer et al., 2006; Tian et al., 2004; 
Weeda et al., 1997b). It is believed that these additional symptoms are due to the roles of XPF-
ERCC1 in interstrand crosslink (ICL) repair, homologous recombination and possibly telomere 
maintenance (Ahmad et al., 2008; Bhagwat et al., 2009a; Gregg et al., 2011; Niedernhofer et al., 
2004; Zhu et al., 2003). 
XPF-ERCC1 forms an obligate heterodimer and contains a number of distinct domains 
that contribute to various aspects of its function (Figure 2-1). Both proteins contain helix-hairpin-
helix (HhH) domains at their C-termini that are required for heterodimer formation (de Laat et 
al., 1998d; Tsodikov et al., 2005). The active site with the conserved nuclease motif is located 
adjacent to the HhH domain in XPF (Enzlin and Schärer, 2002). The central domain of ERCC1 
is structurally homologous to the XPF nuclease domain (Nishino et al., 2003; Tsodikov et al., 
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2005), however, instead of the active site rich in acidic residues, it contains a groove lined with 
basic and aromatic residues that interact with the XPA protein, connecting XPF-ERCC1 to the 
NER machinery (Li et al., 1995; Orelli et al., 2010b; Tripsianes et al., 2007; Tsodikov et al., 
2007). XPF, the larger of the two proteins, contains an N-terminal SF2-helicase like domain 
(HLD), which has lost the ability to bind ATP and to unwind duplex DNA (Sgouros et al., 1999). 
This domain has been implicated in DNA binding and protein-protein interactions, possibly 
mediating an interaction with SLX4 in ICL repair and other pathways (Andersen et al., 2009; 
Fekairi et al., 2009; Munoz et al., 2009a; Svendsen et al., 2009). 
Interestingly, these five domains have been implicated in DNA binding, but evidence to 
date has been based on analysis of individual domains or on s tudies of archaeal XPF proteins 
(Newman et al., 2005; Nishino et al., 2005a; Nishino et al., 2005b; Tripsianes et al., 2005; 
Tripsianes et al., 2007; Tsodikov et al., 2005; Tsodikov et al., 2007). We investigated the role of 
four C-terminal DNA binding domains by mutational analysis in the context of full-length XPF-
ERCC1. Our studies show that mutations in any single domain are insufficient to abolish NER in 
vitro and in vivo. Instead, we report that mutations in multiple domains are necessary to disrupt 
NER and that there is a hierarchy of importance of the individual domains. Our studies are 
consistent with the notion that multiple weak interactions among proteins and DNA substrates 
drive progress through the NER reaction (Gillet and Schärer, 2006; Stauffer and Chazin, 2004). 
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2.2 RESULTS 
2.2.1 Generation of XPF-ERCC1 with mutations in four DNA binding domains 
We used information from structural and functional studies to design XPF-ERCC1 proteins with 
mutations in four DNA binding domains in the C-terminal halves of the two proteins. Previous 
studies have shown that a protein containing only the two HhH, XPF nuclease and ERCC1 
central domains can still cleave ss/dsDNA junctions, albeit with much reduced efficiency 
(Tsodikov et al., 2005). HhH domains have been shown to contribute to DNA binding in XPF-
ERCC1 (Tripsianes et al., 2005; Tsodikov et al., 2005) and other proteins (Doherty et al., 1996). 
Based on structural studies, we chose two basic residues in each HhH domain, K247 and K281 in 
ERCC1, and K850 and R853 in XPF, which have been suggested to play a role in DNA binding 
(Figure 2-1) (Tripsianes et al., 2005; Tsodikov et al., 2005). NMR studies revealed that the HhH 
domain in ERCC1 appears to be more important for DNA binding (Tripsianes et al., 2005). We 
expected the nuclease active site in XPF to interact with DNA directly and chose to include R678 
, as we have previously shown that mutating this residue to alanine resulted in a 
protein with only marginal activity on m odel substrate, while being active in NER in the 
presence of the other NER proteins. We suggest that this residue contributes to positioning of the 
active site on the substrate rather than the catalytic mechanism (Enzlin and Schärer, 2002; 
Staresincic et al., 2009b). Although the central domain of ERCC1 can bind DNA (Tripsianes et 
al., 2007; Tsodikov et al., 2005), its main function is likely to interact with XPA. We included 
the N110A mutant, which has a weakened interaction with XPA (Figure 2-1B) (Tripsianes et al., 
2007; Tsodikov et al., 2007), to determine to what extent defects in the interaction with XPA 
synergize with defects in DNA binding. We mutated all of these residues to alanine and 
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combined the different mutations to study how these four domains contribute to the DNA 
binding and NER activity of XPF-ERCC1. 
 
Figure 2-1 Structure of the XPF-ERCC1 HhH domains and scheme of the DNA binding domains in 
XPF-ERCC1 
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A. The HhH domains of ERCC1 (gray) and XPF (yellow) contribute to dimerization. The 
residues shown in atom color are believed to contribute to DNA binding and were mutated in our 
study. The figure is adapted from (Tsodikov et al., 2005). B. Five domains of XPF-ERCC1 that 
may contribute to DNA binding are shown. Residues in the central and HhH domains of ERCC1 
and in the nuclease and HhH domains of XPF mutated to alanine in our study are highlighted in 
red. 
 
2.2.2 Mutations in the HhH domain of ERCC1 and the nuclease domain of XPF lead to 
the loss of incision activity on stem loop substrates 
Heterodimeric XPF-ERCC1 containing mutations in the HhH, nuclease and central domains 
were expressed in insect cells and purified using our established protocol (Enzlin and Schärer, 
2002). All the proteins, including those containing mutations in two domains formed 
heterodimers similar to the wild-type protein. Only fractions eluting at 60-70ml, representing 
heterodimeric XPF-ERCC1 were collected during the gel filtration chromatography step (Figure 
2-9A). We have previously shown that these fractions contain the active protein (30). 
Furthermore, the CD spectrum of selected mutants were identical to that of wild-type XPF-
ERCC1 suggesting that they were properly folded (Figure 2-8B). The endonuclease activity of 
XPF-ERCC1 in wild-type and mutant form was tested on a 3’ fluorescently labeled stem-loop 
model substrate, in which the protein cut at the ss and dsDNA junction in the presence of Mg2+ 
(de Laat et al., 1998b). XPF-ERCC1 in wild-type form and with mutations in the HhH domain of 
XPF or the central domain of ERCC1, cleaved the stem-loop substrate with similar efficiencies 
as the wild-type protein in a concentration-dependent manner (Figure 2-2). By contrast, no such 
incision products were observed for proteins containing mutations in the HhH domain of ERCC1 
(Figure 2-2) , ERCC1K247A/K281A, lanes 4-5) or in the nuclease domain of XPF (Figure 2-2), 
XPFR678A, lanes 4-5). From these results we conclude that the HhH domain of ERCC1 and the 
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nuclease domain of XPF are more important than the ERCC1 central and XPF HhH domains in 
mediating nuclease activity. 
 
Figure 2-2 Mutations in the HhH domain of ERCC1 and the nuclease domain of XPF impact 
nuclease activity on a stem-loop substrate. 
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XPF-ERCC1 in wild-type form or with mutations in ERCC1 (A.), XPF or both (B.) were 
incubated with 3’-Cy5 labeled stem-loop DNA substrate (6.7 nM) at 37 °C for 30 min, and 
products were visualized on 12%  denaturing polyacrylamide gels. Concentrations of XPF-
ERCC1: lanes 1: no protein; Lanes 2, 4, 6, 8 and 10, 12 and 14: 3.3 nM; Lanes 3, 5, 7, 9 and 11: 
26.7 nM. The position of the substrate and product are indicated on the left side of the gel. 
2.2.3 The HhH domain of ERCC1 is a key contributor for DNA binding affinity 
We wanted to gain insight into whether the reduced nuclease activity caused by mutations in the 
ERCC1 HhH and XPF nuclease domains correlated with reduced DNA binding activity. We 
used fluorescence anisotropy to measure the binding affinity of XPF-ERCC1 to model DNA 
substrates. We titrated 3’ labeled splayed arm, stem loop or duplex DNA substrates with wild-
type XPF-ERCC1 and measured the increase in anisotropy as a function of the protein 
concentration. Surprisingly, XPF-ERCC1 bound dsDNA with similar affinity as the splayed arm 
or stem-loop substrates  (data not shown), although XPF-ERCC1 did not incise dsDNA (de Laat 
et al., 1998b). However, addition of a tenfold excess of non-labeled dsDNA abolished the 
binding of XPF-ERCC1 to dsDNA, but not to the splayed arm and stem loop substrates, 
confirming that XPF-ERCC1 specifically bound ss/dsDNA junctions. 
 To determine the effect of mutations in the four domains on DNA binding quantitatively, 
3’-FAM-labeled spayed arm substrates were incubated with increasing amounts of protein in the 
presence of a tenfold excess of non-labeled dsDNA competitor. The anisotropy binding curves 
for the WT, XPFR678A, ERCC1N110A and XPFK850A/K853A proteins displayed a similar shape, while 
the anisotropy signal of ERCC1K247A/K281A was about 40% lower, suggesting that the architecture 
of this protein-DNA complex was different from that of the wild-type protein (Figure 2-3). 
Quantification of the data revealed that the ERCC1K247A/K281A also displayed the lowest binding 
affinity for the splayed arm substrate (Kd = 219 ± 9 nM), about two fold lower than the WT, 
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XPFR678A and ERCC1N110A proteins. The affinity of XPFK850A/K853A was about 1.6 fold lower than 
that of the wild-type protein. The results suggest that the HhH domains of both ERCC1 and XPF 
contribute to substrate binding by XPF-ERCC1, with a more prominent contribution from the 
ERCC1 HhH domain. Our data also show that mutations in a single domain alone are not 
sufficient to completely abolish DNA binding by XPF-ERCC1. 
 
Figure 2-3 Mutations in the HhH domain of ERCC1 lead to reduced DNA binding affinity. 
Fluorescein-labeled splayed arm DNA substrate (10nM) in the presence of 100 nM non-labeled 
competitor double strand DNA was titrated with wild-type and mutant XPF-ERCC1. DNA 
affinities were measured by fluorescence anisotropy. Error bars represent the standard deviation 
from a minimum of 4 experiments. 
 43 
2.2.4 Mutations in multiple DNA binding domains synergistically affect NER activity in 
vitro 
We then investigated the effect of these mutations on the overall NER reaction in the context of 
cell-free extracts. Plasmids containing site-specific bulky DNA substrates, either 1,3-intrastrand 
cisplatin crosslinks (cis-Pt) or acetylaminofluorene adducts of dG (dG-AAF), were incubated 
with XPF-deficient cell-free extract and wild-type or mutant XPF-ERCC1 to observe the ability 
of the protein to excise DNA in the context of other NER proteins (Dunand-Sauthier et al., 2005; 
Gillet et al., 2005; Shivji et al., 1999). XP-F extracts are devoid of ERCC1 and XPF and did not 
display any NER activity, but addition of wild-type XPF-ERCC1 restored NER activity as shown 
previously (Figure 2-4A/B, lanes 1-3) (Orelli et al., 2010b; Staresincic et al., 2009b). Mutations 
in the HhH domain of ERCC1 (ERCC1K247A/K281A) led to a mild reduction in NER activity, at 
least on the cisplatin substrates, while the analogous mutation in XPF (XPFK850A/R853A) had no 
effect (Figure2-4A/B, lanes 4-5, and 12-13). Therefore, a defect in the intrinsic DNA binding 
activity can be overcome at least partially in the context of the full NER complex. XPFR678A was 
similarly active in NER, although with a slightly shifted incision pattern (Figure2-4, compare 
lanes 10-11 to lanes 2-3). This suggests that R678 contributes to the proper positioning of active 
site residues to carry out the incision. As observed previously, ERCC1N110A displayed reduced 
NER activity, due to a weakened interaction with XPA (Figure 4A/B, lanes 6-7 (Orelli et al., 
2010b). 
 Since mutations in the individual domains led to only partial inhibition of NER activity, 
we tested if a combination of multiple mutations would lead to a more severe defect. We found 
that, in all cases, a combination of mutations in multiple domains led to reduced NER activity 
compared to the respective mutations in any single domain. Combining the ERCC1K247A/K281A 
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mutation with ERCC1N110A (Figure 2-4A, lanes 8-9), XPFK850A/R853A (Figure2-4A, lanes 16-17) 
or XPFR678A (Figure2-4A, lanes 18-19) led to a loss of detectable NER activity on the cis-Pt 
substrate, while some activity was preserved for the dG-AAF substrate for the combination of 
ERCC1K247A/K281A with ERCC1N110A (Figure 2-4B, lanes 8-9) and XPFK850A/R853A (Figure 2-4B, 
lanes 16-17). Similarly, a combination of XPFR678A with XPFK850A/R853A (Figure 2-4A/B, lanes 
14-15) or ERCC1N110A (Figure 2-4A/B, lanes 20-21) led to decreased NER activity with both the 
cis-Pt and dG-AAF substrates. These studies show that combined mutations in multiple DNA 
binding domains of XPF-ERCC1 synergistically affected NER activity and that many domains 
simultaneously contributed to the DNA binding and cleavage activity of XPF-ERCC1. 
Interestingly, the reactions of cis-Pt substrates were generally more severely affected than those 
of the dG-AAF substrates. This could be due to differences in the structure of the substrates in 
the NER complex and/or because dG-AAF were more efficiently processed by NER under our 
reaction conditions. 
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Figure 2-4 Mutations in multiple domains are needed to affect NER in vitro. 
Plasmids containing site-specific cis-Pt (A.) or dG-AAF (B.) lesions were incubated with XPF-
deficient cell extracts and recombinant purified XPF-ERCC1 in wild-type or mutant form. The 
excised 25-32mer oligonucleotide was annealed to a complementary strand with a 4G overhang 
followed by a f ill-in reaction with 32P-dCTP. Products were analyzed on 14%  denaturing 
polyacrylamide gels and visualized by phosphorimaging. XPF-ERCC1 concentrations: lane 1: no 
protein; even lanes: 5 nM; odd lanes except lane 1: 40 nM. An asterisk denotes the unique band 
observed with XPFR678A. 
2.2.5 XPF-ERCC1 with impaired DNA binding ability associates with NER complexes in 
cells 
We wished to define how the DNA binding mutations of XPF-ERCC1 affected NER activity in 
vivo, by studying the recruitment of the protein to sites of UV damage and the repair kinetics of 
6-4 photoproducts ((6-4)PPs). ERCC1-deficient UV20 and XPF-deficient XP2YO cells were 
transduced with lentiviral vectors expressing wild-type or mutant ERCC1 and XPF proteins, 
respectively (Orelli et al., 2010b; Staresincic et al., 2009b). Western blot analysis of the 
transduced cells revealed that wild-type (ERCC1WT, XPFWT) and mutant proteins 
(ERCC1K247A/R281A, ERCC1N110A/K247A/K281A, XPFR678A, XPFK850A/R853A and XPFR678A/K850A/R853A) 
were expressed at or above endogenous level (Figure 2-9). As it has been shown that only about 
30% of the cellular XPF-ERCC1 is engaged in NER following UV irradiation (53), we believe 
that slight differences in expression levels do not  influence the outcome of the experiments 
described here. Cells were irradiated with UV light (254 nm) through a filter with 5 µm pores to 
generate sites of local UV damage in the cell nuclei. After incubation for 30 min following UV 
irradiation, cells were fixed and stained with antibodies to detect (6-4)PPs and XPF-ERCC1. As 
previously shown (Orelli et al., 2010b), around 90% of wild-type protein co-localized with (6-
4)PPs (Figure 2-5). Interestingly, similar amounts of co-localization were observed for the 
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proteins with mutations affecting DNA binding (ERCC1K247A/R281A, XPFR678A, XPFK850A/R853A 
and XPFR678A/K850A/R853A), indicating that the DNA binding activity of XPF-ERCC1 was not 
required for the stable association of XPF-ERCC1 with NER complexes. The only variant that 
showed decreased co-localization with (6-4)PPs was ERCC1N110A/K247A/K281A (Figure 2-5), but 
this was expected, as we have shown previously that the N110A mutation affected binding to 
XPA (Orelli et al., 2010b). 
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Figure 2-5 Mutations in DNA binding domains of XPF-ERCC1 do not affect the recruitment to sites 
of UV damage. 
ERCC1-deficient UV20 cells were transduced with wild-type or mutant ERCC1, and XPF-
deficient XP2YO with wild-type or mutant XPF. Cells were irradiated with UV light (254nm, 
120 J/m2 for UV20 cells; 150 J/m2 for XP2YO cells) through a polycarbonate filter with 5 µm 
pores and incubated at 37°C for 30 min. Cells were fixed and stained with antibodies against (6-
4)PPs (red), XPF-ERCC1 (green, using an anti-HA antibody in UV20 cells (A.), and an anti-
ERCC1 antibody in XP2YO cells (B.)). Nuclear DNA was visualized by DAPI staining. C. 
Graphical representation of the percentage of co-localization of XPF-ERCC1 with (6-4)PPs in 
UV20 cells. D. Graphical representation of the percentage of co-localization of XPF-ERCC1 
with (6-4)PPs in XP2YO cells. The quantification is based on a t least three independent 
experiments and error bars represent the standard deviation. 
2.2.6 The repair of (6-4)PPs is delayed by DNA binding mutations 
We next measured how the mutations in ERCC1 and XPF affected the rate of repair of UV 
lesions. Cells were incubated for various times after local UV irradiation and fixed. The 
percentage of cells containing (6-4)PPs was determined. 30 minutes after UV irradiation, about 
40% of all UV 20 cells contained sites of (6-4)PPs. At 24 h 17%  of the non-transduced UV20 
cells contained 6-4PPs, establishing the rate of removal rate in the absence of NER (Figure 
2-6A,C). In ERCC1WT-expressing cells, the damage was almost all gone at 2h and detectable at 
only marginal levels at later time points. The rate of repair was significantly reduced in 
ERCC1K247A/R281A-expressing cells with 24% and 18% of the cells containing (6-4)PPs at 2 h and 
4 h, respectively. Repair appeared to be mostly completed however at later time points (8 h, 24 
h), indicating that this mutation in the HhH domain of ERCC1 slowed down, but did not 
abrogate NER. Adding the XPA-interacting mutation N110A to K247A/K281A led to further 
delay in repair, although repair was still completed at the 24 h time point (Figure 2-6A,C). 
In the XP-F deficient XP2YO cells, significant level (~ 16%) of (6-4)PPs also persisted at 24 h, 
and the observed damage levels at 30min was slightly higher than in the UV20 cells. 
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Transduction of XPFWT restored the complete removal of (6-4)PPs and the repair rate in 
XPFK850A/R853A-expressing cells was only marginally slower than in wild-type cells. However, the 
damage removal was impaired in XPFR678A-expressing cells, and a combination of the R678A 
and K850A/R853A mutations led to a further reduction in the repair rate (Figure 2-6B,D). The 
cellular studies are thus consistent with the in vitro results showing that DNA binding mutations 
in the nuclease domain of XPF and the HhH domain of ERCC1 synergistically affected NER. 
 
Figure 2-6 Mutations in DNA binding domains of XPF-ERCC1 affect repair kinetics of (6-4)PPs in 
vivo. 
ERCC1-deficient UV20 cells were transduced with wild-type or mutant ERCC1 (A.), XPF-
deficient XP2YO cells with wild-type or mutant XPF (B.). Cells are irradiated with UV light 
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(254nm, 120 J /m2 for UV20; 150 J /m2 for XP2YO) through a polycarbonate filter with 5 µm 
pores, incubated at 37°C for 30 min, 2 h, 4 h, 8 h, 24 h, f ixed and stained with antibody against 
(6-4)PPs (red) and with DAPI (blue). C. Graphical representation of the percentage of cells 
containing (6-4)PPs in (transduced) UV20 cells. D. Graphical representation of the percentage of 
cells containing (6-4)PPs in (transduced) XP2YO. Quantification is based on at least three 
independent experiments and the standard deviation is indicated by error bars. 
2.2.7 Mutations in multiple DNA binding domains render cells hypersensitive to UV and 
Mitomycin C 
Having shown that mutations in DNA binding domains in XPF-ERCC1 synergistically affected 
NER in vitro and in vivo, we wanted to test whether these mutations also render cells 
hypersensitive to UV irradiation as well as Mitomycin C (MMC), an agent that causes DNA 
interstrand crosslinks (ICLs). Cells were first treated with different doses of UV light (254 nm) 
and the sensitivity was assessed using clonogenic survival assays. Consistent with the results 
from the NER studies above, mutations in single domains (XPFR678A, XPFK850A/R853A and 
ERCC1K247A/K281A) led to mild UV sensitivity, while mutations in two domains 
(XPFR678A/K850A/R853A or ERCC1N110A/K247A/K281A) led to a more pronounced effect. The 
hypersensitivity to MMC was even more prominent: Cells expressing XPF-ERCC1 with 
mutations in single domains (XPFR678A, XPFK850A/R853A and ERCC1K247A/K281A) were already 
associated with dramatic sensitivity, especially XPFR678A. Cells expressing XPFR678A/K850A/R853A 
or ERCC1N110A/K247A/K281A were as sensitive as non-transfected cells to MMC (Figure 2-7). These 
results demonstrate that proper DNA binding is even more important in the context of ICL 
repair. 
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Figure 2-7 Mutations in DNA binding residues render cells more sensitive to MMC than to UV. 
Cells were challenged with UV (254nm) to determine the impact of the mutations on NER or 
with MMC to determine the impact on ICL repair. Top row: WT (AA8), ERCC1-deficient 
(UV20) and complemented Chinese hamster ovary cell lines. Bottom row: WT (SV-40, SV40-
transformed human fibroblasts), XPF-deficient (XP2YO) and complemented cell lines. The data 
were plotted as the percentage of colonies that were formed on the treated plates relative to the 
untreated plates ± S.E (error bars) for a minimum of 2 i ndependent experiments each done in 
triplicate. 
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2.3 DISCUSSION 
2.3.1 Multiple DNA- and protein-binding domains of XPF-ERCC1 control its function in 
NER 
In our study, we investigated the role of four C-terminal DNA binding domains in XPF-ERCC1 
(Figure 2-1) and show that there is a hierarchy of importance of these domains in mediating the 
interaction with its DNA substrates. Mutations of DNA binding residues located in the HhH 
domain of ERCC1 and the nuclease domain of XPF have a more deleterious effect on nuclease 
and NER activity than mutations in the HhH domain of XPF or the central domain of ERCC1. 
Importantly, mutations in multiple DNA binding domains are required to significantly suppress 
NER activity in cultured cells and cell-free extracts, whereas mutations in the ERCC1 HhH or 
XPF nuclease domain alone are enough to deplete nuclease activity of the purified heterodimer 
on model substrates. These findings are consistent with current models of NER positing that this 
process is driven by the dynamic assembly and disassembly of the factors involved (Houtsmuller 
et al., 1999; Riedl et al., 2003). Accordingly, multiple protein-protein and protein-DNA 
interactions drive NER and enable the ordered hand-off of the substrates in damage recognition, 
damage verification, pre-incision complex assembly, dual incision, repair synthesis and ligation 
(Gillet and Schärer, 2006; Stauffer and Chazin, 2004). Our studies allow us to propose how 
multiple interactions between XPF-ERCC1, XPA and DNA control incision 5’ to the damage 
during NER. XPF-ERCC1 is recruited to NER complexes by interaction of the central domain of 
ERCC1 with XPA, in the context of a pre-incision complex consisting of XPA, RPA, TFIIH and 
XPG (Orelli et al., 2010b; Tsodikov et al., 2007). Our cellular studies suggest that DNA binding 
of XPF-ERCC1 is not required to localize the endonuclease to NER complexes (Figure 2-5). 
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DNA binding domains therefore anchor the protein at the junction following recruitment, 
allowing the nuclease domain of XPF to be positioned at the incision site and to cleave the DNA, 
triggering dual incision and repair synthesis (Staresincic et al., 2009b). It is likely that 
interactions with other NER proteins, for example RPA and TFIIH (Coin et al., 2004; de Laat et 
al., 1998c), contribute to the fine-tuning of the incision and coordination with other steps in the 
NER pathway. 
2.3.2 The HhH domains of ERCC1 and XPF have distinct roles in NER 
In accordance with NMR studies of individual domains of XPF-ERCC1 (Tripsianes et al., 2005), 
our results show that mutations in the HhH domain of ERCC1 affect DNA binding, nuclease and 
NER activity more severely than analogous mutations in the HhH domain of XPF. XPF and 
ERCC1 are believed to have evolved from a common ancestor (Gaillard and Wood, 2001), 
which has been studied in the form of archaeal XPF homologs (Rouillon and White, 2011). 
During divergent evolution, XPF retained the nuclease active site and ERCC1 conserved a 
typical double HhH domain. ERCC1 now harbors an XPA-interacting domain instead of a 
nuclease domain, and the HhH in XPF has lost some typical features. In accordance with this 
observation and with structural studies, our work demonstrates that the HhH domain of ERCC1 
is more important for substrate binding and NER activity than the analogous domain in XPF 
(Tripsianes et al., 2005). We know less about how the HhH of XPF contributes to the interaction 
with DNA. Based on studies of the homologous domain in the Hef helicase, the HLD is expected 
to contribute to the interaction with ss/dsDNA junctions. Consistent with this observation, human 
XPF-ERCC1 lacking the HLD has been shown to cut model substrates only with marginal 
efficiency (Tsodikov et al., 2005). 
 55 
2.3.3 How does XPF-ERCC1 bind substrates in different pathways? 
XPF-ERCC1 has been known for a long time to have roles outside of NER in the repair of 
interstrand crosslinks and in homologous recombination (Ahmad et al., 2008; Bardwell et al., 
1994; Hoy et al., 1985; Niedernhofer et al., 2004). Deficiencies in these processes have been 
implicated to cause the severe phenotypes of select ERCC1- or XPF-mutant patients and mice 
that cannot be explained by NER deficiency (Jaspers et al., 2007; McWhir et al., 1993b; 
Niedernhofer et al., 2006; Tian et al., 2004; Weeda et al., 1997b). Recent evidence suggests that 
an interaction between XPF and the Fanconi anemia protein SLX4/FANCP, rather than with 
XPA, is crucial for ICL repair (Andersen et al., 2009; Crossan et al., 2011a; Fekairi et al., 2009; 
Kim et al., 2011; Munoz et al., 2009a; Stoepker et al., 2011b; Svendsen et al., 2009). 
 With respect to our present study, it will be of great interest to determine whether DNA 
binding by XPF-ERCC1 in ICL repair is similar as in NER or whether it f ollows a distinct 
pattern. We have shown that even within the NER pathway the repair efficiency of cis-Pt and 
dG-AAF adducts is affected to different extents by mutations in DNA binding domains of XPF-
ERCC1 (Figure 2-4 compare, lanes 8-9, 16-17), perhaps reflecting a different conformation of 
the substrates in the NER complex. These differences may be even bigger between substrates for 
NER and ICL repair, as reflected by the sensitivities to UV light and MMC: cells expressing 
XPFR678A or ERCC1K247A/K281A are more sensitive to MMC than to UV (Figure 2-7). 
 High resolution structures of other structure-specific endonucleases such as FEN1 or 
EXO1 in complex with DNA substrates have shown that these proteins firmly bind the double-
stranded portion of the DNA and induce a kink of about 90° in the non-cleaved DNA strand at 
the junction (Orans et al., 2011; Tsutakawa et al., 2011). The cleaved strand undergoes local 
unpairing of the dsDNA at the incision site, and the ssDNA overhang of the cleaved strand may 
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be bound at different sites of the protein. Based on the structures of archaeal homologs of XPF 
(Newman et al., 2005; Nishino et al., 2005a) a similar arrangement can be envisioned for XPF-
ERCC1. Interestingly, the residue equivalent to R678 in XPF in the Aeropyrum pernix XPF 
homolog (R26) is located at a site that possibly binds the ssDNA overhang. Mutation of R678 of 
XPF affects ICL repair more severely than NER, showing that this residue is more crucial for the 
positioning of the endonuclease in the context of ICL repair. 
 We therefore believe that further studies of the five DNA binding domains in XPF-
ERCC1 will provide valuable insight into how this protein operates in multiple DNA repair 
pathways. Furthermore, introduction of specific mutations in those domains may lead to 
pathway-specific defects, enabling new approaches to study the importance of XPF-ERCC1 in 
maintaining genome stability. 
2.4 EXPERIMENTAL PROCEDURES 
2.4.1 Protein expression and purification 
Site directed mutagenesis of pFastBac-XPF and pFastBac-ERCC1-His (Enzlin and Schärer, 
2002) was performed using the QuikChange site-directed mutagenesis kit (Stratagene) to 
generate the following mutations: XPFR678A, XPFK850A/R853A, XPFR678A/K850A/K853A, 
ERCC1K247A/K281A, ERCC1N110A, and ERCC1N110A/K247A/K281A. Bacmid DNA was generated in 
DH10Bac cells and transfected into the Sf9 insect cells to obtain baculoviruses according to a 
standard protocol (Bac-to-Bac, Invitrogen). The following combination of ERCC1 and XPF 
proteins were co-expressed in Sf9 cells for 60 to 65 hours with an MOI of 5: XPF-ERCC1, XPF-
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ERCC1R678A, XPF-ERCC1K850A/R853A, XPF-ERCC1R678A/K850A/R853A,ERCC1K247A/K281A-XPF, 
ERCC1N110A-XPF, ERCC1N110A/K247A/K281A-XPF, ERCC1K247A/K281A-XPFR678A, ERCC1N110A–
XPFR678A, and ERCC1K247A/K281A-XPFK850A/K853A. Cells were lysed and proteins purified over a 1 
ml Nickel (His Trap) column (Amersham Biosciences), a HiLoad 16/60 Superdex 200 column 
(Amersham Biosciences) and a 1 ml Hitrap Heparin column (Amersham Biosciences) as 
described in (Enzlin and Schärer, 2002). The proteins eluted at 650 mM NaCl from the Heparin 
column and were in some cases concentrated on an Amicon Ultra-4 Centrifugal Filter 
(Millipore). Proteins were frozen in aliquots in liquid N2 and stored at -80°C. 
2.4.2 Endonuclease Assays 
10 pmol of a stem-loop oligonucleotide (GCCAGCGCTCGG(T)22CCGAGCGCTGGC) labeled 
with fluorescent dye Cy5 at the 3’ end (IDT) were annealed in 200 µl solution (10 mM Tris pH 
8.0, 50 mM NaCl, 1 mM MgCl2) by heating at 90°C for 10 min and allowing to cool to RT for 2 
h. 100 fmol of the substrate were incubated in 25 mM Tris pH 8.0, 2 mM MgCl2, 10% glycerol, 
0.5 mM β-mercaptoethanol, 0.1 mg/ml BSA, 40 mM NaCl with various amounts of protein in a 
volume of 15 µl. The reactions were incubated at 37°C for 30 min and quenched by adding 10 µl 
of 80% formamide/10 mM EDTA. After heating at 95°C for 5 min and cooling on ice, 3μl of 
each sample were analyzed on a 12% denaturing polyacrylamide gel. Bands were visualized by 
fluorescence imaging on a Typhoon 9400 imaging system (Amersham Biosciences). 
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2.4.3 In vitro NER Assay 
Extracts derived from XPF-deficient XP2YO cells and plasmids containing dG-
acetylaminofluorene (dG-AAF) or 1,3-intrastrand cisplatin (cis-Pt) lesions were prepared as 
described previously (Biggerstaff and Wood, 1999; Gillet et al., 2005; Shivji et al., 1999). For 
each reaction, 2 µl of repair buffer (200 mM Hepes-KOH (pH 7.8), 25 mM MgCl2, 2.5 m M 
DTT, 10 mM ATP, 110 mM phosphocreatine (di-Tris salt, Sigma), and 1.8 mg/ml BSA), 0.2 µl 
of creatine phosphokinase (2.5 mg/ml, sigma), 3 µl of XPF-deficient cell extract (about 10 
mg/ml), NaCl (to a final concentration of 70 mM), and different amounts of purified XPF-
ERCC1 in a total volume of 9 µl were pre-warmed at 30°C for 10 min. 1 µl plasmid containing 
dG-AAF or cis-Pt (50 ng/µl) was added to each reaction and the samples were incubated at 30°C 
for 45 min. After adding 0.5 µ l of 1 µM of an oligonucleotide complementary to the excision 
product with a 4G overhang for either dG-AAF (5' 
GGGGCATGTGGCGCCGGTAATAGCTACGTAGCTCp-3') or cis-Pt 
(5’GGGGGAAGAGTGCACAGAAGAAGACCTGGTCGACCp-3’), the mixtures were 
denatured by heating at 95°C for 5 min. After cooling to RT for 15 min, 1 µl sequenase mixture 
(0.13 units of sequenase (USB), and 2.0 µCi [α-32P] dCTP for each reaction) was added and 
incubated at 37°C for 3 min, followed by addition of 1.2 µl dNTP mixture (50 µM dCTP, 100 
µM dTTP, 100 µM dATP and 100 µM dGTP). The reactions were incubated at 37°C for 12 min 
and stopped by addition of 8 µl of 80% formamide/10 mM EDTA. After heating to 95°C for 5 
min, samples were placed on i ce and analyzed on a 14% denaturing polyacrylamide gel. Gels 
were exposed to a phosphor screen and visualized by PhosphorImager (Typhoon 9400, 
Amersham Biosciences). 
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2.4.4 DNA binding measurements by fluorescent anisotropy 
For the anisotropy experiments, the protein storage buffer was exchanged to 25 mM KH2PO4 
(7.6), 5 m M -mercaptoethanol, 10% glycerol, 150 m M NaCl. Increasing concentrations of 
protein were incubated with the splayed arm substrate (10 nM) which was made by annealing the 
following oligonucleotides: 5’-CTTTCGAACATCCAGGAGAGCACGGCC 
TTTTTTTTTTTTTTTTTTTT with an FAM label at the 3’ end and 5’-
TTTTTTTTTTTTTTTTTTTTGGCCGTGCTCTCCTGGATGTTCGAAAG. 100nM of 
competitor double stranded DNA (5’-
TCAAAGTCACGACCTAGACACTGCGAGCTCGAATTCACTGGAGTGACCTC and 5’-
GAGGTCACTCCAGTGAATTCGAGCTCGCAGTGTCTAGGTCGTGACTTTGA) were used 
in each reaction. Each reaction was incubated in 20 µl of buffer (25mM Hepes-KOH (pH 8.0), 
15% glycerol, 0.1mg/ml BSA, 2 mM CaCl2, 0.5 mM  β-mercaptoethanol, and 40 mM NaCl) at 
30°C for 5 m in. The experiments were conducted at least 4 t imes and measured on Infinite 
M1000 plate reader (Tecan). The data were fitted using the grafit4 program to the equation 
f=y+a*x^b/(c^b+x^b), where x is the protein concentration, f is the fluorescent anisotropy and c 
is the Kd value. 
2.4.5 Generation of mutant cell lines using lentiviral transduction 
Human XP-F mutant fibroblasts XP2YO, Chinese hamster ovary cells UV20 (with a mutation in 
ERCC1), and 293T cells were cultured in Dulbecco’s modified Eagle’s medium high glucose 1 x 
(GIBCO), 10% fetal bovine serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin at 37°C 
in a 5% CO2 humid incubator. Wild-type or mutant XPF cDNA with an hemaglutinin (HA) tag 
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at C-terminal was inserted into the pWPXL vector, which was co-transfected with the packaging 
plasmid psPAX2 and the envelop plasmid pMD2G into 293T cells to generate lentiviral 
particles. The particles were transduced into XP2YO cells to produce cell lines stably expressing 
wild-type or mutant XPF proteins according to established procedures 
(http://www.lentiweb.com) (Salmon et al., 2000; Salmon and Trono, 2006). The same procedure 
was applied to generate cell lines expressing wild-type or mutant ERCC1 in UV20 cells. 
2.4.6 Local UV-irradiation and immunofluorescence 
About 50,000 cells were plated on a coverslip in 6-well plates, grown for 2-3 days and irradiated 
through a polycarbonate membrane with 5 µm pores (Millipore) with UV light (254 nm) with a 
dose of 150 J /m2 (XP2YO cells) or 120 J /m2 (UV20 cells). Cells were incubated at 37°C, 5% 
CO2 for 30 min to 24 hr. They were washed first with PBS and then with PBS plus 0.05% triton 
X-100 and fixed with 3% paraformaldehyde plus 0.1% triton X-100 (XP2YO cells) or washed 
first with PBS and then with PBS plus 0.1% triton X-100, and fixed by 3% paraformaldehyde 
plus 0.2% triton X-100 (UV20 cells). After fixation, cells were washed with PBS containing 
0.2% triton X-100. To stain for (6-4)PPs, cells were treated with 0.07 M NaOH in PBS for 5 
min, followed by washing with PBS plus 0.2% triton X-100. After blocking with PBS plus 5 
mg/ml BSA and 1.5 m g/ml glycine, cells were stained with mouse monoclonal anti-(6-4)PP 
antibody (Cosmo Bio) 1:400, rabbit polyclonal anti-ERCC1 antibody (FL-297, Santa Cruz) 
1:100, or rabbit polyclonal anti-HA antibody (ChIP grade, Abcam) 1:2000 for 1.5 h and washed 
with PBS containing 0.2% triton X-100. Cells were then incubated with secondary antibodies: 
Cy3-conjugated affinipure goat anti-mouse IgG(H+L) (Jackson ImmunoResearch) 1:1000 and 
Alexa Fluor 488-labeled F(ab')2 fragment of goat anti-rabbit IgG (H+L) (Invitrogen) 1:800 for 1 
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h, followed by washing with PBS with 0.2% triton X-100.  S amples were washed with PBS, 
embedded in Vectashield Mounting Medium with 1.5 µg/ml of DAPI (Vector Laboratories) and 
analyzed using a confocal microscope (Zeiss LSM 510). About 100 cells were counted in at least 
three independent experiments for quantification. 
2.4.7 Clonogenic Survival Assay 
Exponentially growing cells were plated in 6 cm dishes in triplicate at a density of 1-20 x 103-
cells/plate for human cells or 250-5,000 cells/plate for Chinese hamster ovary cells, depending 
on the dose of genotoxin used and the predicted phenotype of the cells. For the hamster cells, 
wild-type cells were plated as follows: 3 plates at 250 cells/plate (untreated) 3 plates at 250 
cells/plate (dose 1), 3 plates at 250 cells/plate (dose 2), 3 plates at 500 cells/plate (dose 3), and 3 
plates at 500 cells/plate (dose 4). For hamster cells, knock-out cells were plated as follows: 3 
plates at 250 cells/plate (untreated), 3 plates at 250 cells/plate (dose 1), 3 plates at 500 cells/plate 
(dose 2), 3 plates at 1000 cells/plate (dose 3), and 3 plates at 5,000 cells/plate (dose 4). The next 
day, the cells were transiently exposed to genotoxins. For UV treatment, the media was aspirated 
from the plates; the cells were washed with PBS; irradiated with UV (254 nm, Spectroline X-15) 
and the cells were replenished with fresh medium. For Mitomycin C (MMC) treatment, the cells 
were treated with medium containing MMC (Fisher) at 37°C for 1 hr. The plates were then 
washed twice with PBS and replenished with fresh medium.  Seven to ten days after exposure to 
genotoxins, when colonies are visible to the naked eye, the cells were fixed and stained with 50% 
methanol, 7% acetic acid and 0.1% Coomassie brilliant blue. The colonies (defined as containing 
>10 cells) were counted using an Olympus SZ61 stereomicroscope with a 10X eyepiece. The 
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data was plotted as the number of colonies on treated plates divided by the number of colonies 
on untreated plates ± S.E. for a minimum of 2 independent experiments, both done in triplicate. 
2.4.8 CD Experiment 
Protein (XPF-ERCC1WT, XPF-ERCC1R678A, ERCC1k247A/K281A-XPFR850/K853A) was 
diluted to 680 nM (dilution buffer containing 25 mM K-phosphate (pH=7.6), 10% glycerol, 5 
mM beta-mercaptoethanol, and 650 mM NaCl), and the CD spectrum measured on an Applied 
Photophysics Chirascan CD spectrometer. The scan was a 1-nm/s interval over 0.1 cm path 
length at 4°C with a wavelength range of 200 n m to 260 nm . The background signal for the 
buffer was subtracted and two experiments were conducted twice. 
2.4.9 Western Blot 
Cells were lysed in NETT buffer (50 mM Tris pH8.0, 150mM NaCl, 1mM EDTA, 0.5% NP40, 
and protease inhibitor (Roche). 30 µg of protein (60 µg for HeLa cell extracts) were separated on 
a 10% sodium dodecyl sulphate (SDS) gel and transferred to a Hybond-LFP membrane (low 
fluorescent Polyvinylidene fluoride (PVDF) membrane, Amersham Biosciences) at 350 mA for 2 
h. After blocking with a 5% bovine serum albumin (BSA) solution, the membranes were 
incubated with primary antibodies: rabbit polyclonal anti-ERCC1 (FL-297, Santa Cruz) 1:200 
(for UV20 cells), mouse monoclonal anti-XPF (3F2/3, Santa Cruz) 1:200 (for XP2YO cells), and 
mouse anti-tubulin (Sigma) 1:1000 for 1.5 h, w ashed by PBS plus 0.1%tween 20. Membranes 
were incubated with secondary antibodies: Cy3-conjugated affinipure goat anti-mouse IgG(H+L) 
(Jackson ImmunoResearch) 1:1000 and Alexa Fluor 488 F(ab')2 fragment of goat anti-rabbit IgG 
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(H+L) (Invitrogen) 1:1000 for 1 h, a nd washed with PBS plus 0.1% tween 20. A t last, 
membranes were washed with PBS, dried at room temperature and visualized by fluorescence on 
a Typhoon imaging system (Amersham Biosciences). 
2.5  SUPPLEMENTAL DATA 
 
Figure 2-8 XPF-ERCC1 proteins with mutations in the HhH, nuclease and central domains are 
properly folded. 
Wild type and mutant XPF-ERCC1 are purified through Nickel column, HiLoad 16/60 Superdex 
200 column and Hitrap Heparin column. On the HiLoad 16/60 Superdex 200 c olumn, 
heterodimeric, active wild type and mutant XPF-ERCC1 were eluted at 60-70 ml and fractions in 
that range were collected around the peaks and used for further purification (A.). Wild type, 
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XPFR678A, and ERCC1K247A/K281A-XPFK850A/R853A proteins were test on t he CD 
spectrum. They had the similar peaks (B.). 
 
Figure 2-9 Expression level of ERCC1 and XPF protein in transduced UV20 and XP2YO cells 
UV20 cells transduced with wild-type or mutant ERCC1 (A.) and XP2YO cells expressing wild-
type or mutant XPF (B.) were lysed and 30 µg of protein from the extracts (60 µg for HeLa cell 
extracts) were separated on a 10% SDS gels and transferred to PVDF membrane. ERCC1 was 
detected using antibody FL-297 (A.), XPF using antibody 3F2/3 (B.). Tubulin was used as a 
loading control. 
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In chapter 2, we examined the role of four C-terminal DNA binding domains in XPF-ERCC1. 
We have shown that there is a hierarchy of importance of these domains in interacting with DNA 
substrates. The effects of mutations in the DNA binding domains were also compared to the 
effect of mutations in the nuclease domain of XPF and the central domain of ERCC1. DNA 
binding residues located in the HhH domain of ERCC1 and the nuclease domain of XPF are 
more important to nuclease activity and NER activity than mutations in the DNA binding 
residues located in the HhH domain of XPF and mutations in the central domain of ERCC1.  
Multiple protein:protein and protein:DNA interactions have been shown to drive NER. 
The results from chapter 2 highlight the importance of protein:DNA interactions for both NER 
and ICL repair. In addition, the interaction between ERCC1 and XPA through the central domain 
of ERCC1 has for long been shown to be absolutely essential for NER. The C-terminus of XPF-
ERCC1, the central domain of ERCC1 and the nuclease domain of XPF have all been well 
characterized. However, very little is known about the N-terminus of XPF. To investigate 
whether the N-terminus of XPF is important to ICL repair, in chapter 3, de scribed below, we 
engineered mutations in multiple conserved residues of the N-terminus and observed the 
sensitivities of the cell lines harboring the mutations to UV, MMC and IR 
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3.0  MUTATIONAL ANALYSIS OF XPF 
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3.1 INTRODUCTION 
The human genome is constantly exposed to extrinsic and intrinsic factors that cause chemical 
modification of DNA. Extrinsic factors include UV light, ionizing radiation, and 
chemotherapeutic drugs, while intrinsic include reactive oxygen species and by-products of lipid 
peroxidation (Friedberg, 1995). Organisms have evolved complex DNA repair mechanisms to 
resolve this damage (Weinert, 1998), which are critical for enabling basic cellular mechanisms 
such as replication and transcription. The cellular consequences of DNA damage are dependent 
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upon the type of lesion (e.g. strand break vs. adduct), when during the cell cycle the lesion is 
detected, and the abundance of damage. Misinterpretation of lesions by the replication machinery 
leads to mutations in the genome that may give rise to cancer (Hoeijmakers, 2009). However, 
extensive damage may result in programmed cell death (apoptosis) or cellular senescence both of 
which can contribute to aging (Schumacher et al., 2008). A mechanistic understanding of how 
DNA damage contributes to cancer and aging can be obtained by probing the robust DNA repair 
pathways that function in our cells to counter the damage induced. 
XPF-ERCC1 is a structure-specific endonuclease (de Laat et al., 1998a; Sijbers et al., 
1996a) that is essential for nucleotide excision repair (NER) (Biggerstaff et al., 1993; Petit and 
Sancar, 1999; Sijbers et al., 1996a), the repair of DNA interstrand crosslinks (ICL) (Bhagwat et 
al., 2009b; Kuraoka et al., 2000) and the repair of some DNA double strand breaks (Ahmad et 
al., 2008). They are obligate heterodimers in which XPF harbors the nuclease domain essential 
for its catalytic activity and ERCC1 is involved in DNA binding (Enzlin and Scharer, 2002). In 
NER, the two proteins aid in the removal of helix-distorting bulky lesions such as UV induced 
pyrimidine dimers (Biggerstaff et al., 1993). XPF-ERCC1 is recruited to the site of DNA damage 
by the interaction of XPA with ERCC1 (Orelli et al., 2010b; Tsodikov et al., 2007). In ICL 
repair, XPF-ERCC1 is involved in the second incision that unhooks the crosslink (Niedernhofer 
et al., 2004). It is well established that ICL repair is distinct from NER, requiring only XPF-
ERCC1 and not other NER factors (McHugh et al., 2001; Niedernhofer et al., 2004). In addition, 
in vitro studies show that the amount of purified XPF-ERCC1 required for the incision of 
crosslinks requires a lot more enzyme than is physiologically relevant indicating that the in vitro 
reaction might be missing a recruiting factor that is contributing to this (Kuraoka et al., 2000). 
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Based on these observations, we hypothesize that similar to NER, XPF-ERCC1 is recruited to 
the DNA for ICL repair via a protein:protein interaction. 
A novel component of ICL repair, FANCP, was identified recently. FANCP, also known 
as SLX4, is a structure-specific endonuclease that was first identified in a synthetic lethal screen 
for mutants that are lethal in the absence of Sgs1 (Mullen et al., 2001). In humans, SLX4 is 
thought to be a multi-domain scaffolding protein that regulates three structure-specific 
endonucleases, XPF-ERCC1, Mus81-EME1, and SLX1, by acting as a docking platform (Munoz 
et al., 2009a; Yildiz et al., 2002). Recently, individuals with Fanconi Anemia, caused by 
defective ICL repair, with mutations in the FANCP/SLX4 gene were identified (Kim et al., 2011; 
Stoepker et al., 2011a). Accordingly, SLX4-depleted cells are hypersensitive to crosslinking 
agents (Munoz et al., 2009a; Svendsen et al., 2009). Deletion analysis of the N-terminus of the 
FANCP protein disrupts its interaction with XPF (Fekairi et al., 2009). These point to an 
interaction between XPF and FANCP that is likely important for ICL repair. In this study, we 
test the hypothesis that disrupting the interaction between XPF and FANCP uncouples the 
functions of XPF-ERCC1 in NER and ICL repair. 
To test this, several XPF mutants were designed and cloned, then expressed in XPF-
deficient human fibroblast cells. The mutant cell lines include XPFHA, which harbors an N-
terminal HA tag, XPFG314E, which harbors a point mutation affecting an amino acid essential for 
interaction with SLX4 in Drosophila, XPFΔ5N, which harbors a 5 amino acid deletion in the N-
terminus of XPF, and XPFD676A, a c atalytically dead mutant. Cells expressing these mutant 
proteins were tested for sensitivity to UV to measure NER, Mitomycin C to measure ICL repair 
and ionizing radiation (IR) to measure double-strand break repair (DSB repair). This study 
provides the first formal proof that the nuclease domain of XPF is absolutely essential for its 
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repair functions. The results also indicate that the G314E mutation renders the cells selectively 
sensitive to crosslinking agents, thus uncoupling repair. However, the inability of the wild-type 
XPF cDNA to correct sensitivity of XP-F cells to crosslinking agents led us to interrogate the 
sequence of the cDNA and endogenous protein.  The published XPF sequence is 11 amino acids 
shorter than the endogenous protein (N-terminus) (Figure 3-10) and contains a G→D substitution 
at residue 703. Both of these are critical for rendering XPF fully functional in ICL repair. 
3.2 RESULTS 
3.2.1 Generation of mutations in conserved domains of XPF to uncouple DNA repair 
function 
Based on structural studies (Andersen et al., 2009; Fekairi et al., 2009; Munoz et al., 2009a; 
Sgouros et al., 1999; Svendsen et al., 2009), modifications in multiple domains of XPF were 
identified as potentially important for ICL repair but not NER. Site-directed mutagenesis was 
used to generate the mutations in specific domains of XPF and lentiviral transduction used to 
generate stable mutant cell lines. To probe the functional importance of the nuclease domain, we 
generated a mutation in a highly conserved aspartic acid residue at position 676, changing it to 
an alanine (XPFD676A). Based on preliminary data from our lab, we knew that a large tag such as 
the GFP tag in the N-terminus and not the C-terminus of XPF makes cells selectively 
hypersensitive to crosslinking agents (Figure 3-9). Consequently, to determine the importance of 
the N-terminus of XPF in protein folding, we generated a mutant that had only the N-terminal 
HA-tag, XPFHA. In addition, a mutant XPF was also generated missing the first 5 amino acid 
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residues, XPFΔ5N. Mutation of G306E in mei-9, the Drosophila homolog of XPF, disrupts its 
interaction with SLX4 (Yildiz et al., 2002). We mutated the corresponding residue in XPF to 
create XPFG314E, and XPFWLF-A in which highly conserved residues W326, L327, F328 were 
mutated to alanines (Table 1). 
 
Table 1 XPF-ERCC1 Mutants 
 
Table listing all the XPF mutations generated the name of the mutant cell lines used, the target 
domain and the anticipated effect. 
3.2.2 Expression of mutant XPF in the mutant cells by lentiviral transfection 
The under expression of proteins can fail to correct sensitivity of the cell lines to genotoxic 
stress. To make sure that the expression levels of the exogenous XPF protein in each of the cell 
lines were comparable to the endogenous XPF levels in the wild-type cells, immunoblot analysis 
was carried out. Sixty micrograms of protein from whole cell extracts of each of the mutant cell 
lines was probed for XPF protein expression by immunoblot and compared to normal expression 
levels of the endogenous protein in wild-type cells. Wild-type cells showed a weak signal for 
ERCC1 and an even weaker one for XPF. XP2YO (XP-F) cells, which serve as a genetic 
negative control, showed a weak signal for ERCC1 but no signal for XPF. In XP2YO cells stably 
expressing mutant XPF, both XPF and ERCC1 expression was increased to greater than 
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endogenous levels (Figure 3-1). This indicates that the mutant constructs are over expressed. 
Since the constructs increased ERCC1 expression, it reveals that indeed ERCC1 is unstable the 
absence of XPF and that all of the mutant XPF proteins can bind and stabilize ERCC1. 
Overexpression of XPF-ERCC1 was approximately equal for all of the mutant cell lines. 
Therefore the differences in sensitivity of the mutant cells to genotoxic agents cannot be 
attributed to differences in nuclease expression. 
 
Figure 3-1 Comparing expression levels of XPF-ERCC1 
Normal (wild-type) and XPF-ERCC1 deficient XPF mutant human fibroblasts (XP2YO), and 
XP2YO cells ( transfected with the cDNA of wild-type XPF, XPFWT, XPFD676A, XPFΔ5N, XPFHA, 
XPFG314E and XPFWLF-A) were lysed and whole cell extracts were collected. The proteins were 
separated by SDS-PAGE (10% polyacrylamide gel), transferred onto nitrocellulose membranes 
and immunostained with antibodies (anti-XPF: Ab1, and anti-ERCC1: D-10). Tubulin was used 
as a loading control. 
3.2.3 Clonogenic survival assay to measure NER, ICL repair and DSB repair 
The data are reported as the percent of cells surviving (proliferating) at each dose of genotoxin 
compared to untreated cells. The three genotoxins employed were UV-C to measure NER, 
Mitomycin C to measure ICL repair, and IR to measure DSB repair. Reported are the average ± 
standard deviation from three independent experiments. In the figure, the survival curves of the 
wild-type cell line in response to all three forms of genotoxic stress is set to represent resistance 
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and the survival curve of the XP2YO cell line represents hypersensitivity. The survival curve of 
the wild-type corrected cell line is utilized as a second measure of resistance in exogenously 
expressed XPF to avoid bias that may be generated due to the mode of XPF expression. All three 
cell lines, for each genotoxin used, are utilized as controls so that the effect of the mutations on 
the protein function of XPF can be classified as resistant, sensitive or hypersensitive. The data 
reveals the survival curves of the XPFD676A nuclease dead mutant, XPFG314E, XPFΔ5N and the 
XPFHA in response to UV, MMC and IR. In response to UV, the survival curves of the XPFG314E, 
XPFΔ5N and the XPFHA mutants indicated that they are resistant (Figure 3-2). The survival curve 
of the XPFD676A mutant corresponds with, and in some cases is, more severe than the XP2YO 
cell line which lacks functional XPF (a). 
 In response to crosslinking agent Mitomycin C, all the mutants analyzed, XPFD676A, 
XPFG314E, XPFΔ5N and the XPFHA were found to be hypersensitive (Figure 3-2b). The most 
perplexing observation however, was the hypersensitivity observed in the wild-type corrected 
cell line XPFWT (Figure 3-2). This was highly unexpected and hinted at the possibility of 
alterations in the XPF gene that might be making the cells selectively sensitive to crosslinking 
agents. 
The survival curves in response to ionizing radiation were used to probe proficiency of 
the DSB repair pathway. The results indicated again that  XPFD676A, XPFG314E, XPFΔ5N were all 
hypersensitive to IR. However, the XPFΔ11NWT and XPFHA were mildly sensitive if not resistant 
to the genotoxin (Figure 3-2c). These results established that alterations in the wild-type 
corrected cell line that was causing the hypersensitive phenotype in response to crosslinking 
agents did not have any effect on the NER or DSB repair ability of the cell line. 
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The hypersensitivity of the XPFD676A mutant in response to UV, MMC and IR in 
comparison to the wild-type and the XP2YO cell line indisputably delineated the importance of 
the nuclease domain of XPF in all the repair pathways. 
 
Figure 3-2 Clonogenic survival assay 
Cells were challenged with UV (254nm) to determine the impact of the mutations on NER, with 
MMC to determine the impact on ICL repair, and IR to determine impact on DSB repair on WT 
(wild-type,  SV40-transformed human fibroblasts),  XPF-deficient (XP2YO) and  complemented 
cell lines.  The data were plotted as the percentage of colonies that were formed on the treated 
plates relative to the untreated plates ± S.E (error bars) for a minimum of 2 i ndependent 
experiments each done in triplicate. 
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3.2.4 Immunodetection of UV lesions to interrogate NER 
Since the survival assay is an indirect measure of repair, secondary endpoints that directly 
measure NER and ICL repair were employed. A local damage assay was used to determine the 
NER proficiency of each cell line. The experiment involved the treatment of cells with UV 
through filter meshes (Volker et al., 2001). The regions of the cell exposed to the UV treatment 
were expected to show both 6-4PP lesion formation and ERCC1 protein recruitment. The 
complete co-localization of the 6-4PP lesion with ERCC1 foci 30 m inutes after irradiation 
followed by the disappearance of both the lesion and the repair protein 24 hours after treatment 
denoted proficient repair. The first column of (Figure 3-3) represents the wild-type corrected cell 
line, XPFWT that was used as the positive control for the experiment. The second column of the 
figure represents the cell line ERCC1N110A/Y154A, which harbors a mutation in ERCC1 that 
disrupts interaction with XPA that is essential for the recruitment of XPF-ERCC1 to NER. This 
mutant has been previously been shown to be defective in NER (Orelli et al., 2010b) and was 
hence used as a negative control line. The recruitment of ERCC1 to the 6-4PP lesions was 
clearly visible 30 minutes post UV irradiation in all the cell lines with the exception of the 
negative control line ERCC1N110A/Y154A in which the recruitment of ERCC1 was not visible. 24h 
post irradiation, proficient NER, denoted by the disappearance of the lesions and ERCC1 foci, 
was observed in XPFG314E, XPFΔ5N and the XPFHA mutants in accordance with the wild-type 
control. The persistence of the damage foci in the nuclease dead cell line XPFD676A supported the 
previous data obtained from the clonogenic survival assay and indicated that the nucleolytic 
activity of XPF was essential for its NER function and additionally implied that the activity was 
not required for the recruitment of XPF-ERCC1 to the NER pathway (Figure 3-3). 
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Figure 3-3 Local UV damage assay 
Wild-type XPF complemented XPF-ERCC1 deficient (XP2YO) cell line (column 1; positive 
control), ERCC1-deficient UV20 cells complemented with NER deficient ERCC1N110A/Y145A 
(column 2; negative control) and XPF-deficient (XP2YO) complemented cell lines were 
challenged with UV light (254nm, 120 J/m2) through a polycarbonate filter with 5  µm pores and 
incubated  at 37°C  for 30 min or 24h. Cells were fixed and stained with antibodies against (6-
4)PPs (red; row1), XPF-ERCC1 (green, using anti-ERCC1 antibody; row2). Nuclear DNA was 
visualized by DAPI staining. Merged images (row3). 
 
 77 
3.2.5 Monoubiquitination of FANCD2 to interrogate ICL repair 
Monoubiquitination of FANCD2 in response to Mitomycin C and the disappearance of the 
monoubiquitinated form are commonly used to interrogate the activation of ICL repair and 
success of that repair (Bhagwat et al., 2009b). Wild-type, XPFG314E, XPFD676A, and XP2YO cell 
lines were treated with 3µM MMC to induce DNA damage by the formation of ICLs. ICL repair 
proficiency, assessed as the function FANCD2 monoubiquitination, was determined by 
monitoring the increase and subsequent decrease in the ratio of FANCD2-L (monoubiquitinated) 
to FANCD2-S (non-ubiquitinated) band at 0, 12 and 4h respectively by immunoblot analysis. 
The wild-type cell line expressing endogenous XPF and the XP2YO cell line lacking XPF 
protein expression were utilized as positive and negative controls respectively. At the 0h time 
point representative of no treatment, the faint FANCD2-L band observed in all cell lines may be 
attributed to the repair that takes place in the cell due to endogenous DNA damage. At 24h, the 
activation of crosslink repair denoted by the formation of the FANCD2-L band was observed in 
all cell lines. By 48h, removal of the lesion characterized by the disappearance of FANCD2-L 
was observed in the wild-type cell line. The persistence of the FANCD2-L band in XPFG314E, 
XPFD676A, and XP2YO demonstrated the inability of the cell lines to complete ICL repair (Figure 
3-4). This data was consistent with data from the clonogenic survival assay in which mutation at 
position 314 was rendering XPFG314E cells selectively hypersensitive to crosslinking agents. In 
addition, this data revealed that FANCD2 is monoubiquitinated in response to cross-linking 
agents irrespective of the nucleolytic status of XPF implying that the nucleolytic ability of XPF-
ERCC1 is not essential for FA pathway activation but is required for the subsequent completion 
of ICL repair. 
 78 
 
Figure 3-4 Monoubiquitination of FANCD2 
Normal (wild type), XPF-ERCC1 deficient (XP2YO) cells and complemented cell lines were 
exposed to 0.3 μM MMC for 12 h and the WCEs were collected at 0, 12 and 48h following 
exposure for the immunodetection of FANCD2. Tubulin was used as the loading control. 
3.2.6 Defects in the original XPF construct 
Mass spectrometric analysis of the XPF protein and its degradation bands observed by silver 
staining (Figure 3-5) lead to the identification of the 11 amino acid deletion in the N-terminus of 
the XPF gene (Figure 3-10). This deletion was attributed to aberrant use of the methionine 
residue 11 amino acids downstream of the actual methionine start site of the gene. Since it was 
highly plausible that the ICL repair sensitivity observed in the mutant cell lines be caused by the 
11 amino acid deletion, new constructs rectifying this deletion were made and the all the 
mutations were regenerated in the correct XPF construct. 
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Figure 3-5 Silver staining of XPF-IP 
The whole cell extract from HeLa cells was subject to immunoprecipitation to pull down XPF 
protein. The immunoprecipitated sample was resolved on a n 8% SDS-PAGE gel and silver 
stained. The XPF band along with the degradation products (1,2, and 3) were dissected from the 
gel for mass spectrometric analysis. 
3.2.7 Addition of the 11 missing amino acids in the N-terminus of XPF does not correct 
ICL repair 
The regenerated cell lines included, XPF916WT the full length 916 amino acid wild-type corrected 
cell line, the XPFG325E FANCP-XPF mutant and a third new mutant XPFWLF-A that had W326, 
L327, F328 mutated to alanines.  These three bulky amino acids occur after the ICL sensitive 
glycine, and all of them have been known to be conserved in mice. In addition, the tryptophan 
and lysine residues are also conserved in the yeast protein.  A ll the mutant cell lines and the 
XPFWT+11aa cell line were moderately sensitive to UV damage (Figure 3-6). The XPFG325E and the 
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XPFWLF-A mutants were hypersensitive to MMC confirming the importance of this region for the 
participation of XPF in ICL repair potentially through its interaction with FANCP (Figure 3-6).  
All the mutants were moderately sensitive to IR. The hypersensitivity of the wild-type corrected 
cell line XPF916WT in response to MMC persisted. This raised questions of the possibility of 
additional imperfections in the original XPF construct. A sequence analysis identified a mutation 
at position 703 that had switched a glycine residue to aspartic acid. 
 
Figure 3-6 Analysis after addition of the first 11 a.a 
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Cells were challenged with UV (254nm) to determine the impact of the mutations on NER, with 
MMC to determine the impact on ICL repair, and IR to determine impact on DSB REPAIR on 
WT (wild-type,  SV40-transformed human fibroblasts),  XPF-deficient (XP2YO) and  
complemented cell lines.  The data were plotted as the percentage of colonies that were formed 
on the treated plates relative to the untreated plates ± S.E (error bars) for a minimum of 2 
independent experiments each done in triplicate. 
3.2.8 Restoration of the glycine residue at position 703 fully corrects NER, and ICL 
repair sensitivity 
To determine the effect of the D703G correction in XPF on the overall survival of the cell lines 
in response to genomic insult, the panel of wild-type corrected cell lines, XPF11ΔN, XPF916WT, 
and XPFWT+D703G were compared with the wild-type and XP2YO controls. The results from 
Figure 5 showed that the XPFWT+D703G cell line is resistant to both UV and MMC thus indicating 
the complete correction of the XPF construct. Curiously, the XPFWT+D703G cell line was found to 
be moderately sensitive to IR (Figure 3-7). An immunoblot analysis was thus carried out to 
compare the XPF protein levels. The protein level in the newly generated XPFWT+D703G was 
much higher than the endogenous control and also the previous XPF916WT cell line (Figure 3-8). 
This over expression could potentially explain the IR sensitivity observed in the new wild-type 
XPF cell line. These results showcase the importance of protein expression levels on cellular 
function. The effects of mutations in different residues in the N-terminus of XPF are summarized 
in Table 2 Table summarizing the observed effect of modification in different regions of XPF 
Table 2. Having corrected the XPF construct completely, new cell lines harboring our mutations 
of interest are being generated bearing in mind the importance of protein expression levels. 
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Figure 3-7 Comparison of wild-types after complete correction of XPF 
Cells were challenged with UV (254nm) to determine the impact of the mutations on NER, with 
MMC to determine the impact on ICL repair, and IR to determine impact on DSB repair on WT 
(wild-type,  SV40-transformed human fibroblasts),  XPF-deficient (XP2YO) and  complemented 
cell lines.  The data were plotted as the percentage of colonies that were formed on the treated 
plates relative to the untreated plates ± S.E (error bars) for a minimum of 2 independent 
experiments each done in triplicate. 
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Figure 3-8 XPF-ERCC1 expression levels 
Normal (wild-type) and XPF-ERCC1 deficient XPF mutant human fibroblasts (XP2YO), and 
XP2YO cells ( transfected with the cDNA of XPFWT+11aa, and XPFWT+D703G) were lysed and 
whole cell extracts were collected. a. The proteins were separated by SDS-PAGE (10%  
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polyacrylamide gel), transferred onto nitrocellulose membranes and immunostained with 
antibodies (anti-XPF: Ab1, and anti-ERCC1: D-10). Tubulin was used as a loading control. b. 
Quantification of expression levels using Image J.  
 
 
Table 2 Table summarizing the observed effect of modification in different regions of XPF 
 
3.3 DISCUSSION 
XPF-ERCC1 are heterodimeric structure specific endonucleases that have affinity for a w ide 
range of substrates (de Laat et al., 1998a; Sijbers et al., 1996a). Both proteins originate from the 
XPF family of endonucleases. In eukaryotes, XPF has been known to have 3 major domains; the 
helicase like domain, the nuclease domain and the helix-hairpin-helix domain (Aravind et al., 
1999; Sgouros et al., 1999).  ERCC1, having lost the helicase like domain to gene divergence, 
has only two of the three conserved domains; the nuclease dead domain that serves as the DNA 
binding component (Tsodikov et al., 2005) and the helix-hairpin-helix domain. XPF and ERCC1 
interact with each other through their HhH domains (Sijbers et al., 1996a). The nucleolytic 
activity of the complex is mediated by the nuclease domain of XPF (Enzlin and Scharer, 2002) 
and the DNA binding that is essential for the nucleolytic activity is carried out by ERCC1. 
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3.3.1 The nuclease domain of XPF 
Even though we know a lot about the structure and the substrate specificity of XPF, the 
functional importance of the nuclease domain is still not well established. Our cellular studies 
show that the active nucleolytic activity of XPF is absolutely essential for NER, ICL repair and 
DSB repair. This is further established by the local damage assay that shows a persistence of the 
6-4PP and ERCC1 foci even after 24h of UV treatment. Similarly, persistence of the 
monoubiquitinated form of FANCD2 provides additional proof that cells harboring the nuclease 
dead XPF are incapable of completing ICL repair (Figure 3-2Figure 3-4). 
3.3.2 Uncoupling repair functions of XPF-ERCC1 
Preliminary data from our lab has shown that the addition of a GFP tag to the N-terminus of the 
XPF gene makes cells hypersensitive to crosslinking agents. Our study has investigated the 
importance of the N-terminus of the XPF gene for ICL repair. A small HA-tag at the N-terminus 
of the protein does not seem to have an effect on the sensitivity of the cells to crosslinking agents 
however a deletion in the N-terminus of the XPF gene seems to have a profound effect on 
crosslink sensitivity (Figure3-2). 
 It is now well established that the recruitment of XPF-ERCC1 to the NER pathway is 
mediated by the interaction between XPA and ERCC1 (Orelli et al., 2010b; Tripsianes et al., 
2007; Tsodikov et al., 2007). Our study investigates regions of the XPF gene involved in the 
recruitment of XPF-ERCC1 to the ICL repair pathway. The glycine residue in the 325 position of 
the XPF gene when mutated seems to make cells hypersensitive to crosslinking agents (Figure 
3-6). Additionally, the conversion of bulky residues W, L and F in positions 326, 327 and 328 of 
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XPF to alanine residues, preferentially makes cells hypersensitive to crosslinking agents 
(Figure3-6). The unexpected mutation of G703D identified in the nuclease domain of the XPF 
mimics the hypersensitivity seen in the XPFG325E and XPFWLF-A cell lines (Figure 3-6). This 
result identifies a new region within the nuclease domain of XPF that seems to be important to 
its ICL repair function. The exact nature of the association remains unknown. 
3.3.3 XPF-ERCC1 in aging 
Mice deficient in Xpf-Ercc1 display an exaggerated accelerated aging phenotype characterized 
by numerous degenerative changes associated with aging including osteoporosis, 
neurodegeneration, bone marrow failure, thin skin and reduced kidney and liver function 
(Prasher et al., 2005). On the other hand, NER deficient Xpa null mice are almost identical to 
their wild type litter mates (van Steeg et al., 2001). Additionally, a new human progeroid 
syndrome, XFE, caused by a mutation in the XPF gene was identified in 2006 (Niedernhofer et 
al., 2006). XFE is characterized by death before sexual maturation, weight loss, epidermal 
atrophy, hypertension, liver dysfunction and renal insufficiency and an immunoblot analysis 
comparing the protein levels of XP patients with the XFE patient revealed highly reduced levels 
of XPF-ERCC1 in the XFE patient (Niedernhofer et al., 2006). This was an intriguing finding as 
mutations in the XP-family of genes usually result in Xeroderma pigmentosum, a disorder 
characterized by a deficiency in NER and patients with a deficiency in XPF usually show 
residual NER activity and only have mild XP (McWhir et al., 1993a; Sijbers et al., 1998). The 
phenotype of the XFE patient was found to be almost identical to the Ercc1 deficient mouse 
model and cells from the XFE patient were hypersensitive to crosslinking agents. All these 
observations collectively highlight the fact that dramatic depletion of XPF-ERCC1 results in an 
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exaggerated symptoms in both humans and mice that are characteristic of accelerated aging. This 
phenotype observed is due to functions of XPF-ERCC1 that are distinct from NER with a heavy 
implication towards ICL repair. Our study identifies mutations that uncouple the repair functions 
of the XPF-ERCC1 in NER and ICL repair (Figure 3-2) and provides us with a unique 
opportunity to test the hypothesis that the accumulation of unrepaired interstrand crosslinks in 
cells is accelerating the aging process. In the future, this contribution can be better understood by 
looking at the phenotype of a mouse model harboring these XPF mutations. 
3.3.4 XPF-ERCC1 in chemoresistance 
Numerous studies have implicated XPF-ERCC1 in platin-resistance (Reed, 2006). The initial 
assumption was that increased levels of NER mediated by XPF-ERCC1 was contributing to the 
resistance (Olaussen et al., 2007). This however was proved wrong by studies that have shown 
that the disruption of NER by knocking down proteins involved solely in the nucleotide excision 
repair pathway has no discernible effect on crosslink sensitivity of the cells. However, when 
ERCC1, involved in NER and ICL repair is knocked down by siRNA, the cells become 
hypersensitive to crosslinking agents (Cummings et al., 2006). This was further established by 
Orelli et al. in a study that showed that the disruption of the recruitment of XPF-ERCC1 by XPA 
to the NER pathway does not have an effect on crosslink sensitivity of the cells. Our study 
identifies regions of the XPF gene that are important for the function of XPF-ERCC1 in ICL 
repair but not NER (Figure 3-6). This work paves the way for the development of small molecule 
inhibitors to specific regions of the XPF gene that have the potential to overcome 
chemoresistance. 
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3.4 EXPERIMENTAL PROCEDURES 
3.4.1 Cell Lines 
SV40 transformed human fibroblast cell line wild type (normal), XP2YO (XP-F) were cultured 
in either Ham’s F10 or RPMI supplemented with 10% fetal bovine serum albumin, antibiotics, 
and non-essential amino acids respectively. The cells were all grown at 37 ⁰C in a 5% carbon 
dioxide (CO2) incubator. 
3.4.2 Lentiviral Cell Transduction 
The cDNA of wild-type XPF, XPFWT, XPFD676A, XPFΔ5N, XPFHA, XPFG314E and XPFWLF-A were 
cloned into the lentiviral vector pWPXL by substituting the green fluorescent protein cDNA. 
293T cells were co-transfected with the lentiviral vector containing the different constructs, the 
packaging plasmid psPAX2, and the envelope plasmid pMD2G. Details of the vectors, the 
production of high titer viruses, and lentiviral transduction can be found through LentiWeb 
(Salmon et al., 2000; Salmon and Trono, 2006). XPF deficient human XP2YO fibroblast cells at 
50% confluency were infected with the viral particles containing the different XPF recombinant 
constructs with a multiplicity of infection of 10 a nd cultured as described above. The 
transduction efficiency was assessed by immunofluorescence. 
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3.4.3 Immunoblotting 
Cells were trypnized, washed with PBS and were lysed with NETT buffer (100mM NaCl, 50mM 
Tris base, pH 7.5, 5mM EDTA, pH 8.0, 0.5% Triton X-100) containing Complete mini-protease 
inhibitor cocktail and phosphatase inhibitor cocktail (Roche). 60ug of total protein was boiled for 
5 min in 4X protein loading buffer (0.25 M Tris-HCl, pH 8.5, 8% SDS, 1.6 mM EDTA, 0.1M 
DTT, 0.04% bromophenol blue and 40% glycerol), separated by SDS-PAGE (10% 
polyacrylamide gel), and transferred to a nitrocellulose membrane. The expression of XPF (anti-
XPF: Ab1; Neomarkers; 1:1000) or ERCC1 (anti-ERCC1: D-10; Santa Cruz; 1:100) was 
estimated by immunodetection. Tubulin antibody (Promega) was used as the loading control. 
3.4.4 Local UV Irradiation and Immunofluorescence 
Cells were seeded and cultured on g lass coverslips and processed as described (Volker et al., 
2001). Briefly, cells were covered with a polycarbonate filter with 5-μm pores (Millipore) and 
irradiated with 120 J /m2 using a UV-C lamp (EL series, UVP, model UVLS-28). After a 
recovery period, the cells were washed with PBS, permeabilized with 0.2% Triton X-100 in PBS 
for 30 s, and then fixed with 3% paraformaldehyde containing 0.2% Triton X-100 for 15 min at 
room temperature. Cells were washed with PBS containing 0.1% Triton five times. To detect (6-
4)PP, cells were treated with 0.07 M NaOH in PBS for 5 min and washed. Cells were blocked 
with PBS+ (PBS containing 0.15% glycine and 0.5% bovine serum albumin) for 30 min and then 
incubated with the primary antibodies (murine monoclonal antibody 64M-2 against (6-4)PP 
(kindly provided by Stuart Clarkson, Geneva, Switzerland), 1:400; rabbit polyclonal antibody 
FL-297 against ERCC1 (Santa Cruz Biotechnology), 1:300, diluted in PBS+) for 2 h under dark 
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and humid conditions. The samples were embedded in VECTASHIELD mounting medium 
(Vector Laboratories) containing 4′-6′-diamino-2-phenylindole at a concentration of 0.1 mg/ml. 
Cells were analyzed using a confocal microscope (Zeiss LSM 510). For quantification, at least 
100 cells were analyzed and counted each in three independent experiments. 
3.4.5 Clonogenic Survival Assay 
Exponentially growing cells were plated in 6 cm dishes in triplicate at a density of 1-20 x 103-
cells/plate for human cells depending on the dose of genotoxin used and the predicted phenotype 
of the cells. For example for human cells, wild-type cells were plated as follows: 3 plates at 1000 
cells/plate (untreated), 3 plates at 1000 cells/plate (dose 1), 3 plates at 1000 cells/plate (dose 2), 3 
plates at 2000 cells/plate (dose 3), and 3 plates at 2000 cells/plate (dose 4). For human cells, 
knock-out cells were plated as follows: 3 plates at 1000 cells/plate (untreated) 3 plates at 1000 
cells/plate (dose 1), 3 plates at 2000 cells/plate (dose 2), 3 plates at 4000 cells/plate (dose 3), and 
3 plates at 20,000 c ells/plate (dose 4). The next day, the cells were transiently exposed to 
genotoxins. For UV treatment, the media was aspirated from the plates, the cells were washed 
with PBS, irradiated with UV-C (254 nm, Spectroline X-15) and the cells were replenished with 
fresh medium. For Mitomycin C (MMC) treatment, the cells were treated with medium 
containing Mitomycin C (Fisher) dissolved in deionized water at 37 ⁰C for 1 hr. The plates were 
then washed twice with PBS and replenished with fresh medium.  Seven to ten days after 
exposure to genotoxins, when colonies are visible to the naked eye, the cells were fixed and 
stained with 50% methanol, 7% acetic acid and 0.1% Coomassie brilliant blue. The colonies 
(defined as containing >10 cells) were counted using an Olympus SZ61 stereomicroscope with a 
10X eyepiece. The data was plotted as the number of colonies on treated plates divided by the 
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number of colonies on untreated plates ± S.E. for a minimum of 2 independent experiments, both 
done in triplicate. 
3.4.6 Immunoprecipitation for silver staining 
Protein A/G beads were incubated for 4 hours at 4˚C with 10µg of the anti-XPF antibody clone 
219 (Neomarkers), then washed once with PBS and once with 0.2M Sodium Tetraborate 
Decahydrate (Na2B4O7.10H2O) (pH9.0) at room temperature. The beads were then incubated 
with crosslinking buffer containing 0.02M Dimethyl Pimelimidate (DMP) for 30 minutes at 
room temperature to crosslink the antibody to the beads and then in 0.2M Ethanolamine (pH8.0) 
for 30 m inutes to stop the reaction. The beads were then thoroughly washed at 4˚C with two 
changes of PBS and two changes of RIPA buffer, and stored at 4˚C for further use. 
 HeLa cells were trypsinized, pelleted, washed twice with PBS and then lysed with RIPA 
buffer on ice for 30 minutes. The whole cell lysate (WCE) was clarified by centrifugation and 
then precleared with protein A/G beads. The precleared lysate was then mixed with the anti-XPF 
antibody crosslinked to protein A/G beads as described above, and incubated at 4˚C for 4 hours. 
The beads were spun down, washed thoroughly with RIPA buffer, and then incubated with 
4xLaemmli buffer (0.25 M Tris-HCl, pH 8.5, 8 % SDS, 1.6 mM EDTA, 0.1 M  DTT, 0.04% 
bromophenol blue and 40% glycerol) for 10 minutes at 90˚C. The sample was resolved on an 8% 
SDS-PAGE gel and silver stained using the Bio-Rad silver stain plus kit according to the 
manufacturer’s instructions. Bands corresponding to the expected mass of XPF were dissected 
and immediately frozen at -80˚C for mass spectrometric analysis. 
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3.4.7 LC-MS/MS and Data analysis 
Gel bands of the protein of interest, obtained from silver staining, were subjected to in-gel 
digestion. The gel bands were destained in 50% acetonitrile in 50 mM NH4HCO3, pH 8.4 and 
vacuum dried. Trypsin (20 μg/ml in 25 mM NH4HCO3, pH 8.4) was added and samples were 
allowed to incubate on ice for 45 minutes. The supernatant was removed and the gel bands were 
covered with 25 mM NH4HCO3, pH 8.4, and incubated at 37 
οC overnight. From the gel pieces, 
tryptic peptides were extracted using 70% acetonitrile, 5% formic acid, lyophilized to dryness 
and resuspended in 10 μl of 0.1% trifluoroacetic acid prior to mass spectrometry (MS) analysis. 
3.4.8 Immunodetection of FANCD2 foci 
Wild-type and XP2YO human fibroblasts  were plated on glass coverslips at 50% confluence and 
then 16 h l ater were exposed to 3 μM MMC for 1 h or left untreated. At 6, 12, 24, and 48 h 
following exposure, cells were fixed as described previously (Wang et al., 2004) with some 
modifications. Briefly, cells were washed with PBS, permeabilized with ice-cold 0.5% Triton X-
100 in PBS, and then fixed with 2% paraformaldehyde and blocked with 5% bovine serum 
albumin at room temperature. FANCD2 was detected by incubation with rabbit polyclonal anti-
FANCD2 antibody (1:1,000; Novus Biologicals) for 90 min at room temperature and then with 
goat anti-rabbit antibody-Alexa-488 (1:1,000; Invitrogen). Images were taken of 20 f ields of 
cells for each genotype. The total number of nuclei and the number of nuclei with foci were 
counted in each field. The sum from all fields was used to calculate the percent of nuclei with 
foci. The experiment was done in triplicate. Student's t test was used to probe significant 
differences between cell lines. 
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3.5 SUPPLEMENTARY DATA 
 
Figure 3-9 GFP tag in the N-terminus and not the C-terminus of XPF makes cells selectively 
hypersensitive 
Cells were challenged with UV (254nm) to compare the impact of a GFP tag, in the N-terminus 
versus the C-terminus, on NER, and ICL repair. WT (wild-type, SV40-transformed human 
fibroblasts), XPF-deficient (XPF-/-) and cell lines complemented with XPF harboring a N-
terminal GFP tag (GFP-XPF), C-terminal GFP tag (XPF-GFP).  T he data were plotted as the 
percentage of colonies that were formed on the treated plates relative to the untreated plates ± 
S.E (error bars) for a minimum of two independent experiments each done in triplicate. 
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XPF 
MESGQPARRIAMAPLLEYERQLVLELLDTDGLVVCARGLGADRLLYHFLQLHCHPACLVLVLNTQPAEEEYFINQLKIEG
VEHLPRRVTNEITSNSRYEVYTQGGVIFATSRILVVDFLTDRIPSDLITGILVYRAHRIIESCQEAFILRLFRQKNKRGFIKAFT
DNAVAFDTGFCHVERVMRNLFVRKLYLWPRFHVAVNSFLEQHKPEVVEIHVSMTPTMLAIQTAILDILNACLKELKCHN
PSLEVEDLSLENAIGKPFDKTIRHYLDPLWHQLGAKTKSLVQDLKILRTLLQYLSQYDCVTFLNLLESLRATEKAFGQNSG
WLFLDSSTSMFINARARVYHLPDAKMSKKEKISEKMEIKEGEETKKELVLESNPKWEALTEVLKEIEAENKESEALGGPG
QVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEKDSKAEEVWMKFRKEDSSKRIRKSHKRPKDPQNKERASTKERTLK
KKKRKLTLTQMVGKPEELEEEGDVEEGYRREISSSPESCPEEIKHEEFDVNLSSDAAFGILKEPLTIIHPLLGCSDPYALTRVL
HEVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFEKLIREKASMVVPEEREGRDET
NLDLVRGTASADVSTDTRKAGGQEQNGTQQSIVVDMREFRSELPSLIHRRGIDIEPVTLEVGDYILTPEMCVERKSISDLI
GSLNNGRLYSQCISMSRYYKRPVLLIEFDPSKPFSLTSRGALFQEISSNDISSKLTLLTLHFPRLRILWCPSPHATAELFEELK
QSKPQPDAATALAITADSETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELAALSQDELTSILGNAANAK
QLYDFIHTSFAEVVSKGKGKK 
XPF degradation band 1 
MESGQPARRIAMAPLLEYERQLVLELLDTDGLVVCARGLGADRLLYHFLQLHCHPACLVLVLNTQPAEEEYFINQLKIEG
VEHLPRRVTNEITSNSRYEVYTQGGVIFATSRILVVDFLTDRIPSDLITGILVYRAHRIIESCQEAFILRLFRQKNKRGFIKAFT
DNAVAFDTGFCHVERVMRNLFVRKLYLWPRFHVAVNSFLEQHKPEVVEIHVSMTPTMLAIQTAILDILNACLKELKCHN
PSLEVEDLSLENAIGKPFDKTIRHYLDPLWHQLGAKTKSLVQDLKILRTLLQYLSQYDCVTFLNLLESLRATEKAFGQNSG
WLFLDSSTSMFINARARVYHLPDAKMSKKEKISEKMEIKEGEETKKELVLESNPKWEALTEVLKEIEAENKESEALGGPG
QVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEKDSKAEEVWMKFRKEDSSKRIRKSHKRPKDPQNKERASTKERTLK
KKKRKLTLTQMVGKPEELEEEGDVEEGYRREISSSPESCPEEIKHEEFDVNLSSDAAFGILKEPLTIIHPLLGCSDPYALTRVL
HEVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFEKLIREKASMVVPEEREGRDET
NLDLVRGTASADVSTDTRKAGGQEQNGTQQSIVVDMREFRSELPSLIHRRGIDIEPVTLEVGDYILTPEMCVERKSISDLI
GSLNNGRLYSQCISMSRYYKRPVLLIEFDPSKPFSLTSRGALFQEISSNDISSKLTLLTLHFPRLRILWCPSPHATAELFEELK
QSKPQPDAATALAITADSETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELAALSQDELTSILGNAANAK
QLYDFIHTSFAEVVSKGKGKK 
XPF degradation band 2 
MESGQPARRIAMAPLLEYERQLVLELLDTDGLVVCARGLGADRLLYHFLQLHCHPACLVLVLNTQPAEEEYFINQLKIEG
VEHLPRRVTNEITSNSRYEVYTQGGVIFATSRILVVDFLTDRIPSDLITGILVYRAHRIIESCQEAFILRLFRQKNKRGFIKAFT
DNAVAFDTGFCHVERVMRNLFVRKLYLWPRFHVAVNSFLEQHKPEVVEIHVSMTPTMLAIQTAILDILNACLKELKCHN
PSLEVEDLSLENAIGKPFDKTIRHYLDPLWHQLGAKTKSLVQDLKILRTLLQYLSQYDCVTFLNLLESLRATEKAFGQNSG
WLFLDSSTSMFINARARVYHLPDAKMSKKEKISEKMEIKEGEETKKELVLESNPKWEALTEVLKEIEAENKESEALGGPG
QVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEKDSKAEEVWMKFRKEDSSKRIRKSHKRPKDPQNKERASTKERTLK
KKKRKLTLTQMVGKPEELEEEGDVEEGYRREISSSPESCPEEIKHEEFDVNLSSDAAFGILKEPLTIIHPLLGCSDPYALTRVL
HEVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFEKLIREKASMVVPEEREGRDET
NLDLVRGTASADVSTDTRKAGGQEQNGTQQSIVVDMREFRSELPSLIHRRGIDIEPVTLEVGDYILTPEMCVERKSISDLI
GSLNNGRLYSQCISMSRYYKRPVLLIEFDPSKPFSLTSRGALFQEISSNDISSKLTLLTLHFPRLRILWCPSPHATAELFEELK  
Figure 3-10 Peptide coverage for different bands from silver stained XPF-IP 
Each highlighted segment represents one fragment. Where fragments overlap, different emphasis 
(font color, underline or italics) was used. The bold letters are the first eleven amino acids in the 
new XPF sequence. The green highlight shows the peptide found by MS that confirms the new 
XPF sequence. 
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In Chapter 3, we investigated the importance of the N-terminus of XPF to NER, ICL repair and 
DSR repair by mutational analysis. The study included mutations in multiple conserved residues 
in the N-terminus, investigated for their importance in protein:protein interaction that recruit 
XPF-ERCC1 to the ICL repair pathway. We identified two mutations in the N-terminus of XPF 
that renders cells selectively sensitive to crosslinking agents thereby generating an ICL repair 
deficient mutant. This study was designed to identify regions of the XPF gene that could be 
exploited to answer two important questions. Is the accelerated aging phenotype observed in both 
mice and humans, deficient in XPF-ERCC1, due to the accumulation of unrepaired ICLs. This 
could be accomplished by making mouse models expressing the newly identified XPF proteins. 
Secondly, since XPF-ERCC1 have been implicated in conferring chemoresistance, designing 
small molecule inhibitors to the regions of the XPF gene identified in this study, will help 
overcome chemoresistance. 
 There are over thousand papers in the last few decades aimed at establishing a correlation 
between XPF-ERCC1 SNP data, mRNA levels and protein levels with chemoresistance. The 
perplexing fact is that there is yet no convincing evidence of such an association. Focusing on 
protein levels, the reason for the lack of a conclusive association between XPF-ERCC1 protein 
levels and sensitivity to chemotherapeutic regimes, is due to the unavailability of powerful 
antibodies. The kind of antibodies that have good specificity and sensitivity towards their 
antigen, and are compatible with immunohistochemical detection. Chapter four of this 
dissertation, described below, aims to develop and stringently characterize monoclonal 
antibodies raised against purified recombinant XPF-ERCC1 in complex. 
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4.1 INTRODUCTION 
Many of the most effective cancer therapies involve genotoxic agents that induce DNA damage, 
including ionizing radiation, alkylating agents and platinum drugs. Cisplatin is a widely used 
chemotherapeutic agent that forms lesions that are thought to be selectively toxic to rapidly 
dividing cells (similar to tumor cells) by blocking DNA replication (McHugh et al., 2001; Rice et 
al., 1988). Cisplatin is used to treat a variety of solid tumors including ovarian, lung, and head 
and neck carcinoma (Lebwohl and Canetta, 1998; Lokich and Anderson, 1998) but 25-50% of 
tumors are resistant. Amongst the factors that are thought to contribute to chemoresistance is 
decreased tumor blood flow, defective binding of drug to ligand, reduced apoptosis, quiescent 
populations of cells in the tumor, multi-drug resistance pumps, and increased DNA repair (Rabik 
and Dolan, 2007; Stewart, 2007; Vasey, 2003). 
 Tumorigenesis occurs as cells acquire multiple mutations that contribute to a growth 
advantage. The accumulation of mutations is facilitated if cells have some aspect of DNA repair 
that is impaired.  Hence, cancer cells are thought to be defective in at least one DNA repair 
mechanism in order to accumulate mutations at an accelerated rate. A novel approach to cancer 
therapy is to exploit this difference in DNA repair capacity between normal and tumoral cells to 
create synthetic lethality by treating with an inhibitor of a second DNA repair pathway. This will 
render tumor cells hypersensitive to genotoxic agents because they are missing two DNA repair 
mechanisms, compared to normal tissue in which only one pathway is inhibited.  This is thought 
to give selective killing of the tumoral tissues over the host tissues. There is a huge body of 
literature that details attempts to analyze whether cancer cells preferentially up-regulate the 
expression of specific DNA repair proteins in order to tolerate the damage induced by genotoxic 
agents. But there is no conclusive evidence of this. 
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 Most of the lesions formed by cisplatin are repaired by nucleotide excision repair. 
However, chemo effectiveness is majorly contributed by ICLs, which constitute less than 5% of 
the lesions, and are repaired by the ICL repair pathway (Bhagwat et al., 2009b; Dronkert and 
Kanaar, 2001; Lawley and Phillips, 1996). The endonuclease XPF-ERCC1 is essential for NER 
(Petit and Sancar, 1999; Sijbers et al., 1996a) and the repair of interstrand crosslinks (De Silva et 
al., 2000; Kuraoka et al., 2000). Being the only protein complex that is essential to both 
pathways has made XPF-ERCC1 a possible biomarker of tumor outcome. XPF harbors the 
catalytic domain that is required for nuclease activity (Enzlin and Scharer, 2002) and ERCC1 is 
required for DNA binding (Tsodikov et al., 2005). The proteins are known to bind and stabilize 
each other in vivo and this has been established by studies that show that the levels of XPF are 
reduced in ERCC1 deficient cells and vice versa (Niedernhofer et al., 2006). The obligate 
heterodimeric nature of the proteins suggests that either of the two could be used as a good 
biomarker to predict chemosensitivity. 
 Much effort has been put into determining if XPF-ERCC1 levels (mRNA or protein) 
could be predictive of chemotherapeutic outcome which determines whether or not a cancer 
patient will respond to genotoxic agents. A number of studies have suggested that ERCC1 levels 
correlate with chemotherapy effectiveness and that high ERCC1 expression correlates with a 
poor patient outcome (Lee et al., 2008; Zheng et al., 2007). Many of these studies use an 
antibody 8F1 that lacks specificity to ERCC1 (Niedernhofer et al., 2007), bringing into question 
their interpretation with respect to the mechanism of tumor resistance. Down-regulation of XPF-
ERCC1 by RNAi in cells lines from NSCLC, breast and ovarian cancer patients leads to a 
significant increase in cisplatin cytotoxicity (Arora et al., 2010), suggesting that XPF-ERCC1 
would be a good target to induce synthetic lethality or as a biomarker to tumor sensitivity to 
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genotoxins. The use of XPF as a biomarker to predict patient outcome has been largely 
unexplored with the exception of a recent study that reports a significant correlation between 
lower XPF protein expression and longer progression-free survival in HNSCC patients treated 
with DNA damaging agents (Vaezi et al., 2011). 
 In this study, we sought to identify and rigorously test a panel of novel murine 
monoclonal antibodies raised against recombinant XPF-ERCC1 complex. Our testing regime 
involves evaluating each hybridoma clone for its specificity for XPF-ERCC1 in several 
applications including immunohistochemistry, using XPF-ERCC1-deficient human cells as a 
negative control. Our ultimate aim is to identify an antibody that can reproducibly detect 
variations in expression levels of XFP-ERCC1 by immunohistochemical analysis. In addition, 
the novel approach of raising antibodies against the protein complex has the potential to yield 
antibodies that inhibit the complex or disrupt protein:protein interactions that are imperative for 
targeting the complex to specific repair pathways (Orelli et al., 2010a). This study has the 
promise to 1. identify an antibody that can be used to critically discern the utility of XPF-ERCC1 
as a biomarker in cancer and 2. uncouple the functions of the XPF-ERCC1 in DNA repair and 
thereby be utilized for adjuvant antibody therapy. The combination has the potential to improve 
personalized cancer therapy and improve patient prognosis. 
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4.2 RESULTS 
4.2.1 Antibodies 
Murine antibodies were generated using full-length recombinant his-tagged XPF-ERCC1 as the 
antigen via hybridoma technology. XPF-ERCC1 is an obligate heterodimer (Biggerstaff et al., 
1993) that is recruited to different DNA repair pathways via protein:protein interactions (Orelli 
et al., 2010a). Therefore, antibodies raised against the complex, as opposed to single subunits, 
could potentially be used to separate functions of the complex by disrupting some but not other 
protein:protein interactions. The ten best hybridoma cell lines were identified by Enzyme-linked 
immunosorbent assay using the antigen for solid-phase screening. Three milliliters of the crude 
supernatant from each of the ten clones were screened for specificity using a rigorous testing 
regime to determine the utility of each antibody in a multiple immune techniques. Validated 
negative controls, including cell lines from humans with inherited mutations in XPF or ERCC1 
affecting expression of the repair complex, were used at each step to demonstrate specificity of 
the antibodies, which has been a problem with commercially available antibodies (Niedernhofer 
et al., 2007). 
4.2.2 Primary screening of the supernatants by immunoprecipitation 
The crude antibody supernatants (30 µL) from the 10 h ybridoma clones were tested for their 
ability to immunoprecipitate XPF-ERCC1 from whole cell extracts from normal human 
fibroblasts. The precipitates were probed for XPF via immunoblotting using antibody Ab1 
(Neomarkers) and ERCC1 using antibody D10 (Santa Cruz), both of which we previously 
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validated for specificity (Bhagwat et al., 2009c). XPF-ERCC1 was immunoprecipitated by 
supernatants from all of the hybridoma clones with the exception of 2B-10 (Figure 4-1). The 
yield of XPF-ERCC1 by immunoprecipitation varied significantly between the different clones. 
To rank the utility of the various hybridoma clones for immunoprecipitation, they were classified 
as +, +/- or – based on the relative yield of XPF-ERCC1 immunoprecipitated with 10µl of the 
validated antibody D10. 
 
Figure 4-1 4-1 Immunoprecipitation of XPF-ERCC1 using crude antibody 
WCEs from normal human fibroblasts were immunoprecipitated with test antibodies 1E4, 3A-
11, 1H3, 3H4, 3G7, 2B4, 3A-10, 2B-10, 4C4, and 2E2. Anti-ERCC1 antibody D-10 was used as 
the control. Precipitates were separated by SDS-PAGE, blotted and immunostained with 
antibody Ab-1 to detect XPF protein and antibody D-10 to detect ERCC1. 
4.2.3 Immunoblotting 
Immunoprecipitation revealed if the antibodies recognized XPF-ERCC1, but cannot distinguish 
which subunit the antibody is recognizing. To determine this, the hybridoma supernatants were 
next screened for their ability to detect XPF and ERCC1 by immunoblotting. In addition, XPF-
ERCC1-deficient cells were used to establish specificity of the antibodies. Whole cell extracts 
from normal and XP-F human fibroblasts were used. Ab1 (anti-XPF) and D10 (anti-ERCC1) 
were used as positive controls. Of the 10 antibodies screened, 1E4, 3H4, 3A-11, 3G7, and 1H3 
detected XPF at varying intensities (Figure 4-2a). The 1E4 antibody appeared to be the most 
sensitive for detecting XPF. None of the supernatants detected exclusively ERCC1, suggesting 
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that XPF is more antigenic or occupies a significantly greater portion of the surface of the XPF-
ERCC1 complex. Interestingly, 3G7 detected both XPF and ERCC1 with equivalent intensities. 
This was verified by probing recombinant His-tagged XPF-ERCC1 (Figure 4-2b). 
 Because of the utility of Chinese hamster ovary cells and murine models of XPF-ERCC1 
deficiency for interrogating the function of the repair complex, the ability of the antibodies to 
detect hamster and mouse XPF-ERCC1 was determined by blotting whole cell extracts from 
wild-type hamster and mouse cells. Xpf mutant or Ercc1 knock-out cells, respectively, were used 
as negative controls. 3H4 detected mouse XPF (Figure 4-2c). None of the other antibodies 
detected either XPF or ERCC1 in the mouse and hamster whole cell extracts (data not shown). 
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Figure 4-2 Immunodetection of XPF ERCC1 using crude antibody 
a. Normal (wild-type) and XPF-ERCC1 deficient XPF mutant human fibroblasts (XP2YO) were 
lysed and whole cell extracts were collected. The proteins were separated SDS-PAGE (10% 
polyacrylamide gel), transferred onto nitrocellulose membranes and immunostained with each 
test antibody (1E4, 3A-11, 1H3, 3H4, 3G7, 2B4, 3A-10, 2B-10, 4C4, and 2E2). Previously 
characterized antibodies, anti-XPF: Ab1, and anti-ERCC1: D-10 were used as controls. Tubulin 
was used as a loading control. b. Recombinant His-tagged XPF-ERCC1 was separated by SDS-
PAGE and was immunostained with 3G7 to confirm XPF and ERCC1 dual antigen specificity.  
c. Whole cell extracts from Normal (wild-type), XPF-ERCC1 deficient XPF mutant human 
fibroblasts (XP2YO), wild-type and ERCC1-/- mouse embryonic fibroblasts were SDS-PAGE 
separated and immunostained with antibodies, 1E4 and 3H4. Tubulin was used as a loading 
control. 
4.2.4 Immunofluorescence 
Immunofluorescence is an important method for determining the sub-cellular localization of 
proteins within a cell. The crude supernatants were screened for their ability to detect XPF-
ERCC1 in cells fixed with paraformaldehyde. To establish specificity, differential 
immunofluorescence was used (Volker et al., 2001). Normal and XPF-ERCC1-deficient human 
fibroblasts (XP2YO) were labeled with 3µm and 0.6µm latex beads, respectively, and then 
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subsequently co-cultured on glass coverslips. The coverslips were immunostained with two 
antibodies: the test antibody and FL297 (anti-ERCC1; Santa Cruz), which was previously 
established to be specific (Bhagwat et al., 2009c). The expectation was that if the test antibodies 
were specific for XPF-ERCC1, then the signals from both antibodies would co-localize and only 
in the nuclei of cells with small beads (Figure 4-3). The test antibodies were detected by the 
FITC (green) channel and the control antibody FL297 was detected in the TRITC (red) channel. 
The nuclei of the cells were stained with DAPI. Bright-field microscopy was used to identify 
cells differentially labeled with beads. The test antibody was considered effective for 
immunofluorescence only if it p referentially stained the nuclei of cells labeled with the 3 µm 
beads and the FITC signal co-localized with that of the TRITC, similar to what was observed 
with the positive control (D10 anti-ERCC1). The antibodies 1E4, 1H3, and 3A-11 distinguished 
between cells with XPF-ERCC1 and those without (Figure 4-3). The remainder of the antibodies 
were unable to distinguish between normal and XP-F mutant cells or caused cytoplasmic staining 
under the conditions tested (Figure 4-8). 
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Figure 4-3 Immunofluorescence detection of XPF-ERCC1 using crude antibody 
The cytoplasm of normal (wild-type) and XPF-ERCC1 deficient XPF mutant human fibroblasts 
(XP2YO) was labeled with large (black arrow) and small latex beads (white arrows), 
respectively. The cells were then co-cultured on glass coverslips, fixed and stained. (i) 
Brightfield images reveal differentially labelled cells in the same field. (ii) The nuclei are stained 
with DAPI. (iii) Immunostaining with test antibodies (1E4, 1H3, 3A-11, and D-10; secondary 
antibody Alexa 488, in green). (iv) Co-mmunostaining with antibody FL297 against ERCC1 to 
distinguish between the normal and XPF-ERCC1 deficient cells (Alexa 594, in red). 
4.2.5 Immunohistochemistry 
Immunohistochemistry is the most important application for antibodies that have potential to be 
used to detect tumor biomarkers due to the predominance of fixed tissues and tumor microarrays. 
However, the specificity of antibodies in immunohistochemical applications is rarely tested due 
to the lack of negative control tissues. To address this, we created paraffin blocks of normal 
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human fibroblasts (C5RO) and XP-F fibroblasts (XP51RO), deficient in XPF-ERCC1. These 
were sectioned and stained like tissue, using hematoxylin as a counterstain. An antibody was 
considered useful for immununohistochemistry if it gave a clear nuclear stain in the normal cells 
but not XP-F. The supernatants from clones 1E4 and 3A-11 were the only two that specifically 
stained cells containing XPF-ERCC1. The 1H3 antibody detected XPF-ERCC1 in both the 
positive and negative control slides reiterating the importance and the need for negative controls 
while screening antibodies for immunohistochemistry. The rest of the antibodies did not stain 
either sample brown indicating either their lack of sensitivity or their incompatibility with 
immunohistochemistry (Figure 4-4). 
 The results obtained from the preliminary screening of the crude antibody supertants is 
summarized in Table 3 
 106 
 
Figure 4-4 Immunohistochemical detection of XPF-ERCC1 using crude antibody 
Immunohistochemical detection. Normal (C5RO) or XPF-ERCC1 deficient human fibroblasts 
(XP51RO) were fixed in paraformaldehyde, pelleted in agarose, paraffin embedded, sectioned 
and stained to serve as positive and negative controls, respectively. IHC was carried out with test 
antibodies against XPF (1E4, 3A-11, 1H3, 3H4, 3G7, 2B4, 3A-10, 2B-10, 4C4, and 2E2). 
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Table 3 Summary of results from preliminary screening of crude antibody supernatants 
 
4.2.6 Purification and characterization of monoclonal antibodies 
Based on the results obtained from the primary screening, two clones, 1E4 and 3H4, were 
amplified using roller bottle technique and the antibodies were protein A purified by Rockland 
Immunologicals. The yield was 23.0 mg for 1E4 and 83.7 mg for 3H4. These purified antibodies 
were tested for sensitivity and specificity by immunoblot, IF and IHC. For immunoblot, whole 
cell extracts from normal and XPF-ERCC1 deficient human fibroblasts and mouse embryonic 
fibroblasts were used in addition to recombinant His-tagged XPF-ERCC1 protein. 3H4 
recognized both human and mouse XPF protein (Figure 4-5). The 1E4 antibody recognized only 
the human XPF protein (Figure 4-5). Neither of the antibodies detected ERCC1 in either human 
or mouse samples (data not shown). At a dilution of 1:500, the 1E4 antibody gave a more intense 
signal than the 3H4 antibody, indicating that it is more sensitive for detecting human XPF. 
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Figure 4-5 Immunodetection of XPF-ERCC1 using purified antibodies 
Whole cell extracts were obtained from Normal (wild-type), XPF-ERCC1 deficient XPF mutant 
human fibroblasts (XP2YO), wild-type and ERCC1-/- mouse embryonic fibroblasts. Proteins 
were separated by SDS-PAGE and detected on the blot by loading recombinant His-tagged XPF-
ERCC1. Blots were immunostained with test antibodies a. 3H4 and b. 1E4 and previously 
characterized antibodies, anti-XPF: Ab1, and anti-ERCC1: D-10 were used as controls. Tubulin 
was used as a loading control. 
 
 
To test the utility of the antibodies for immunofluorescence, normal and XPF-ERCC1-
deficient transformed human fibroblasts were fixed on coverslips and immunostained with the 
1E4 and 3H4 antibodies. The samples were co-stained with FL297, a validated ERCC1 antibody. 
1E4 stained normal but not XPF-ERCC1-deficient XP2YO cells, with a pattern identical to that 
of FL297 (Figure 4-6). The 3H4 antibody did not exclusively stain the nuclei of either cell type. 
When the same antibodies were tested on mouse cells, neither detected murine XPF by 
immunofluorescence (data not shown). 
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Figure 4-6 Immunofluorescence detection of XPF-ERCC1 using purified antibody 
Normal (wild-type) and XPF-ERCC1 deficient XPF mutant human fibroblasts (XP2YO) was 
cultured on g lass coverslips, fixed and stained. (i) The nuclei are stained with DAPI. (ii) 
Immunostaining with antibody FL297 against ERCC1 to distinguish between the normal and 
XPF-ERCC1 deficient cells (Alexa 488, in green). (iii) Co-immunostaining with test antibodies 
(1E4, 1H3, 3A-11, and D-10; secondary antibody Alexa 594, in red). 
 
The 1E4 antibody was next tested for immunohistochemical applications at dilutions 
ranging from 1:250, 1:350, 1:450 to 1:4000, 1: 7500 and 1:10,000. At a dilution of 1:4000, 1E4 
gave a strong nuclear stain in paraffin sections of cells expressing XPF-ERCC1 (HeLa) but not 
in XP-F cells (XP51RO), indicating that the purified antibody does work for 
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immunohistochemistry (Figure 4-7a;i/ii).  I n addition, at a dilution of 1:250, 1E4 stained the 
nuclei of human tonsil sections, demonstrating the utility of the antibody in staining human 
tissues (Figure 4-7a;iii) The 1E4 and 3H4 antibodies were then tested for detecting XPF-ERCC1 
in mouse tissues. Testis sections from wild-type and Ercc1-/Δ mice, which express ~5% of the 
normal complement of XPF-ERCC1, were immunostained using an antibody dilution of 1:25 
(Dolle et al., 2006),  T he 1E4 antibody  stained the nuclei of both wild-type and the mutant 
tissue, whereas 3H4 stained the nuclei of wild-type testis only (Figure 4-7b). This indicates that 
3H4 may be useful for immunohistochemistry of murine but not human tissues. 
 
 
Figure 4-7 Immunohistochemical detection of XPF-ERCC1 using purified antibody 
a. Mouse wild-type and ERCC1-/Δ testis was paraffin embedded, sectioned and stained by IHC 
using antibodies 1E4 and 3H4. (i) Normal (HeLa) or (ii) XPF-ERCC1 deficient human 
fibroblasts (XP51RO) were fixed in paraformaldehyde, pelleted in agarose, paraffin embedded, 
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sectioned and stained to serve as positive and negative controls, respectively. (iii) To standardize 
protocol to human tissue section, paraffin embedded human tonsil was sectioned and stained 
along with the cells by IHC with test antibodies against XPF (1E4, and 3H4). 
4.3 DISCUSSION 
Platin based drugs have been the mainstay for cancer chemotherapy ever since it was first 
approved by the FDA in 1978. The non responsiveness of more than 50-75% of the patients is a 
cause of major concern in the public health sector. Among the various tumors that develop 
resistance to cisplatin are head and neck squamous cell carcinoma, ovarian cancer, and NSCLC. 
There is an immediate need to devise a treatment plan which will improve patient prognosis and 
this calls for the identification of novel biomarkers that can help predict patient response so that 
therapy can be tailored to suite each individual. 
 In recent years, XPF and ERCC1 are two proteins that have gained a lot of importance as 
potential biomarkers to chemoresistance. XPF-ERCC1 is a structure specific endonuclease that is 
involved in multiple DNA repair pathways and telomere maintenance. They are obligate 
heterodimers that bind and stabilize each other. Fibroblasts isolated from human XPF patients 
show highly reduced levels of ERCC1 (Yagi et al., 1997). The same is true in the case of XPF 
where only a small level of the protein has been detected in ERCC1 deficient mammalian cells 
(Gaillard and Wood, 2001).  XPF and ERCC1 can only function when they form a complex and 
so their individual functions are interdependent. Having observed that the levels of XPF and 
ERCC1 are closely correlated in normal human cells and mouse models, it would be safe to 
assume that the same would be true in the case of tumor samples. This has lead to the 
interchangeable usage of the two proteins as potential predictors of chemoresistance. 
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 Immunohistochemical analysis is an invaluable tool that can be used to assess patient 
prognosis by measuring the expression levels of certain key proteins. The most important aspects 
of IHC analysis involve sample availability, sample fixation, antigen retrieval, the antibody 
utilized and the interpretation of results. Each of these steps is crucial and has to be fine tuned for 
every antibody developed. The selection of the best antibody for a specific antigen is complex, 
and it is  essential to employ a highly selective and stringent screening strategy to characterize 
each antibody so that they can be confidently utilized for IHC analysis. One of the major 
drawbacks of IHC is that it is impossible to tell whether the antibody in question is detecting our 
proteins, XPF or ERCC1. The first reason for this is the lack of a molecular marker as in the case 
of an immunoblot analysis. This makes it essential to first confirm by immunoblotting that our 
antibody is highly specific to XPF-ERCC1 before using it for IHC analysis. Secondly, when we 
do an IHC analysis on tumor samples, it is very difficult if not impossible to procure a negative 
control and so to circumvent this problem, we have used paraffin embedded human cells from 
XPF-ERCC1 proficient and deficient cell lines. These measures ensure the specificity of the 
antibody being used. 
 The third issue that could confound our results is the sensitivity of the antibody to XPF-
ERCC1.  Most of the antibodies available commercially are polyclonal which means that they 
could be detecting more than one epitope on t he antigen and this would lead to a lot of non 
specific background staining due to cross reactivity of the antibody with other proteins when 
applied to immunohistochemistry. In addition, the presence of multiple subtypes in a polyclonal 
antibody makes it tricky to choose a secondary antibody for accurate detection. To avoid any 
such issues, we have used only monoclonal antibodies in this study. They have very high 
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homogeneity and since they bind only one epitope, the results are reproducible and highly 
accurate. 
 Among the numerous XPF-ERCC1 antibodies that are available, only a small subset is 
applicable to immunohistochemical analysis. A critical evaluation of all the commercially 
available XPF and ERCC1 antibodies revealed that the ERCC1 antibodies FL297, 3F2 and 4H4 
are the only ones compatible for IHC (Bhagwat et al., 2009c). 
 In this paper, with the help of Abnova, using the recombinant XPF-ERCC1 purified by 
Rick Wood as the antigen, we developed and tested a panel of ten monoclonal antibodies. Our 
testing regime involved using SV40 immortalized human fibroblasts or HeLa cells as the 
positive control and XPF-ERCC1 deficient patient cell line, XP2YO as the negative control. 
Using established methods and the above mentioned stringent controls, we discovered four 
antibodies that are applicable to a variety of immunodetection techniques. The antibodies 1E4, 
and 3A11 were successful in detecting human XPF in all the tested applications. The 3H4 
antibody detected both human and mouse XPF by immunoblotting and immunohistochemistry 
(Figure 4-2Figure 4-5). Based on these results, the antibodies 1E4 and 3H4 were purified and 
were subsequently standardized for IHC analysis on tumor samples (Figure 4-7). In addition to 
these antibodies, a fourth monoclonal antibody, 3G7, that could detect both XPF and ERCC1 by 
immunoblotting was identified (Figure 4-2). 
 There are two major implications to this study; it has helped identify a very sensitive and 
specific monoclonal antibody, 1E4 that can be used for the immunodetection of XPF-ERCC1 in 
tumor samples to predict patient response to chemo radiotherapy. Secondly, the antibody 3G7 is 
of particular interest to us due to its dual antigen specificity. Mapping the epitope of this 
antibody will help elucidate the domain of XPF and ERCC1 that it is specific to. A monoclonal 
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antibody of this nature would be invaluable due to its potential application in adjuvant antibody 
therapy. We plan to explore the potential of this antibody in our future studies. 
4.4 EXPERIMENTAL PROCEDURES 
4.4.1 Cell Culture 
SV40 transformed normal human fibroblast cell lines and XP2YO (XP-F) were cultured in either 
Ham’s F10 or RPMI supplemented, respectively, each supplemented with 10% fetal bovine 
serum albumin, antibiotics and non-essential amino acids. Primary human fibroblasts 
immortalized by the stable expression of human telomerase, C5RO (normal) and XP51RO (XP-
F) were cultured in Ham’s F10 media supplemented with 10% fetal bovine serum albumin, 
antibiotics and non-essential amino acids. Wild-type and Ercc1-/- primary mouse embryonic 
fibroblasts were grown in a 1:1 mixture of Ham’s F10 and DMEM supplemented with 10% fetal 
bovine serum albumin, antibiotics, and non-essential amino acids. The cells were all grown at 
37ºC in a 5% CO2 incubator. 
4.4.2 Antibodies 
Murine antibodies (1E4, 1H3, 2B-10, 2B4, 2E2, 3A-10, 3A-11, 3G7, 3H4, and 4C4) were 
generated using full-length recombinant his-tagged XPF-ERCC1 as the immunogen via 
hybridoma technology. The ten best hybridoma cell lines were identified by Enzyme-linked 
immunosorbent assay using the recombinant his-tagged XPF-ERCC1, his-tagged Protein A and 
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His-FLAG-tagged peptide B for solid-phase screening. Three milliliters of the crude supernatant 
from each of the ten clones were characterized for immunoblotting and immunostaining by 
immunofluorescence and immunohistochemistry. 
4.4.3 Immunoprecipitation 
Cells were trypsinized, washed with PBS and lysed with NETT buffer (100 mM NaCl, 50 mM 
Tris base, pH 7.5, 5  mM EDTA, pH 8.0 a nd 0.5% Triton X-100) containing Complete mini-
protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche).  For immunoprecipitation, 
80 µg of protein from WCEs of each cell line was pre-cleared by incubating them with protein 
A+G beads (Calbiochem) for 30 mins followed by incubation with 100 µl of each test antibody 
and 25 µ l of protein A+G beads with continuous mixing overnight. The beads were then 
collected by centrifugation at 13,000 rpm for 15 mins, washed three times with the NETT buffer 
and PBS; boiled for 5 min in 4X protein loading buffer (0.25 M Tris-HCl, pH 8.5, 8% SDS, 1.6 
mM EDTA, 0.1M DTT, 0.04% bromophenol blue and 40% glycerol), and the eluted proteins 
were separated by SDS-PAGE (10% polyacrylamide gel). Immunoprecipitated XPF was 
detected by anti-XPF antibody (Ab1; Neomarkers; 1:1000) and AP conjugated goat anti-mouse 
secondary antibody (Promega; 1:7500). 
4.4.4 Immunoblotting 
Cells were trypnized, washed with PBS and were lysed with NETT buffer (100mM NaCl, 50 
mM Tris base, pH 7.5, 5 mM EDTA, pH 8.0, 0 .5% Triton X-100) containing Complete mini-
protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche). 60 µg of total protein was 
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boiled for 5 m in in 4X protein loading buffer (0.25 M Tris-HCl, pH 8.5, 8%  SDS, 1.6 m M 
EDTA, 0.1M DTT, 0.04% bromophenol blue and 40% glycerol), separated by SDS-PAGE (10% 
polyacrylamide gel), and transferred to a nitrocellulose membrane. Antibodies were tested for 
their ability to specifically detect XPF or ERCC1. 
4.4.5 Immunofluorescence 
SV40 wild-type, XP2YO human fibroblast cells, and wild-type and ERCC1-/- primary mouse 
embryonic fibroblast cells were seeded and cultured on cover slips. After 24hr, the cells were 
fixed with 2% paraformaldehyde (ICN Biomedicals) at 37 ⁰C for 15 min. The cells were then 
permeabilized with Triton X-100 (0.2% in PBS) by 2 10min washes, and blocked with 3% BSA 
in PBS for 20min. Antibodies were tested for their ability to specifically detect XPF or ERCC1 
at a concentration of 1:100. Goat anti-mouse IgG (1:1000), chicken anti-rabbit IgG (1:1000) 
conjugated with Alexa fluor 488 or Alexa fluor 594 (Invitrogen) were used for visualization. 
4.4.6 Immunohistochemistry 
HeLa and XP2YO cells were grown to 75-80% confluence, fixed with 10% neutral-buffered 
formalin for 15min at room temperature, and collected by scraping.  Cells were stored in neutral-
buffered formalin at 4°C for at least 3 hr, then pelleted by centrifugation (1,200 rpm, 5 min) and 
washed twice with PBS. Cells were resuspended in 500 µ l of 80% ethanol, transferred to 
Eppendorf tubes containing 300 µl of solidified 1% low melting point agarose in PBS, and re-
pelleted. The ethanol was aspirated and the bottoms of the tubes cut off. The agarose plugs 
containing the cells were pushed and molded into the caps of Eppendorf tubes and snap frozen 
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on dry ice. The solidified pellets were extruded from the caps and paraffin embedded according 
to standard methods for tissue. 
 For immunohistochemical staining of the cell plug and paraffin embedded tissue sections, 
heat induced epitope retrieval was carried out with citrate buffer at pH 6 (Dako Target retrieval 
solution, Dako) at 95°C for 20 min. Endogenous peroxidase was quenched using 3% Hydrogen 
peroxide (Fisher Scientific) at room temperature (RT) for 15min. Cell lines were blocked with 
5% goat serum and 3% BSA for 30 m in followed by a avidin/biotin block at RT for 15min. 
Mouse testis sections were blocked using Biocare Rodent Block M for 10 minutes. The cell line 
sections and the mouse testis sections were then incubated with the primary antibodies (mouse 
monoclonal, 1:100, 1:250, 1:500 etc) for optimization for 60 min at room temperature. Primary 
antibody signal was then detected using biotinylated anti-rabbit or anti-mouse secondary 
antibody for 30 m in and DAB+ for 10 min at room temperature (Vectastain ABC kit; Vector 
Laboratories). Haematoxylin was used for counterstaining. 
 For the purified antibodies, the same protocol was used to test paraffin embedded 
sections of HeLa cells, XP2YO cells and human tonsil section. 
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4.5 SUPPLEMENTARY DATA 
 
Figure 4-8 Immunofluorescence detection of XPF-ERCC1 using crude antibodies 3G7 and 3H4 
Normal (wild-type) and XPF-ERCC1 deficient XPF mutant human fibroblasts (XP2YO) was 
cultured on g lass coverslips, fixed and stained. (i) The nuclei are stained with DAPI. (ii) 
Immunostaining with antibody FL297 against ERCC1 to distinguish between the normal and 
XPF-ERCC1 deficient cells (Alexa 488, in green). (iii) Co-immunostaining with test antibodies 
(1E4, 1H3, 3A-11, and D-10; secondary antibody Alexa 594, in red). 
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Chapter four of the dissertation document describes the identification of a monoclonal antibody, 
IE4, against XPF that can be used for immunohistochemical detection of human tumor samples. 
In addition, three other antibodies were also identified. The antibody 3H4, sensitively detects 
human and mouse XPF protein by western blot analysis and is applicable to 
immunohistochemical detection of mouse tissues. Similar to the 1E4 antibody, the 3A-11 
antibody detects human XPF. The most unique antibody identified however, was the 3G7 
antibody that has specificity for both XPF and ERCC1. The dual antigen specificity is an 
invaluable tool that can be utilized, in the future, to destabilize the interaction between XPF-
ERCC1. The 1E4 antibody identified can be used to measure different panels of tumors to 
establish a the presence of absence of a definitive correlation between protein levels and patient 
outcome as measured by immunohistochemical analysis.  
Having established this, we designed our next study, described below in chapter five, to 
measure the nucleotide excision repair capacity of suspension cells. This project is designed to 
semi-automate the measurement of NER using flow cytometry and also to make the 
measurement applicable to blood cells so that the procedure can, in the future, be incorporated in 
diagnostic settings 
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5.0  A METHOD TO MEASURE NUCLEOTIDE EXCISION REPAIR IN 
SUSPENSION CELLS USING CLICK-IT CHEMISTRY AND FLOW CYTOMETRY 
1Madireddy, A., 1Kammerer, C.M. and L.J. Niedernhofer2 
 
1Department of Human Genetics, University  of  Pittsburgh Graduate School of Public Health, 
130 DeSoto Street, Pittsburgh, PA, 15261, USA 
2Department of Microbiology and Molecular Genetics, University of Pittsburgh School of 
Medicine, Pittsburgh, PA. 
5.1 INTRODUCTION 
Our body is constantly exposed to endogenous and environmental agents that cause DNA 
damage. The magnitude of this damage is estimated to be >10,000 new DNA lesions per cell per 
day (Lindahl and Barnes, 2000). At the cellular level, this is combated by orchestrating one of 
five highly complex DNA repair pathways each specific for a particular type of lesion. This 
ensures that DNA can be accurately replicated and transcribed. The importance of each of these 
DNA repair pathways and their role in maintaining the integrity of the genome is clearly 
illustrated by the multitude of inherited diseases caused by defects in DNA repair.  T hese 
diseases are predominantly characterized by early onset of malignant neoplasms and aging-
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related degenerative changes, implicating DNA repair as critical for protecting against cancer 
and aging. 
 Nucleotide excision repair (NER) is an evolutionarily conserved DNA repair pathway 
that removes DNA lesions that are large or bulky enough to distort the DNA helix. These lesions 
arise as a consequence of exposure to aromatic hydrocarbons (e.g. cigarette smoke), 
chemotherapeutic drugs such as cisplatin, and the UV component of sunlight. UV light induces 
two major lesions: 6-4 photo products (6-4PP) (Mitchell and Nairn, 1989) and cyclobutane 
pyrimidine dimers (CPD) (Lippke et al., 1981), both of which are exclusively repaired by NER 
in placental mammals. There are two sub-pathways of NER. Global genome nucleotide excision 
repair (GG-NER) repairs lesions throughout the genome, while transcription-coupled nucleotide 
excision repair (TC-NER) repairs lesions only on the transcribed strand of actively transcribed 
genes (de Laat et al., 1999). 
Inherited defects in NER lead to three diseases: xeroderma pigmentosum, Cockayne 
syndrome (Bertola et al., 2006) or Trichothiodystrophy (Tay, 1971). All three diseases are 
characterized by extreme sunlight sensitivity. Xeroderma pigmentosum is a can cer-prone 
syndrome in which patients have a >10,000-fold increased risk of skin cancer in sun-exposed 
areas of the skin (DiGiovanna and Kraemer, 2012). Cockayne syndrome and 
Trichothiodystrophy are characterized by developmental abnormalities and premature aging. 
This is attributed to defective TC-NER, which in turn leads to defects in transcription. The 
development of an approach to measure the DNA repair capacity of an individual to predict the 
predisposition of a person to such syndromes will help them make cautious choices so as to 
avoid exposure to agents that might make them vulnerable to faster disease progression and will 
thereby help ensure one’s quality of life. 
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This can be better understood with the example of a child who has XP. The exposure of 
babies with XP to sunlight results in extreme sunlight sensitivity characterized by frequent 
sunburns. Only after multiple sunlight exposures do pa rents usually realize that there is 
something wrong with their child. The diagnosis of XP is carried out by functional tests that 
measure a patient cell’s nucleotide excision repair capacity. But the tests that currently exist are 
restricted primarily by their applicability to adherent cells such as fibroblasts that can only be 
obtained by skin biopsies and secondarily by the extended time that it takes to establish the cell 
lines. Due to these reasons, molecular genetic testing is available only in a research setting and is 
not extended to clinical laboratories. An early diagnosis of the disease made using patient blood 
can help guide families to take necessary precaution to retard disease progression. 
Taking a step back from disorders of NER, when we consider cancer, a large majority of 
the chemoradiotherapeutic regimes that exist exploit DNA damage as the key mediator of 
cytotoxicity. However, ~50% of the patients are resistant to treatment and DNA repair that 
counters the damage induced has been implicated as a m ajor factor in conferring resistance. 
Consequently, measuring DNA repair in tumors has been a priority for over a decade and there 
are hundreds of studies that measure repair as a function of individual proteins (Koberle et al., 
1999; Olaussen et al., 2006b). DNA repair is an important factor that determines the inter-
individual differences that come into play in predicting a patient’s response to a therapeutic 
regime. Much effort has been channeled into developing assays, such as the comet assay to 
measure strand breaks that can measure DNA repair. However, there is a lot of conflict over the 
validity of each of these assays in accurately measuring “DNA repair”. The major cause for this 
concern stems from the fact that a large majority of the assays developed predict repair capacity 
based on the activity of one or more proteins. This is a problem because most repair pathways 
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such as NER, involve the coordinated activity of more than 30 different proteins (de Laat et al., 
1999). Determining which of these proteins is rate limiting to repair is important to avoid 
misinterpretation of results obtained from these assays. 
Unscheduled DNA synthesis (UDS) is a well-established assay that directly measures 
NER and is the mainstay of XP-diagnostic laboratories. It was first described by Rasmussen and 
Painter in 1964 and was used to discover that XP is caused by a defect in NER (Cleaver, 1968).  
UDS is also used to assign patients to different genetic complementation groups of XP (De 
Weerd-Kastelein et al., 1972). The attractive aspect of UDS is that the assay assesses the 
function of the entire NER pathway and not the activity of one protein. UDS is a measure DNA 
synthesis that takes place outside of the S-phase of the cell cycle. By definition this is DNA 
repair. Furthermore, in cells exposed to UV, UDS is by definition NER. Treatment of cells with 
UV results in the formation of bulky lesions in the DNA which are repaired by NER.  W hen 
these cells are pulsed with 3[H] –thymidine, this involves the incorporation of 3[H] –thymidine 
into the DNA during the process of repair synthesis (Christmann et al., 2003; Kelly and Latimer, 
2005). Repair is then measured as a function of thymidine uptake which is visualized as “repair 
foci” typically detected either using autoradiography or by liquid scintillation counting. The 
autoradiography based method of measuring UDS is extremely sensitive and accurate but the 
procedure is hazardous, time consuming (3 weeks) and laborious. In addition, the procedure 
requires adherent cells such as fibroblasts that are typically obtained from skin biopsies and main 
problem associated with this technique is that the procurement of skin biopsies is invasive and 
also the development of fibroblasts from the biopsies is time consuming (3 months). There is a 
driving need to automate the process in such a way that it can be applied to human peripheral 
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blood so that results can be obtained much faster and the technique can be efficiently used in a 
lab to measure DNA repair. 
Here we report the development of a semi-automated UDS assay by flow cytometry. This 
assay has been adapted from a recent study where UDS is measured by a non-radioactive method 
by using an azide-conjugated thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU) 
(Limsirichaikul et al., 2009). The degree of automation in the currently existing methods has 
been restricted to analysis using fluorescent imaging (Nakazawa et al., 2010). In our approach, 
repair synthesis is measured in UV-irradiated peripheral blood mononuclear cells using flow 
cytometry to detect non-replicating cells that have incorporated EdU into their genome. The 
chemistry permitting detection of genomic EdU was first described by Salic et al. in 2008. In this 
assay, live cells are labeled with a thymidine analogue EdU, which is incorporated into the 
nuclear DNA during replication in the S-phase of the cell cycle. The EdU is designed such that it 
has a terminal alkyne group that can be induced to react with a fluorescently-labeled azide 
moiety via “Click-iT” chemistry. The EdU is then detected by fluorescence emission, EdU 
incorporation is measured and the results are depicted as univariate histograms that depict EdU 
uptake across the x-axis or bivariate histograms that depict the EdU uptake of cells in different 
phases of the cell cycle. We attempted to adapt the existing protocol that measures UDS as a 
function of EdU uptake in lymphoblastoid cells using fluorescent imaging to make it compatible 
by flow cytometry. 
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5.2 RESULTS 
We adapted an assay to measure the NER capacity of suspension cells by detecting the amount 
of EdU incorporated into the nuclear genome after UV radiation using “Click-iT” chemistry and 
flow cytometry. We used lymphoblastoid cells for standardization of the assay so that the assay 
can eventually be applied to peripheral blood cells, which are more readily obtained from 
patients than fibroblasts. The exact protocol for the assay is detailed in the methods but briefly, 
cells were treated with UV-C which was expected to induce DNA damage. The cells were then 
allowed to repair the damage induced by incubating them at 37 degrees and EdU was added at 
this step to trace the repair process. Following repair synthesis, the cells were collected, excess 
EdU was washed off, they were fixed and permeabilized, and the incorporated EdU was detected 
with a fluorescently labeled azide moiety by Click-iT chemistry. Cell cycle profiles of the cells 
were obtained by staining with a DNA dye and the samples were analyzed by flow cytometry 
(FCM). Repair synthesis can readily be distinguished from DNA replication by the fact that the 
EdU signal is significantly greater in replicating cells than cells undergoing DNA repair (Figure 
5-1). A very strong, pan-nuclear fluorescent signal was observed in S-phase cells, whereas 
distinct foci were seen in cells carrying out DNA repair.  This however, illustrates the biggest 
challenge of this assay and that is to detect a rather weak fluorescent signal representing DNA 
repair in a background of strong signal due to S-phase cells. Hence our first priority was to 
devise a means to arrest the cell cycle, in order to minimize the fraction of cells in S-phase. 
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Figure 5-1 Fluorescent imaging of EdU labeled cells 
EBV transformed wild-type human lymphoblastoid cells were irradiated with 60J/m2 of UV-C. 
The cells were allowed to repair the UV damage by incubation in media containing 10µM EdU 
for 1h a t 37°C. Incorporated EdU was detected using Click-iT chemistry and the cells were 
cytospun onto glass slides and visualized by fluorescent imaging. The micrograph depicting the 
difference in the appearance of a cell undergoing unscheduled DNA synthesis (nuclei containing 
hotspots of fluorescence visible as foci) and cells in the S-phase of cell cycle are represented 
(completely fluorescent nuclei). 
5.2.1 Synchronization: serum starvation  
To synchronize cells by serum starvation, wild-type and XP-A lymphoblast cell lines were grow 
under standard conditions, but with different serum concentrations (0-2%) for 24 to 72 hrs and 
the impact on the cell cycle measured by flow cytometry using DAPI detect the DNA content of 
cells (Table 4). Upon serum starvation, this percentage appeared to increase two fold. The reason 
for this is unknown. The percentage of cells in each phase of the cell cycle is calculated but 
manually drawing gates in the software to calculate the percentages. This however is not the best 
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way due to the difficulty in properly representing the percentage of cells in each phase of the cell 
cycle considering they overlap with each other. Keeping this bias in mind, the percentage of cells 
in the different phases of the cell cycle was calculated after serum starvation. Under normal 
growth conditions (10% serum), the fraction of S-phase cells is 7%. This was not affected even 
by complete serum starvation for three days. This could be due to the fact that both cell lines are 
EBV transformed and the most prominent characteristics of a transformed cell are lower serum 
requirements, mitogen-stimulation independent division, loss of contact inhibition and anchorage 
independent growth (Hui-Yuen et al., 2011). 
Table 4 Approaches to Minimize S-phase Cells: Serum Starvation 
Sample 
Name 
Time of 
starvation 
Serum 
concentration 
G0/G1 
(%) 
S 
(%) 
G2/M 
(%) 
            
Normal 24h 10.0% 74 16 12 
Normal 24h 0.0% 82 14 2 
Normal 24h 0.5% 77 17 4 
Normal 24h 1.0% 80 15 3 
Normal 24h 2.0% 80 15 3 
            
Normal 72h 0.0% 73 20 6 
Normal 72h 0.5% 74 20 4 
Normal 72h 1.0% 73 21 4 
Normal 72h 2.0% 74 20 4 
            
XP-A 24h 0.0% 78 17 4 
XP-A 24h 0.5% 73 20 5 
XP-A 24h 1.0% 73 21 5 
XP-A 24h 2.0% 73 20 5 
            
XP-A 72h 0.0% 80 15 4 
XP-A 72h 0.5% 79 15 4 
XP-A 72h 1.0% 76 17 6 
XP-A 72h 2.0% 77 17 5 
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5.2.2 Synchronization: Transiently using inhibitors of DNA replication such as 
hydroxyurea and mimosine 
In an attempt to synchronize cells, cells were treated with two commonly used drugs 
Hydroxyurea and mimosine (Krek and DeCaprio, 1995; Lalande, 1990). A comparison of the 
cell cycle profiles of wild-type cells treated with mimosine and hydroxyurea individually did not 
show a d ecrease in the S-phase population of cells compared to untreated cells (Figure 5-2a). 
Hydroxyurea and mimosine can induce DNA damage (Darzynkiewicz et al., 2011; Mladenov 
and Anachkova, 2003; Sakano et al., 2001). To determine if this affected EdU incorporation, we 
compared the EdU uptake of cells treated with mimosine or hydroxyurea to untreated cells 
experiment in the absence of UV radiation. The results (Figure 5-2b) reveal that the treatment of 
cells with inhibitors of DNA replication does indeed increase the EdU incorporation by 20% as 
compared to the untreated cells. 
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Figure 5-2 Approaches to minimize s-phase cells 
Histograms showing the cell cycle profile and the EdU incorporation after treatment with 
mimosine or hydroxyurea. The cells were incubated in media containing either 0.4µM Mimosine 
or 10mM Hydroxyurea or were left untreated for 12h. Following incubation, the cells were 
washed with 1X PBS and incubated in media containing 10µM EdU for 1h at 37°C. After 1h, the 
cells were fixed and the incorporated EdU was fluorescently labeled by Click-iT chemistry. The 
DNA was stained (api, x-axis) and the fluorescence intensity (EDU-FITC, y-axis) of cells were 
analyzed using flow cytometry (FCM). a. Single parameter histogram representing the 
percentage of cells in different phases of the cell cycle upon t reatment with inhibitors of DNA 
replication. b. Dual parameter histogram representing the cell cycle profile (DAPI, x-axis) and 
the corresponding EdU incorporation (EDU-FITC, y-axis) of cells in the different stages of the 
cell cycle. 
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5.2.3 Immunodetection of the S-phase antigen Ki67 to detect proliferating cells 
Ki67 is a proliferation specific nuclear antigen (Gerdes et al., 1991). It is expressed in cells in all 
phases of the cell cycle with the exception of the G0 phase. PE-Ki67 (Invitrogen) was used to 
distinguish between resting cells that were only capable of repair synthesis from S-phase cells. 
Results from this experiment revealed that PE-Ki67 staining was successful only in cases where 
it was the only fluorophore used. When Ki67 staining was combined with EdU staining, the EdU 
staining turned out to be successful while no detectable signal was obtained from the PE channel 
that was used to measure Ki67 intensity (Figure 5-3). Switching to a different channel to detect 
the Ki67 turned out to be unsuccessful as well indicating perhaps that the Click-iT chemistry is 
incompatible with immunodetection. 
 
Figure 5-3 Immunostaining for Ki67 does not affect the number of S phase cells. 
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Single parameter histograms showing either EdU intensity or Ki67 intensity in samples labeled 
with Ki67 only and samples labeled with both Ki67 and EdU. Quadrant A represents the 
background fluorescence generated by autofluorescence. Quadrant B represents true signal. 
5.2.4 Optimizing the UV dose 
A second approach to increasing the signal to noise ratio is to increase the fraction of cells 
undergoing UDS in response to UV-induced DNA damage. To optimize this, various doses of 
UV-C were used to induce DNA damage. Wild-type and XP-A EBV-transformed 
lymphoblastoid cells were treated with 20, and 60 J/m2 of UV-C. Following incubation, the cells 
were stained to detect UDS as described in the methods section. At 20 J/m2 of UV, no increase in 
EdU incorporation was detected compared to unirradiated cells (Figure 5-4). Similar results were 
observed in the XP-A cells (data not shown). At 60 J /m2 of UV-C, the level of EdU 
incorporation changed. There was a shift in the intensity of EdU signal in cells irradiated with 60 
J/m2 compared to unirradiated cells (Figure 5-4). This would be consistent with a robust cell 
cycle arrest caused by high dose genotoxic stress leading to a loss of S-phase cells (high EdU 
signal), but an increase in DNA repair (UDS; low EdU signal). Treatment with 100 J/m2 of UV 
produced the same results as 60J/m2 UV-C but the percent of apoptotic cells was much higher 
(data not shown). Henceforth, 60 J/m2 UV-C was used as the standard treatment dose for EBV-
transformed lymphoblastoid cells in our assay. 
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Figure 5-4 Optimization of the UV dosage for UDS measurement in EBV transformed 
lymphoblastoid cell 
Wild-type cells were treated with a. 20J/m2 or b. 60 J/m2 of UV-C and incubated with media 
containing 10µM EdU for 1h at 37°C. Following incubation, the cells were collected, fixed, and 
EdU was fluorescently labeled with 25uM Alexa Fluor 488-azide using the Click-iT kit. cells 
were collected, filtered and analyzed by FCM for fluorescence intensity (EdU-FITC; x-axis) 
using single parameter histograms. Quadrant A represents the background fluorescence 
generated by autofluorescence. Quadrant B represents true signal. 
5.2.5 Determination of time point for EdU addition and incorporation 
UV has been known to induce cell cycle arrest (Gentile et al., 2003). Based on the robust cell 
cycle arrest that was observed in (Figure 5-4), we rationalized that exploiting this arrest to get 
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EdU incorporation only for UV-induced UDS and not replication will help eliminate some of the 
background. The next two experiments were planned to determine initially the time point at 
which synthesis-phase(s-phase) arrest was maximum and secondly, to determine the duration of 
EdU incubation to avoid s-phase restart. The duration of DNA repair synthesis however varies 
depending on the type of UV lesion being repaired.  CPDs are repaired much slower by NER 
than 6,4PPs (Mitchell, 1988). Wild-type human fibroblasts take 6-8h to repair 50% of 6,4PPs 
where as XP-A cells take 24h to remove 15% of the 6-4 PP (Friedberg, 2006). Cells were treated 
with UV-C and were allowed to recover for varying periods of time. The cell cycle profile was 
measured at 15, 30, and 45   minutes post UV-C irradiation to identify the time-point when UV-
induced cell cycle arrest was maximal (Figure 5-5a). The percent of cells in s-phase was found to 
be 9% 15  minutes after UV irradiation, 6% (lowest observed) at the 30  minutes time point, but 
this percent increased again and reached 13% by 45  min utes implying that maximal s-phase 
arrest took place at 30 minutes (Figure 5-5a). Hence, we concluded that the optimal time point to 
add EdU to the culture media was 30   minutes post-UV in order to minimize S-phase signal. 
 The determine incubation time for EdU incorporation that would be essential to avoid 
non specific EdU uptake upon replication restart, incorporating the 30 minutes time point from 
the previous experiment, we tried multiple time points to determine the time point at which non 
specific EdU uptake due to replication restart occurred. The data from the multiple time points 
was compared to the original 1h incubation time represented in quadrant 2. T he first reaction 
involved treating cells with UV followed by incubation for 30 minutes at which point EdU was 
added. Upon EdU addition, the cells were allowed to recover for either 30 minutes (Quadrant 3) 
or 1hr (Quadrant 5). In one individual reaction, cells were exposed to two pulses of UV 15 
minutes apart. EdU was added immediately after the second pulse and the cells were henceforth 
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given 30 m inutes for repair synthesis (Quadrant 4). These experiments collectively helped 
determine that replicative arrest took place 30 minutes after UV irradiation (Figure 5-5a) and 
replication restart occurred 1h a fter UV irradiation (Figure 5-5b) implying that EdU must be 
added 30   minutes after irradiation and cells must be collected for analysis 30  minutes post EdU 
addition (Quadrant 3). However, the addition of EdU after 30 minutes followed by a 30 minute 
incubation resulted in very low EdU intensity peak (Quadrant 3) in comparison to the treated and 
untreated controls displayed in Quadrants 1 and 2 respectively. This raised the concern that the 
Flow cytometry approach might not be sensitive enough to detect signals of such low magnitude. 
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Figure 5-5 Analysis of time points for UV addition and incorporation 
EBV transformed wild-type human lymphoblastoid cells were irradiated with 60 J/m2 of UV-C. 
a. 15 minutes, 30 minutes and 45 minutes post irradiation, the cells were collected, DNA stained 
using DAPI and the cell cycle profiles were analyzed by FCM. b. 30 minutes post irradiation, the 
cells were incubated in media 10µM EdU for 1h at 37°C. The cells were then collected, fixed, 
and EdU was fluorescently labeled with 25uM Alexa Fluor 488-azide using the Click-iT kit. 
Analysis was conducted by FCM for fluorescence intensity (EdU-FITC; x-axis) using single 
parameter histograms. Quadrant 1 represents cells that were not irradiated. Quadrant 2 represents 
cells that received EdU immediately after irradiation (0h) with a 1h i ncubation. Quadrant 3 
represents cells that received UV 30 minutes after irradiation with a 30   min utes incubation. 
Quadrant 4 represents cells that received 2 pulses of 60 J/m2 of UV 15 minutes apart, EdU was 
added 15   m inutes after the second UV pulse and the cells were then incubated for 30 minutes. 
Quadrant 5 represents cells that received EdU 30 minutes after irradiation with a 1h incubation. 
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5.2.6 Optimizing fixation and permeabilization 
Cellular integrity can be detected during flow cytometry based on t he populations of cells 
observed on a f orwardscatter/sidescatter (FS/SS) histogram. When cells enter the flow 
cytometer, they scatter light that is represented as the forward and side scatter. Forward scatter 
measures size while the side scatter measures cellular density. Taken together, different cellular 
populations can be distinguished based on F S and SS. The initial method for the fixation of 
Epstein Barr virus (EBV) -transformed cells employed PBS containing 2% paraformaldehyde, 
0.5% triton-X 100 a nd 300mM sucrose for 20   m inutes on i ce, as previously described 
(Nakazawa et al., 2010). However, this method compromised cell integrity as illustrated by the 
multiple cell populations on a FS/SS histogram (Figure 5-6). To troubleshoot this, cells were 
treated with different fixatives such as 70% ethanol, methanol, 100% ethanol and sequential 
treatment with 2% paraformaldehyde for fixation followed by treatment with 0.5% triton-X 100 
(Figure 5-6) or 0.1 % triton-X for permeabilization. The forward scatter and side scatter plots 
generated by flow cytometry (FCM) analysis were used to determine cell size and integrity. The 
results revealed that treatment with 70% ethanol and 100% methanol for 30   minutes on ice 
helped retain cellular integrity while effectively fixing and permeabilizing cells (Figure 5-6). 
70% ethanol was henceforth used in our analysis as the fixative due the reproducibility, optimal 
staining with Alexa fluor 488 and minimal background obtained. 
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Figure 5-6 Optimization of the FIX/PERM method to protect cellular integrity 
Exponentially growing EBV transformed wild-type human lymphoblastoid cells were fixed and 
permeabilized with 2% paraformaldehyde-0.5% Triton X-100, and 300mM sucrose for 15 
minutes on ice, 2% paraformaldehyde for 15 minutes on ice followed by 0.1% Triton X-100 for 
10 minutes at RT, Methanol for 30 m inutes on ice, and 70% ethanol for 30 m inutes on ice. 
Following incubation, the cells were washed twice with 1X PBS and were analyzed by FCM. 
Dual parameter histograms representing cellular size (forward scatter, x-axis) and cellular 
granularity (side scatter, y-axis) are shown. 
 
5.2.7 Eliminating spectral overlap 
Unscheduled DNA synthesis is carried out by cells outside the S-phase. To determine the 
proportion of cells that are non S-phase, a DNA staining step was incorporated after the EdU 
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staining. However, for efficient analysis, the DNA stain had to be chosen such that its spectra did 
not overlap, with the Alexa Fluor 488 that was used in our analysis, to minimize channel bleed 
through. Propidium iodide (PI) with an excitation (ex) wavelength of 488nm emission (em) 
wavelength of 619nm and DAPI ex 350nm em 461nm was checked for compatibility with Alexa 
Fluor-488 ex 495 nm  em519 nm for our analysis. Ideally, these should not overlap with the 
excitation and emission wavelengths of the fluorophore used to detect EdU, which is Alex Fluor-
488. When PI was used in combination with Alexa Fluor-488, the EdU signal (fluorescence at 
488 nm) was completely quenched, likely due to spectral overlap between PI and Alexa-Fluor-
488 (Figure 5-7a). In contrast, when DAPI was used there was no quenching of the EdU signal 
(b). The same results were obtained when EdU was detected with Alexa Fluor-647 in 
combination with PI (data not shown). 
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Figure 5-7 Optimizing the combination of fluorescent dyes 
EBV transformed wild-type lymphoblastoid cells were irradiated with 60J/m2 of UV-C (or not). 
10uM EdU was added to the samples. The cells were allowed to incubate at 37C for 1 hr  to 
attempt repair of UV-induced DNA damage. Then the cells were fixed with 2% 
paraformaldehyde-0.5% Triton X-100, and 300mM sucrose and the click-it kit was used to 
fluorescently label EdU with 25uM Alexa Fluor 488-azide. The cells were collected, filtered and 
analyzed by FCM for DNA content and fluorescence intensity using a combination of a. EdU 
and PI; b. EdU and DAPI. 
5.2.8 Click-iT reaction 
The results from the standardized assay indicate that there was a 10 fold increase in the EdU 
incorporation between UV treated and untreated wild-type (Figure 5-8a) and that there is no 
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difference in the 13% incorporation observed in untreated XP-A cells when they were subjected 
to UV treatment (Figure 5-8b). Analysis of the results using a dual parameter histogram that 
measured the EdU intensity obtained from cells in distinct phases of the cell cycle revealed that 
there was a 30% increase in the EdU incorporation by wild-type cells in the G0/G1 phase of the 
cell cycle when they were treated with UV. Only 2% of untreated wild-type cells in G0/G1 
showed EdU incorporation (Figure 5-8c). Furthermore, when XP-A cells were treated with UV, 
there was no increase in the percent of cells incorporating EdU between the UV treated (2%) and 
untreated samples (2%), as expected since the cells are NER-deficient and therefore should have 
no UDS (Figure 5-8c). 
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Figure 5-8  Flow cytometric detection of EdU labeled cells 
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DNA repair proficient (wild type) and DNA repair deficient (XP-A) cells were irradiated with 
60J/m2 of UV-C (or not). 10uM EdU was added to the samples. The cells were allowed to 
incubate at 37°C for 1 hr to attempt repair of UV-induced DNA damage. Then the cells were 
fixed with 70% ethanol and the Click-iT kit was used to fluorescently label EdU with 25uM 
Alexa Fluor 488-azide. The cells were collected, filtered and analyzed by flow for DNA content 
(DAPI, x-axis) and fluorescence intensity (EdU-FITC; y-axis). Single parameter histograms are 
shown for. a. Wild-type lymphoblastoid cells b. XP-A deficient lymphoblastoid cells where 
quadrant A represents autofluorescence and quadrant B represents true signal c. Dual parameter 
histograms where quadrant R1 (in blue; 2n DNA, low fluorescence) represents G0/G1 cells with 
no DNA synthesis; quadrant R2 (in orange; 2n DNA, intermediate fluorescence) represents NER 
of UV-induced DNA damage; quadrant R3 (in yellow; 2-4n DNA, high fluorescence) represents 
S phase cells; quadrant R4 (in red; 4n DNA, low fluorescence) represents G2/M cells. 
5.3 DISCUSSION 
Over the years, a plethora of assays have been developed in an attempt to measure DNA repair. 
The most common assays include those that measure repair synthesis such as the unscheduled 
DNA synthesis (UDS) assay, the comet assay which is used to measure strand breaks, the host 
cell reactivation assay that measures TC-NER, and the γH2AX assay that is usually used to 
measure double strand breaks. Since 1964 when the Unscheduled DNA synthesis assay was first 
developed to measure NER, it has been adapted in multiple ways to overcome the 3 m ajor 
disadvantages of the initial technique: labor intensiveness, extensive duration of the assay and 
hazard issues due to the use of autoradiography. 
 Attempts made to accomplish this goal over the last decade involve immunodetection of 
the incorporated nucleoside analog bromodeoxyuridine (BrdU) using an anti-BrdU antibody. 
This approach has considerably shortened the time required for the assay from 3 m onths to 3 
days but is still not automated and hence is very laborious. Flow cytometry (FCM) has been 
considered an attractive approach to semi automate measurement of repair synthesis. However, 
there is very minimal literature on the use of flow cytometry (FCM) to measure NER. In 1988, 
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Beisker and Hittelman described a flow cytometric approach to measure GG-NER by detecting 
the incorporation of BrdU into the DNA by cultured human fibroblasts after UV irradiation. 
Over the years, flow cytometry in combination with BrdU immunocytochemical staining has 
been employed in a number of studies that have measured repair by human fibroblasts, Chinese 
hamster ovary cells, cancerous cells and also primary rat hepatocytes (Affentranger and Burkart, 
1992; Selden and Dolbeare, 1994; Selden et al., 1993; Srivastava et al., 1993).  T he major 
problem with the BrdU method is that for its detection, DNA is denatured with heat or HCl and 
such harsh treatments usually destroy the antigen recognition sites. In addition, it is not possible 
to combine cell cycle analysis dyes such as DAPI while using BrdU. 
 In this study, we have developed an assay to quantitatively measure NER in a semi-
automated manner. The assay measures repair synthesis by the incorporation of EdU into the 
DNA of non S -phase cells after subjecting them to UV induced DNA damage using flow 
cytometry. In this version of the assay, 3[H]-thymidine is replaced by the thymidine analogue 
EdU. This eliminates the need to use autoradiography as we can now use flow cytometry instead. 
In addition, this assay is standardized to measure the repair synthesis in suspension cells so as to 
eventually extend its application to human blood samples. During standardization, one of the 
most important things to ensure was the discrimination of signal obtained from cells in the S 
phase from cells in all other phases of the cell cycle and we accomplished this by (i) clearly 
segregating true signal from background generated through autofluorescence (ii) eliminating S-
phase generated background (iii) accurately and sensitively measuring the “true signal” obtained 
from non S-phase cells. The first problem was efficiently resolved in 2 ways. Every experimental 
panel included stringent controls that were used to set the background generated by 
autofluorescence. This involved including unstained cells that did not receive either EdU or PI to 
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set the machine generated autofluorescence, single color controls such as cells stained with either 
the cell cycle dye or with EdU and each of these were used to determine the autofluorescence 
and also the color bleed from one channel to the other. This helped standardize the FCM 
machine prior to each analysis and using fresh controls with each experimental panel helped 
avoid variability introduced by the batch of reagents used, incubation temperature, and 
incubations times from one day to the other. 
 These modifications have reduced the total time taken for one reaction panel to 3 hours 
which is a tremendous change from the 3 months that the initial assay used to take. In addition to 
this assay being sensitive enough to distinguish between repair proficient and deficient cells 
(Figure 5-8), it is highly reproducible (data not shown) and by using an automated flow 
cytometer, 24 samples can be analyzed every 30 minutes. In conclusion, the flow cytometric 
measurement of NER by measuring EdU incorporation has the potential for being used as a 
future standard diagnostic measure in a clinical setting. 
5.4 EXPERIMENTAL PROCEDURES 
5.4.1 Cell Lines 
GM02345 XP-A lymphoblastoid cell line and GM03798 normal wild-type lymphoblasts were 
obtained from Coriell. The cells were grown in RPMI Glutamax media (Invitrogen) 
supplemented with 10% FBS and Pen/Strep. The cells were all grown in a humidified 5% CO2 
incubator at 37ºC. 
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5.4.2 Serum Starvation 
Exponentially growing cells were pelleted by centrifugation at 1000 rpm for 5   minutes at 37ºC. 
The supernatant was discarded and the cells were resuspended in media containing 0, 0.5, 1 a nd 
2% serum and incubated for 0, 12, 24, 48 and 72h in a 5% CO2 incubator at 37ºC. 
5.4.3 Drug Treatments 
Exponentially growing cells were pelleted by centrifugation at 1000 rpm for 5   m inutes. The 
supernatant was discarded and the cells were resuspended in 20 ml of media containing either 10 
µM hydroxyurea (Sigma) or 0.4 µM Mimosine (Sigma) and incubated for 12, 24 and 48 h in a 
5% CO2 incubator at 37ºC. Following incubation, the cells were pelleted and washed two times 
with PBS to remove the drug. 
5.4.4 UV Irradiation 
Exponentially growing cells were spun down in a 15 ml falcon tube at 1000 rpm for 5 minutes. 
The supernatant was discarded. The cell pellet was resuspended in 2 ml of PBS, and the cells 
were irradiated with 20, 60 or 100 J/m2 of UV-C (Spectroline X-15 254nm) in an uncovered petri 
dish. The cells were then replenished with fresh medium containing 10 µM EdU (Invitrogen) and 
incubated at 37 ºC in a 5% CO2 incubator. 
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5.4.5 Removing unincorporated EdU 
After incubation, the cells were pelleted by centrifugation at 1000 r pm for 5 m inutes. The 
supernatant was discarded and the cell pellet was resuspended in 5 ml PBS by pipeting gently up 
and down. The cells were then repelleted and the process was repeated one more time. 
5.4.6 Fixing and Permeabilizing 
The washed cell pellet was resuspended in 100 µl of PBS and the cell suspension was filtered 
through a 3µm filter (Falcon). The 2 ml of ice-cold 70% ethanol (Decon laboratories, Inc.) was 
added drop by drop to the cell suspension through the filter. Three more ml of 70% ethanol was 
added and the cells were incubated on ice for 30   m inutes. After 30   m inutes, the cells were 
pelleted by centrifugation at 1000 rpm for 5   m inutes. The pellet was rehydrated and traces of 
70% ethanol were removed by washing 2 times with PBS. 
5.4.7 Blocking 
The cells were then blocked by resuspending the pellet in 10% FBS or 3% BSA in PBS, and 
incubation at 37ºC for 20   m inutes. After incubation, residual FBS/BSA was removed by 
centrifugation at 1000 rpm for 5   minutes and discarding the supernatant. 
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5.4.8 Ki67 Staining 
The cell pellet was resuspended in 1 m l PBS containing 20 µ l PE-Ki67 (Invitrogen) and 
incubated at RT for 30   minutes. Following incubation, the cells were pelleted by centrifugation 
at 1000 rpm for 5   minutes, the supernatant was discarded and the cells were washed two times 
with PBS as described previously. 
5.4.9 Click-iT Reaction 
For EdU staining, the Click-iT kit (Invitrogen) protocol was followed. Briefly, the cells were 
incubated in 500 µ l of the reaction mixture which contained 25 µM Alexa Fluor647-azide, 50 
mM TBS pH 7.3, 4mM copper and 10 mM sodium ascorbate. Each cell pellet was then gently 
resuspended in 500 µl of the reaction mixture and incubated at RT in the dark for 30   minutes. 
5.4.10 Washing 
After incubation, the cells were pelleted by centrifugation at 1000 r pm for 5   m inutes. The 
supernatant was discarded and the cell pellet was resuspended in 5 ml PBS by pipeting up and 
down gently. The cells were then pelleted as described previously and the process was repeated 
one more time. 
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5.4.11 DNA Staining 
The cell pellet was resuspended in 1ml PBS in a 5 ml poly propylene tube (Falcon). To this, 100 
ug/ml RNase A and 40 ug/ml Propidium iodide was added and the cells were incubated at RT. 
After 30 minutes, the cells were directly analyzed by flow cytometry. 
5.4.12 Flow Cytometry 
Becton and Coulter Gallios, Becton, Coulter Cyan Blue and Accuri C6 flow cytometers were 
used to analyze the cells. 
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6.0  OVERALL DISCUSSION AND FUTURE DIRECTIONS 
The overarching goal of my doctoral dissertation was to understand the contribution of DNA 
repair mediated by XPF-ERCC1 to cancer and aging. The basic foundation of this research arose 
from the fact that misinterpretation of lesions by the repair and replication machinery leads to 
mutations in the genome giving rise to cancer. However, extensive damage results in either 
programmed cell death (apoptosis) or cellular senescence both of which can contribute to aging. 
It is a well established that deficiency of NER proteins result in Xeroderma Pigmentosum, a 
disease characterized by extreme sensitivity to sunlight and a predisposition to cancer.  However, 
a severe deficiency of the NER endonuclease XPF-ERCC1 leads to an accelerated aging 
phenotype in both mice and humans, implying that this exaggerated phenotype is due to the 
functions of XPF-ERCC1 outside of NER. Genetic dissection of the DNA repair mechanism or 
the type of DNA lesions that promote cancer and aging will help devise ways to delay 
degenerative changes that are associated with age and will also help improve cancer treatment. 
My dissertation lays the foundation to answering some of the key questions that remain 
unanswered in our field, such as (i) Do the accumulation of unrepaired crosslinks promote 
aging? (ii) Are XPF-ERCC1 good biomarkers of chemoresistance, and if so, what is the 
mechanism underlying this resistance? and finally, (iii) Can we efficiently and accurately 
measure the DNA repair capacity of an individual to use as a prognostic tool? The answers to 
these basic questions bring us one step closer to translating bench research to bedside treatment. 
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To accomplish this, we set out to uncouple the functions of XPF-ERCC1 in NER and ICL 
repair by engineering mutations in different regions of the XPF gene using site-directed 
mutagenesis. The evolutionary conservation of the proteins combined with the fact that XPF-
ERCC1 has an essential role in multiple genome maintenance mechanisms highlight the 
biological importance of the complex. 
In Chapter 2 of my dissertation, we have analyzed the importance of four DNA binding 
domains in the C-terminus of XPF-ERCC1 for NER. Based on data from structural and 
functional studies of XPF-ERCC1, two basic residues in the HhH domains, K247 and K281 in 
ERCC1 and K850 and R853 in XPF were chosen as they have previously been implicated in 
DNA binding (Figure 2-1). In addition, the R678 residue in the nuclease domain of XPF and the 
N110A mutant previously shown to have weakened interaction with XP-A were also included. 
Our results indicate that multiple protein and DNA binding domains of XPF-ERCC1 control its 
function in NER and that mutations in the HhH domain of ERCC1 affect DNA binding, nuclease 
and NER activity more severely than analogous mutations in XPF. The synergistic effect of 
mutations in multiple DNA binding domains is essential to affect NER activity. 
In Chapter 3, we engineered mutations in specific domains of XPF to generate pathway 
specific defects. The regions selected for mutagenesis included the nuclease domain of XPF in 
the C-terminus, the FANCP interaction domain in the N-terminus, and a 5 amino acid deletion in 
the N-terminus of the protein. The data presented herein demonstrate that multiple domains of 
XPF are likely good candidates to uncouple the function of XPF-ERCC1 such that they are 
proficient in NER, but are deficient in ICL repair. This project also provides the first formal 
proof that the nuclease domain of XPF is essential for repair (Figure 3-2). The primary endpoint 
analyzed was the overall cellular survival in response to UV, crosslinking agent-mitomycin C 
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mitomycin C and ionizing radiation as measured by a clonogenic survival assay. The results 
from the initial survival curves identified the mutation in position 314 to make cells selectively 
hypersensitive to crosslinking agents (Figure 3-2b). To support and confirm the proficiency of 
each repair pathway in question, I examined secondary endpoints measuring either well known 
markers or key events in each repair pathway. The local damage assay used as a s econdary 
endpoint for NER revealed that the D676A mutation in the nuclease domain of XPF that made it 
nucleolytically dead compromised the NER function of XPF-ERCC1 (Figure 3-3). In support of 
the primary data, the secondary endpoint for the ICL repair pathways, measured by the activation 
of the FA pathway denoted by FANCD2-L (monoubiquitinated form) and FANCD2-S 
(monoubiquitinated form) indicated that the potential disruption of the interaction betweeen XPF 
and FANCP compromises ICL repair ability (Figure 3-4). Much to our surprise, the 
hypersensitivity of the wild-type corrected cell line observed in response to MMC lead to the 
identification of defects in the XPF construct being used. The results shown in (Figure 3-7) 
confirm the complete rectification of the XPF construct. Based on the inferences drawn from this 
study, we in the future, plan to take this approach in vivo to determine the phenotype of a mouse 
carrying nucleolytically dead XPF, D687A and ICL repair deficient XPF, G325E and G703D 
independently. This study will aid in understanding the contribution of ICL repair to aging and 
also help identify regions of the XPF gene that when targeted with small molecule inhibitors, 
sensitizes cells specifically to crosslinking agents.  
Chapter 4 of my dissertation details the development and stringent evaluation of a panel 
of new monoclonal antibodies that could be used to measure XPF-ERCC1 protein expression 
levels in tumors. The data herein demonstrates the applicability of three of the 10 monoclonal 
antibodies for immunoprecipitation, immunoblotting, immunofluorescence, and 
 152 
immunohistochemistry (Table 3). The 1E4 antibody has excellent specificity and sensitivity 
toward human XPF protein (Figures 1 & 3). The 3H4 antibody identified has specificity toward 
both mouse and human XPF (Figure 4-2c). In addition, the identification of the 3G7 antibody 
that detects both XPF and ERCC1 (Figure 4-2b), is of special importance as it can help establish 
an accurate correlation of the expression levels of both proteins in tumor cells and an antibody of 
this nature has the potential to probe the functional domains of the complex. The two antibodies, 
1E4 and 3H4, selectively purified were standardized for the IHC detection of XPF-ERCC1 in 
human and mouse tissue respectively. The initial standardization of the human 1E4 antibody for 
IHC was carried out using wild-type cell sections as positive control, XPF-deficient XP2YO 
cells as negative control and tonsil sections to estimate tissue applicability (Figure 4-7). I used 
cell lines for standardization to assess the specificity of the antibody to XPF as it is  difficult if 
not impossible to procure tissue samples that can serve as negative controls. In addition, the use 
of negative controls that receive only the secondary antibody after treatment with serum in place 
of the primary antibody, helps ascertain that the signal obtained is purely due to accurate protein 
detection. 
In the future, we plan to standardize the 3G7 antibody for IHC analysis so that a parallel 
measure of levels of both XPF and ERCC1 can be obtained. An antibody of this nature is 
invaluable as it eliminates issues of bias, sensitivity and specificity. In addition, we plan to map 
the epitope of the 3G7 antibody on X PF and ERCC1 to determine the region of binding. 
Depending on the region of binding, this antibody has the potential to disrupt interaction between 
XPF and ERCC1 and thereby disrupt DNA repair mediated by XPF-ERCC1 eliminating the need 
for mutagenesis. 
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Chapter 5 o f my dissertation provides a detailed description of the development of an 
assay to measure the DNA repair capacity of cells. Even though there are multiple established 
ways to measure repair, the major disadvantage of most if not all of the protocols in that they 
measure the expression of one or more proteins in the repair pathways. In other cases, the assays 
employ complex transfection-based methods that are both laborious and time consuming with 
variations in applicability to specific cell types. To circumvent these problems, I took an 
approach that will measure repair as an event rather than as a measure of specific proteins. The 
most common repair pathways include base excision repair (BER), NER, ICL repair, and DSB 
repair. This study aimed to measure NER, ICL repair and DSB repair specifically as lesions 
repaired by BER are generated by endogenous sources of DNA damage where as the other repair 
pathways have a major environmental contribution. NER was first quantified by measuring 
Unscheduled DNA Synthesis using fluorescent nucleotides and flow cytometry. I used 
lymphoblastoid suspension cells for the standardization procedure so as to extend the potential of 
this approach in the future to clinical blood samples. Wild-type EBV-transformed cells were 
used as positive controls and NER deficient XP-A cells were used as negative controls to 
ascertain specificity of the assay. The repair capacity as measured by flow cytometry shows a 
23% difference in UDS between UV exposed and UV non-exposed wild-type cells (Figure 5-7a). 
There was no difference in the UDS levels between the treated and untreated XP-A cells. The 
13% difference in UDS between UV treated wild-type and UV treated XP-A cells is 
representative of the NER capacity between two individuals, one who is normal and one who has 
type A Xeroderma pigmentosum (Figure 5-8). 
In the future, this study will be extended to measuring ICL repair capacity of the cells by 
treatment with mitomycin C following transfection of cells with the traffic light reporter (TLR) 
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plasmid. DSB will be measured by quantifying γH2AX foci generated in response to IR 
treatment by using the Amnis flow cytometer. These approaches have the potential to automate 
repair measure facilitating a q uick and accurate estimate of the DNA repair capacity of an 
individual. The mean outcome of the measure of the three repair pathways can be the compared 
between long-lived individuals, their offspring and spouse controls to determine whether high 
DNA repair capacity contributes to longer survival of an individual and also to determine the 
heritability of DNA repair capacity. In addition, measuring the repair capacity of patients with 
cancer will help predict their response to chemoradiotherapeutic regimes and will help tailor 
therapy to each person. 
These studies have made minor yet significant advances in understanding and tackling 
two major public health issues of the 21st century namely, aging and cancer. 
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7.0  PUBLIC HEALTH SIGNIFICANCE 
DNA damage is one of the major contributing factors to cancer and a large number of age related 
degenerative changes. Somatic mutations that accumulate with age due to gradual functional 
decline, have the potential to disrupt controlled cellular proliferation giving rise to cancer. Aging 
is defined as the gradual but progressive functional decline in the physiological function of an 
organism. According to the World Health Organization (WHO), two billion people will be 65 
years and above by 2050 and this is more than three times the number observed in the year 2000. 
Moving one step further, when we consider people over age 85, the population is projected to 
increase from 4.2 million in 2000 to 6.6 million in 2020. This poses a problem because the cost 
of providing health care for an older individual is nearly five times greater than someone 
younger (The State of Aging and health in America 2007 CDC Merck company). Based on this 
statistic, the nation’s health care cost is projected to increase 25% by the year 2030. Therefore, it 
is crucial to understand the basic mechanisms behind aging. With advancing age comes the 
susceptibility to a wide range of age-associated disorders such as arthritis, cardiovascular 
disease, osteoporosis, and cancer. Cancer, the second most common cause of death in the United 
States of America, is a disorder of aging. Beyond the age of 60, the cancer incidence is known to 
double every 5 years and by 80 years, people have a 50% chance of developing cancer (Siegel et 
al., 2012). The year of 2012 ha s been estimated to have 1,638,910 n ew cancer cases with 
577,190 representing the number of cancer deaths leading us to a staggering number of more 
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than 1,500 d eaths per day. Looking at the contribution of cancer to overall mortality, this 
accounts for nearly 1 o f every 4 de aths in the US. The four major cancer types include lung, 
colorectum, breast, and prostate. Current research has helped in the decline of lung cancer in men 
by almost 40% and decline of breast cancer accounting for 34% in women. The year 2012 has 
seen 1,024,400 fewer deaths due to cancer and this promising number is only predicted to 
increase by advocating and extending the current cancer control measures which include both 
public awareness and research generated therapeutic measures to all segments of society. 
 “The prolongation of life is the most noble of all medical pursuits, for if any such things 
be found out (it) would be the greatest of worldly donations” Francis Bacon 
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APPENDIX A 
ABBREVIATIONS 
BrdU –Bromodeoxyuridine 
BSA- Bovine Serum Albumin 
CPD- Cyclobutane Pyrimidine Dimers 
DAB- 3,3’-Diaminobenzidine 
DAPI - 4′-6′-diamino-2-phenylindole 
DSB repair- Double strand Break Repair 
EDTA- Ethylenediaminetetraacetic acid 
EdU- 5-ethynyl-2’-deoxyuridine 
em – emission 
ERCC1-Excision Repair Cross Complementation group 1 
FBS- Fetal Bovine Serum 
FCM – Flow cytometry 
GFP – Green Fluorescence Protein 
GG-NER- Global Genome Nucleotide Excision Repair 
HCl – Hydrochloric acid 
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ICL-R- Interstrand Crosslink Repair 
IR –Ionizing Radiation 
MMC-Mitomycin C 
NER- Nucleotide exchange repair 
P/S – Penicillin/streptomycin 
PBS- Phosphate buffered saline 
PBST- Phosphate buffered saline -Tween-20 
PI – Propidium iodide 
PP-Photo Products 
RT- Room temperature 
RT-Room Temperature 
SDS-PAGE-Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SDS-Sodium Dodecyl Sulfate 
SS/FS- Side scatter/forward scatter  
SSA- Single strand annealing  
TBS- Tris buffered saline 
UDS-Unscheduled DNA Synthesis 
UV- Ultraviolet radiation 
WCE- Whole Cell Extracts 
XP- Xeroderma pigmentosum 
XPF- Xeroderma pigmentosum group F 
 159 
APPENDIX B 
LIST OF CELL LINES 
Table 5 List of Cell Lines  
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